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Stellingen behorende bij het proefschrift 
Targeting apoptosis in cancer cells: improving TRAIL death receptor signaling 1. Caspase 8 speelt een cruciale rol in de verhoging van rh1RAIL gevoeligheid in cisplatine­en rh1RAIL-resistente ovariurnkankercellen na behandeling met cisplatine. (dit proefschrift) 2. Specifieke activatie van wild-type p53 middels nutlin-3 versterkt met name DRS­gemedieerde apoptose-inductie. (dit proefschrift) 3. Blokkering van de insulinereceptor induceert verhoogde 1RAIL death receptor gevoeligheid via een reductie in cellulaire glucose opname. (dit proefschrift) 4. Beide isovormen van DRS kunnen een apoptotisch signaal initieren na rh1RAIL-binding. (dit proefschrift) 5. Remming van de insulinereceptor client als een potentiele anti-kankertherapie beschouwd te worden. (oa dit proefschrift) 6. Regelmatige fysieke inspanning na de diagnose borstkanker zou overleving kunnen verbeteren via verlaging van insulinespiegels. (Holmes et al, JAMA 2005, Ligibel et al, J Clin Oncol 2008) 7. De rol van DR4 en DRS in oncogenese dient nader onderzocht te worden, gezien het feit dat het TNF familielid CD95 receptor oncogene activiteit in verschillende kankers blijkt te hebben. (Chen et al Nature 2010) 8. Noordse stormvogels zijn een indicator voor de grote hoeveelheid plastic afval in de Noordzee, aangezien bij 95% van de dode Noordse stormvogels aan de Noordzeekust plastic in de maag werd aangetroffen. (Franeker et al, Environ Pollut 2011) 9. Naast het verminderen van het gebruik van het aantal proefdieren dient het verminderen van de afvalproductie tijdens preklinisch onderzoek te worden nagestreefd. 10. Biomedische wetenschap en voetbal kampen in Nederland met hetzelfde probleem; we leiden onze beste spelers op tot excellente hoogvliegers, waarna we hen laten uitvliegen naar het buitenland. 11. Aangezien neuronen alleen glucose kunnen opnemen als energiebron, is snoepen tijdens het werk zeer verantwoord. 12. De aanblik van de zee werkt geestverruimend. 13. Wanneer je de juiste hamer hebt gevonden wordt elk probleem als een willekeurige spijker. 
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Chapter 1 I General introduction General introduction 
In order to eliminate aged, damaged or infected cells, multi-cellular organisms have 
developed a highly regulated form of cell death termed apoptosis, which is essential for 
homeostasis (1). Typical morphological features that characterize apoptosis include cellular 
shrinkage, membrane blebbing, nuclear condensation and eventually the formation of 
apoptotic bodies that are removed by the immune system without inducing an inflammation 
response (2). Evasion of apoptosis was recognized by Hanahan and Weinberg as one of the 
six hallmarks of cancer (3). Hence, induction of apoptosis has been an important strategy 
in anti-cancer treatment and most chemotherapeutics exert their effect via this type of cell 
death. Unfortunately, loss of apoptotic capacity due to mutations in apoptotic proteins or 
altered expression levels of anti-apoptotic proteins is the main cause of chemo-resistance. 
Therefore, it is of major interest to unravel the mechanism of resistance and to restore 
apoptosis induction in cancer cells. 
Apoptosis can be initiated via two inter-connected pathways, the intrinsic (or 
mitochondrial) apoptotic pathway and the extrinsic (or death receptor) apoptotic 
pathway (2). Both pathways are regulated by caspases, a family of cysteine proteases (4,5). 
Chemotherapeutic agents and radiation activate the intrinsic pathway which comprises the 
tumor suppressor protein pS3, an important oncogenic transcription factor for apoptosis 
and cell cycle arrest (6). In the intrinsic pathway, apoptotic factors are released from the 
mitochondria, leading to caspase 9 and caspase 3 cleavage and apoptosis (7). The extrinsic 
apoptotic pathway is activated upon binding of death ligands of the tumor necrosis factor 
(TNF) superfamily such as TNF-related apoptosis inducing ligand (1RAIL), Fas ligand 
or TNFa to their cognate death receptors, initiating apoptosis. As recombinant human 
(rh) 1RAIL (Apo2L/dulanermin) is well tolerated in patients and induces apoptosis in 
cancer cells, while sparing normal cells, this death ligand is tested in the clinic for tumor 
apoptosis induction (8-10). Rh1RAIL is a type II trans-membrane protein that is expressed 
as a homotrimer (11,12). Following binding of rhTRAIL to its two death receptors (DRs) 
DR4 and DRS, the death inducing signaling complex (DISC) is formed, leading to cleavage 
of caspases 8 and 3 and eventually to apoptosis. The intrinsic and extrinsic apoptotic 
pathways are connected via caspase 8-induced cleavage of the Bcl-2 family member Bid. In 
order to circumvent apoptosis-resistance in either the extrinsic or intrinsic pathway, it is of 
interest to stimulate both pathways simultaneously (13). Pre-clinically, rh1RAIL has been 
combined extensively with various chemotherapeutic agents and radiation and showed 
enhanced apoptotic effects in vitro and in vivo (14-22). However, recent randomized phase 
II data showed no clear effects in patients when combined with chemotherapy in non­
small cell lung cancer (23,24). 
To increase the efficacy of rh1RAIL, DR-selective rhTRAIL variants have been generated 
to specifically target one DR (25-28). D269H/El9SR, a DRS-selective variant of rhTRAIL, 
was a more effective apoptosis inducer as compared to rhTRAIL in various cell lines and in 
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a bioluminescent xenograft model of ovarian cancer (15,28). 4C7, a DR4-selective rhTRAIL 
variant, showed enhanced apoptotic efficacy compared to rhTRAIL in a large panel of cell 
lines (29). 
The aim of this thesis is to enhance the efficacy of rhTRAIL-induced apoptosis. First, 
different combination strategies with rhTRAIL are explored to get more insight into the 
mechanisms that enable enhanced apoptotic signaling in order to guide optimal testing 
of rhTRAIL in the clinic. Second, DR4 and DRS-selective rhTRAIL-variants are used to 
examine DR-specific modulation by chemotherapeutics and targeted agents to further 
optimize apoptosis induction. Outline of the thesis 
The initial event following rhTRAIL binding to its DRs is the formation of the DISC (30). 
In chapter 2, an extensive literature overview of the factors that affect DISC formation is 
presented, with a focus on mechanisms modulating DISC assembly, caspase activation and 
rhTRAIL sensitization at the DISC. 
RhTRAIL resistance has been reported in approximately SO% of a large cell line panel 
(31). In addition, chemo-resistance is a major problem in ovarian cancer (32,33). Studies 
examining drug resistance are often performed using cell lines with different genetic 
backgrounds and sensitivity patterns, which impedes interpretation of causal relationships. 
Platinum-based chemotherapy forms the golden standard in treatment of ovarian cancer. 
In chapter 3, cisplatin and rhTRAIL resistance has been examined in an isogenic ovarian 
cancer cell model. The molecular determinants for rhTRAIL sensitivity, the mechanism 
of synergy between cisplatin and rhTRAIL and the role of functional pS3 and caspase 8 
in this synergy have been investigated using overexpression and RNA interference. As 
cisplatin induces DNA damage, which subsequently activates pS3, the specific effect of pS3 
induction on rhTRAIL sensitivity in several wild type pS3 expressing cancer cell models 
has been studied in chapter 4. Nutlin-3, a small molecule anticancer drug that disrupts the 
MDM2-pS3 interaction, has been used to accumulate pS3 without inducing DNA damage 
(34). The effect of nutin-3 on rhTRAIL-induced apoptosis was examined in ovarian, lung 
and colon cancer cell lines. As DRS is a transcriptional target of pS3, the DRS-selective 
rhTRAIL variant D269H/E19SR has been included in this study (28,35). The sensitization 
mechanism has been assessed via MDM2, p53 and Bid RNA interference. Additionally, the 
apoptosis inducing ability of nutlin-3, cisplatin and rhTRAIL or D269H/E195R has been 
tested in a novel living ex-patient model of primary human ovarian cancers. In this model, 
cancer tissue slices have been generated and individually cultured ex vivo, thus allowing 
exposure of the same tumor to different drug combinations. Treatment effects have been 
assessed via immunohistochemisrty on tissue slides generated from these slices. 
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Chapter 1 I General introduction Apart from combination studies with agents that induce the apoptosis pathway, combination of rhTRAIL and/or rhTRAIL-receptor selective variants with other targeted therapies is also of interest. It can be hypothesized that rhTRAIL-induced apoptosis could be enhanced via simultaneous inhibition of pro-survival signaling. The insulin-like growth factor (IGF) system plays an important role in regulation of normal energy metabolism and proliferation via activation of the phosphatidylinositol-3-kinase (PI3K) and mitogen­activated protein kinase (MAPK) signaling pathways (36). The IGF system is known to contribute to carcinogenesis (37). Micro-array data from our institute obtained in tumors of 157 ovarian carcinoma patients have demonstrated that deregulation of the IGF system may influence survival of ovarian cancer patients (38). In chapter 5, siRNA has been used to specifically downregulate the two main receptors that are of importance for IGF signaling; the insulin receptor (IR) and the IGF-lR. The effect of receptor specific downregulation on rhTRAIL DR-induced apoptosis has been investigated using rhTRAIL, the DR4 selective rhTRAIL variant 4C7 and the DRS selective rhTRAIL variant D269H/El9SR. The mechanism of rhTRAIL sensitization has been investigated in order to link the effect of IR and IGF-lR downregulation to cellular glucose metabolism, as cancer cells partially depend on the IR for their glucose uptake (39). Two isoforms of DRS have been identified a decade ago, but the precise function of these isoforms is still unclear (40). Both DRS isoforms are expressed in normal and cancer cells, but the ratio of expression levels varied among the tissues and cell lines studied (40). Further insight in the functionality of the DRS isoforms may provide the rationale to develop DRS isoform-specific targeted agents. In chapter 6, the functionality of the two DRS isoforms was investigated using a stably transfected DRS isoform specific overexpression model. Binding capacity to rhTRAIL, expression levels in a large panel of human cell lines and apoptosis-inducing capacity of each isoform have been studied. In addition, the development of agonistic antibodies against DRS with known isoform-specific binding characteristics is described. Finally, a summary of all study results is presented in chapter 7, along with a general discussion regarding the interpretation, implication, potential clinical application and future perspectives. 
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Abstract 
Formation of the pro-apoptotic death-inducing signaling complex (DISC) can be initiated 
in cancer cells via binding of tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) to its two proapoptotic receptors, death receptor 4 (DR4) or TRAIL receptor 1 
(TRAIL-Rl) and death receptor S (DRS) or TRAIL-R2. Primary components of the DISC 
are trimerized DR4/DRS, FADD, caspase 8 and caspase 10. The anti-apoptotic protein 
FLIP can also be recruited to the DISC to replace caspase 8 and form an inactive complex. 
Caspase 8/10 processing at the DISC triggers the caspase cascade, which eventually leads to 
apoptotic cell death. Besides TRAIL, DR4- or DRS-selective variants of TRAIL and agonistic 
antibodies have been designed. These ligands are of interest as anti-cancer agents since 
they selectively kill tumor cells. To increase tumor sensitivity to TRAIL death receptor­
mediated apoptosis and to overcome drug resistance, TRAIL receptor ligands have already 
been combined with various therapies in preclinical models. In this review, we discuss 
factors influencing the initial steps of TRAIL apoptosis signaling pathway, focusing on 
mechanisms modulating DISC assembly and caspase activation at the DISC. These insights 
will direct rational design of drug combinations with TRAIL receptor ligands to maximize 
DISC signaling. 
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C. TRAIL-induced DISC formation and apoptotic signaling pathway 
D. Combination therapy enhances TRAIL-induced apoptosis 
E. TRAIL combination therapy enhances DISC formation 
F. Loss of DR4 and DRS expression 
G. DISC component polymorphisms and functionality 
H. Death receptor-selective TRAIL variants 
I. TRAIL death receptor-specific antibodies 
J. Regulation of TRAIL death receptor-mediated apoptotic signaling at the cell membrane 1. DR4 and DRS aggregation promotes DISC formation 
2. Lipid raft localization stimulates TRAIL death receptor aggregation 3. Receptor internalization hampers TRAIL death receptor-mediated apoptosis 
K. Post-translational modifications of the DISC components 1. TRAIL death receptor O-glycosylation facilitates receptor aggregation 
2. DR4 S-nitrosylation stimulates caspase 8 cleavage 3. S-palmitoylation of DR4 promotes its oligomerization 4. Caspase 8 phosphorylation prevents its cleavage at the DISC 5. FLIP phosphorylation lowers its affinity for the DISC 
6. DISC protein ubiquitination differentially regulates DISC composition 
L. Influence of survival pathways on DISC formation 
1. The pro- and anti-DISC effects of protein kinase C 
2. The ERK.1/2 signaling pathway inhibits caspase 8 cleavage 3. The anti-DISC effects of active CKia and CKIIa 
M. DISC regulation by recruitment of additional proteins 1. PEDIPEA-15 blocks caspase 8 cleavage at the DISC 
2. Blockade of DISC formation by the DDX3/GSK3/cIAP-1 capping complex 3. The pro- and anti-DISC properties of the various IG20 gene family isoforms 4. Regulation of cell membrane DR4 levels by the signal recognition particle complex 
N.  Conclusions 
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer A I Introduction Programmed apoptotic cell death (or apoptosis) is a process by which unwanted cells are eliminated from multicellular organisms in a non-harmful way (1-4). The list of such unwanted cells includes malignant cells, infected cells or certain lymphocytes. Interestingly, although cancer originates from uncontrolled cell proliferation, cancer cells tend to exhibit more apoptosis than normal cells (5-7). This property may contribute to the effectiveness of some of the cytotoxic and targeted agents used in the clinic (8). Apoptosis can be initiated via two canonical pathways: the intrinsic and the extrinsic pathway, which both ultimately activate the same effector caspases and apoptosis effector molecules. Extrinsic cell death is triggered by the binding of tumor necrosis factor (TNF) superfamily ligands to their cognate receptors, stimulating their respective apoptotic pathways. Although the CD95-mediated apoptotic pathway is by far the best understood of these pathways, the TRAIL death receptor-mediated apoptotic pathway is clinically more attractive while it still shares numerous key components with the CD95-mediated apoptotic pathway (9,10). The trimeric [3-sheet endogenous protein TRAIL binds to its trimeric membrane DR4 and DRS, initiating the formation of death-inducing signaling complexes (DISCs) that stimulate the caspase cascade, eventually leading to apoptosis. Although CD95-mediated apoptosis has offered a very useful mechanistic model for the TRAIL apoptotic pathway, sensitivity to stimulation of these two pathways is not necessarily the same in identical cancer cells, suggesting critical regulatory differences (11,12). Importantly, the clinical development of TRAIL receptor ligands is markedly more advanced than that of CD95 ligands because of the minimal toxicity of the former and the high toxicity of the latter observed in preclinical studies (13,14). Two types of cancer cells have been identified based on their sensitivity to stimulation of the extrinsic pathway. Type I cells do not need the mitochondria to enter apoptosis, while type II cells require mitochondrial amplification of the extrinsic signal to achieve sufficient caspase cleavage for the initiation of apoptosis (15). Since most cancer cells express membrane TRAIL death receptors, there is a strong rational for modulating TRAIL-induced apoptosis directly at the DISC or at the level of the intrinsic pathway. Many of the drugs that have been combined with TRAIL receptor ligands thus far have been chosen based on their primary ability to activate the mitochondrial pathway of apoptosis; the goal was thereby to stimulate both the intrinsic and extrinsic pathway. Substantial data show that TRAIL death receptor-mediated apoptosis can already be modulated at the cell membrane itself. This review will discuss the proteins and pathways that offer interesting or novel targets for combination with TRAIL receptor-targeted therapies, with a focus on approaches influencing caspase 8 activation at the DISC. We will emphasize on TRAIL receptor ligand-specific and drug-specific abilities to promote DISC formation, TRAIL death receptor signaling modulation in close proximity to the cell membrane and regulation of DISC formation at the intracellular level. 
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer B I  TRAIL TRAIL was first identified independently by Wiley et al. and Pitti et al. (10,16). This naturally­occurring ligand is, in its recombinant human (rh) form rhTRAIL, a promising therapeutic agent. This is in part due to TRAIL' s ability to induce apoptosis in a wide variety of tumor cells while sparing normal cells. Endogenous TRAIL is expressed on natural killer (NK) cells, macrophages, T-cells, and dendritic cells and is thought to function as an immune defense mechanism by killing virus-infected and malignant cells (17). TRAIL knockout (-/-) mice were viable and did not display any hematological defects (18). An important role for TRAIL in tumor immune surveillance was demonstrated using TRAIL-/- mice. Compared to wild type (wt) mice, the TRAIL-/- mice showed increased susceptibility to experimental as well as spontaneous tumor metastases and showed increased tumor initiation following treatment with the chemical carcinogen 3-methylcholanthrene (MCA) (18). In addition, administration of a neutralizing monoclonal antibody against endogenous TRAIL increased MCA-induced tumor development in wt mice (19). In TRAIL receptor-deficient mice, the primary tumor as induced by the carcinogen 7,12-dimethyl-benz-anthracene (DMBA) and the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TP A) were unaffected by TRAIL neutralization (20). However, TRAIL receptor-deficient mice showed enhanced lymph node metastases, suggesting a more specific role for the TRAIL-TRAIL receptor interaction in the prevention of metastases. Several TRAIL molecules have been generated to utilize TRAIL as an anti-cancer agent, namely histidine (his)-tagged TRAIL, leucine zipper (LZ)-TRAIL, isoleucine zipper (IZ)­TRAIL, flag-tagged TRAIL and recombinant human (rh)TRAIL. A central zinc atom bound to cysteine-230 of each rhTRAIL subunit is essential for stability and function of the trimer rhTRAIL molecule (21). LZ-TRAIL was formed by linkage of exogenous leucine zipper to the extracellular region of TRAIL, resulting in a stable trimeric molecule. His-tagged TRAIL and flag-tagged TRAIL induced apoptosis in cultured human hepatocytes and in human brain slices respectively, raising concerns about toxicity (22,23). In vitro and in vivo experiments with LZ-TRAIL and rhTRAIL demonstrated that these molecules, as stable trimers devoid of a his- or flag-tag, can be used safely without causing (liver ) toxicity (24-26). The safety and pharmacokinetics of rhTRAIL as a single agent has been tested in a phase 1 clinical trial. RhTRAIL can be administered safely as drug-related toxicity was mild to moderate and the maximum tolerated dose was not reached. From the 51 patients included in the trial, 1 had a partial response and 17 patients experienced a stable disease (27). 
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer C I TRAIL-induced DISC formation and apoptotic signaling pathway TRAIL can bind five receptors, including DR4/TRAIL-Rl and DR5/TRAIL-R2, which contain a death domain (DD), and two decoy receptors (DcRs), DcRl/TRAIL-R3 and DcR2/ TRAIL-R4 without a functional DD. Osteoprotegerin (OPG) is a secreted soluble TRAIL receptor. Two isoforms of DRS have been described, designated DR5(L)/TRAIL­R2(L) for the longer form and DR5(S)/TRAIL-R2(S) for the shorter form (28). Both forms are expressed in normal and tumor tissues, but the ratio varied among the tissues and cell lines that were examined. Whether the two isoforms differ functionally is still unclear (28). A decoy function for DcRl and DcR2 has only been demonstrated in overexpression studies 
(29,30). It has been shown that TRAIL decoy receptors could prevent apoptosis signaling via complex formation with DR4 and/or DRS, resulting in an ineffective DISC (31,32). Upon binding of TRAIL to the TRAIL death receptors, receptor trimerization occurs, which leads to clustering of their DDs and formation of the DISC comprising of Fas-associated death domain (FADD), caspase 8 and 10 (33). The anti-apoptotic protein FLIP can also be recruited to the DISC to replace caspase 8 and form an inactive complex (34). While caspase 8 is essential, caspase 10 is not required for apoptosis induction by TRAIL (35). DISC formation results in caspase 8 activation. In so-called type I cells, the extrinsic ( or death receptor ) pathway is induced whereby active caspase 8 directly activates the effector caspases 3, 6 and 7, eventually triggering apoptosis. In type II cells, the intrinsic ( or mitochondrial) pathway is necessary to fully activate caspase 3 via caspase 8-dependent cleavage of the Bcl-2 family member Bid into its active form tBid. Translocation of tBid to the mitochondria induces Bax and Bak to form pores in the outer mitochondrial membrane. This allows release of the pro-apoptotic intermembrane space of mitochondria proteins cytochrome c, apoptosis inducing factor (AIF) and Smac/DIABLO into the cytoplasm. In the presence of dATP, cytochrome c induces the interaction of apoptotic protease activating factor 1 (Apaf-1) with caspase 9 resulting in the formation of the so-called apoptosome in which caspase 9 is activated. This subsequently leads to the activation of effector caspases and apoptosis. In type I cells, this mitochondrial pathway can be activated as well, but is not essential for apoptosis induction. In addition to activation of apoptosis signaling pathways, TRAIL has been linked to non-apoptotic pathways as well, namely nuclear factor (NF)-kappaB, protein kinase B (PKB/ Akt) and the mitogen-activated protein kinase (MAPK) signaling pathways, thereby promoting cell survival. This suggests that there is an important balance between cell death and survival signaling upon TRAIL binding, as extensively reviewed by Falschlehner et al. (36). 
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1RAIL targets the extrinsic apoptosis pathway, while chemo- and radio-therapy mainly 
inhibit cell growth and/or activate the intrinsic apoptosis pathway. Combination of either 
chemo- or radio-therapy with 1RAIL can activate both apoptosis pathways and increase 
their anti-tumor effect. Moreover, activation of both the extrinsic and the intrinsic pathway 
can initiate crosstalk between the two pathways. Such crosstalk can take place via caspase 
8-induced tBid resulting in stronger activation of the mitochondrial apoptotic pathway, or 
via chemo- or radio-therapy induced enhanced expression levels of 1RAIL death receptors. 
Combinatorial treatments with 1RAIL can therefore overcome tumor cell resistance 
to single agent therapies. In Table 1, examples are given of combination studies of TRAIL 
with various therapies such as proteasome inhibitors, DNA damaging agents, non­
steroidal anti-inflammatory drugs, and ionizing radiation (37). Combined treatment with 
these therapies induced the expression of DR4 and/or DRS and promoted 1RAIL-induced 
apoptosis. In many studies, the enhancement of TRAIL-induced apoptosis has only been 
attributed to TRAIL death receptor upregulation. The overview presented in Table 1 
demonstrates that there is a large variation in drug- or irradiation-induced DR4 and/or 
DRS upregulation. Although DRS was upregulated more frequently than DR4, there is 
no drug that specifically upregulates either DR4 or DRS, or tumor-specific upregulation 
of a particular TRAIL death receptor. In addition, basal TRAIL death receptor membrane 
expression itself does not seem to correlate with 1RAIL sensitivity, indicating the 
involvement of more downstream mechanisms (38). In this respect, drug-induced effects 
on other DISC components FADD, caspase 8 and 10, and FLIP have been considered (33). 
Transcription- and translation-dependent decreases in caspase 8 levels or increases in FLIP 
levels have both been frequently associated with 1RAIL resistance. Numerous drugs have 
indeed been shown to restore 1RAIL sensitivity primarily by increasing caspase 8 levels 
and/or decreasing FLIP levels (39-41). 
In the clinic, rh1RAIL has been combined with rituximab, a CD20-targeting antibody 
and chemotherapy. The combination of rh1RAIL with rituximab was well tolerated and 
the maximum tolerated dose was not reached. Twelve patients with relapsed low-grade 
non-Hodgkin's lymphoma (NHL) were included and three complete tumor responses 
were observed as well as three partial responses (42). In another clinical trial, rhTRAIL 
was combined with carboplatin, paclitaxel and bevacizumab, an anti-VEGF antibody. The 
preliminary data reports of this ongoing study in non-small cell lung cancer (NSCLC) 
patients showed one complete response and nine partial responses out of twenty four 
patients (43). The clinical data obtained so far in phase 1 trials demonstrate that rhTRAIL 
can be administered safely and shows potential as an anti-tumor agent, especially when 
combined with other therapies. 
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer Table 1 I Effects of anti-cancer treatments on DR4 and/or DRS expression. 
Treabnent DR4 DRS Tumor type Reference 
mRNA protein mRNA protein Proteasome inhibitors n.d. t n.d. t Cervical (44) 
t t t t Prostate (45) n.d. t n.d. tt Lung (46) n.d. t n.d. tt Lung (47) n.d. t n.d. t Colon, pancreatic, hepatoma (48) HDAC inhibitors n.d. n.d. t Breast, leukemia (49,50) 
t t t t Breast, myeloma (51,52) 
t t Renal, bladder (53,54) 
t t t t Leukemia (55) n.d. J, n.d. t Leukemia (56) 
NSAIDs n.d. t t Colon (57) 
t n.d. tt t Prostate (57) n.d. n.d. t Colon (58) 
t t t tt Lung (59) Irradiation t t Prostate (60) n.d. n.d. t Colon, lung, head and neck (61) n.d. t n.d. - Leukemia (62) n.d. t n.d. t Cervix (63) Leukemia (64) Topoisomerase t t t Renal (65) inhibitors t t Colon (66) n.d. n.d. t Colon, leukemia (67,68) 
t t t t Prostate (69) 
t t tt tt Breast (70) 
t n.d. t n.d. Colon (71) n.d. n.d. t Myeloma (72) Cisplatin n.d. t n.d. t Esophageal (73) n.p. n.p. n.d. t Ovarian (74) n.d. n.d. t Lung (75) 5-FU n.d. t n.d. tt Hepatocellular (76) Legends: not determined (n.d.), not present (n.p.), upregulation (t), downregulation (,l.), no effect (=), Histone Deacetylase (HDAC), non-steroidal anti-inflammatory drugs (NSAIDs), 5-FU (5-fluorouracil). Bold references represent studies that examined DISC formation. E I TRAIL combination therapy enhances DISC formation 
In order to dissect the underlying mechanisms that contribute to TRAIL sensitization, 
the efficiency of DISC formation needs to be addressed. Indeed, several studies have 
shown that the effect of pre-treatment with various therapies not only caused DR4/DR5 22 
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upregulation but also enhanced DISC formation as described by some examples below 
(bold references in Table 1). 
Irradiation of Jurkat cells overexpressing Bcl-2 slightly induced DRS membrane 
expression but greatly modulated the TRAIL-DISC as shown by immunoprecipitation 
(IP) of this complex using flag-tagged TRAIL (64). FADD recruitment to the DISC was 
four- to five-fold increased. As a consequence, the TRAIL-DISC contained more activated 
caspase 8 and 10 following irradiation while the level of the long FLIP isoform (FLIPL) was 
unchanged, resulting in an higher caspase 8 and 10/FLIP L ratio (64). 
The effect of the proteasome inhibitor bortezomib on TRAIL-induced apoptosis has 
been examined in hepatocellular, colonic, and pancreatic cancer cell lines (48,77). Both DR4 
and DRS surface expression were enhanced following bortezomib treatment in all tumor 
types. TRAIL death receptor upregulation was, however, only partially responsible for 
TRAIL sensitization since pre-incubation with TRAIL followed by single treatment with 
bortezomib still sensitized cells. In addition to this, Kyritsis et al. showed that TRAIL 
sensitivity was generally unrelated to DRS expression levels in a panel of eight glioma cell 
lines but instead was due to FLIP downregulation and caspase dependent Akt inhibition 
(78). Bortezomib was also used in primary human glioma cells. A collection of TRAIL­
resistant primary tumor cells were sensitized to TRAIL by co-treatment with bortezomib 
(77). Subsequent analysis of the TRAIL-DISC employing biotinylated IZ-TRAIL revealed 
that pre-treatment with bortezomib increased the caspase 8/FLIP ratio at the DISC (48). 
On the contrary, proteasome inhibition was found to inhibit TRAIL-induced apoptosis in 
cervical cancer cells by blocking FLIP and XIAP degradation, which decreased the caspase 
8/FLIP ratio at the DISC (79). It was demonstrated that timing of treatment with proteasome 
inhibitors prior to TRAIL treatment was important; first the proteasome inhibitor plays an 
anti-apoptotic role by stabilizing FLIP and XIAP but at a later stage it has a pro-apoptotic 
function by blocking degradation of caspases (79). The opposite effects of proteasome 
inhibition depending on the timing of administration reveal the importance of the caspase 
8/FLIP ratio at the DISC. 
TRAIL-resistant hepatocellular carcinoma cells co-treated with S-fluorouracil (S-FU) 
and TRAIL demonstrated synergistic effects on apoptosis induction (76). DRS membrane 
expression was induced in all cell lines tested, DR4 surface expression only in one cell 
line. The authors showed that DR4/DRS upregulation by S-FU was not required for TRAIL 
sensitization since pre-incubation with TRAIL followed by treatment with S-FU alone 
still sensitized cells. DISC-IP with biotinylated TRAIL showed that although DR4 and 
DRS levels at the DISC remained similar following S-FU combination treatment, TRAIL 
recruited more FADD and caspase 8, and similar levels of FLIP to the DISC in the cells 
co-treated with S-FU (76). Colon carcinoma cells were also sensitized to TRAIL by S-FU and 
by the chemotherapeutic drugs cisplatin and doxorubicin (74). Again, DISC-IP with flag­
tagged TRAIL showed that chemotherapy enhanced FADD and pro-caspase 8 recruitment 
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to the DISC, while recruibnent of FLIP was decreased (74). The results of both studies 
imply that treabnent with various drugs can result in a higher caspase 8/FLIP ratio at the 
TRAIL-DISC. 
Histone deacetylase (HDAC) inhibitors have been shown to affect TRAIL-DISC 
formation. In both renal cell carcinoma and bladder tumor cells, TRAIL sensitization was 
accompanied by enhanced DRS but not DR4 surface expression. Treabnent of cells with 
TRAIL and HDAC inhibitors increased DRS levels and enhanced FADD recruibnent to 
the DISC as demonstrated by DISC-IP with flag-tagged TRAIL (53,54). Both DR4 and DRS 
protein and mRNA levels were upregulated by the HDAC inhibitor LAQ284 in acute 
myelocitic leukemia (AML) cells (55). Membrane expression of DRS and to a lesser extent 
of DR4 was induced, suggesting that HDAC inhibitors are not DR4 specific. DISC-IP with 
a DR4 antibody showed that pre-treabnent with LAQ284 increased caspase 8 and FADD 
levels at the DISC, while FLIP levels were unchanged (55). Similarly, other HDAC inhibitors 
had a synergistic effect when combined with TRAIL in chronic lymphocytic leukemia 
(CLL) cells (56). DRS surface expression levels were only slightly affected. DISC-IP with 
biotinylated TRAIL showed that DRS, FADD and caspase 8 recruibnent to the DISC was 
increased following pretreabnent with HDAC inhibitors, resulting in a higher caspase 8/ 
FLIP ratio at the DISC (56). 
These studies clearly demonstrate that irradiation- or drug-induced TRAIL sensitization 
facilitate the formation of DISCs and is a main factor in combined treabnent sensitization. 
It is noteworthy that in all these studies biotinylated or flag-tagged TRAIL was used to 
immunoprecipitate the DISC and these tagged ligands are known to be both more potent 
than un-tagged TRAIL and toxic to normal cells (25). It remains to be elucidated whether 
these DISC-IP findings are representative for signaling induced by non-tagged TRAIL. In 
order to fully exploit the apoptotic effect of TRAIL or combination treabnent with TRAIL, 
we should gain more insight into the mechanisms underlying TRAIL sensitivity and 
drug-induced TRAIL sensitization in relation to DISC formation. The studies mentioned 
above demonstrate that the caspase 8/FLIP ratio at the DISC is unequivocally important 
for effective TRAIL signaling. Apart from differences in caspase 8/FLIP ratios at the DISC, 
other factors have been described to influence DISC formation and these will be addressed 
in the next section. F I Loss of DR4 and DRS expression 
The genes coding for the four membrane TRAIL receptors are located on the 8p21-22 
chromosome (80-82). This chromosome is a hot-spot for deletions and is frequently subject 
to allelic loss in various cancer types, including non-Hodgkin's lymphoma and lung, colon, 
breast, prostate, hepatocellular, ovarian, and head and neck cancer (83-92). Epigenetic 
silencing of DR4 and/or DRS has been reported in melanoma and ovarian cancer (93,94). 
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Because of monoallelic deletion, frequent downregulation of these TRAIL death receptors 
has been found in primary B-cell non-Hodgkin's lymphoma (B-NHL) (95). TRAIL resistance 
was correlated with 8p chromosome deletion and reduced TRAIL death receptor expression 
in most lymphoma cell lines tested. Enhancing DR4 or DRS expression by less than two­
fold re-sensitized these cells to TRAIL, which suggests a gene-dosage effect of these 
deletions. In the FaDu nasopharyngeal cancer cell line, homozygous loss of DR4 has led to 
TRAIL resistance, while re-expression of DR4 could again sensitize this cell line to TRAIL 
(96). Similar results were seen in the ovarian cancer line A2780, where reestablishing DR4 
expression with the demethylating agent S-aza-2' -deoxycytidin or transient transfection 
with a full-length DR4 construct restored sensitivity to TRAIL (94). It is noteworthy that 
TRAIL resistance in A2780 cells could also be overcome by specific targeting of DRS with 
a DRS-specific form of TRAIL or combination with cisplatin, both in vitro and in vivo (97). 
Additional data indicate that membrane DR4 levels correlate with TRAIL sensitivity in 
different cancer cell types (98-100). Conversely, studies showed that TRAIL death receptor 
expression generally tends to increase during carcinogenesis, and tumors often express at 
least one TRAIL death receptor (72,101,102). Thus, although complete loss of both DR4 and 
DRS might not be frequent, loss of one TRAIL death receptor only is sufficient to induce 
TRAIL resistance. In cells that have lost one of the TRAIL death receptors, combination 
therapies that either increase TRAIL-signaling via the remaining receptor or reestablish 
expression of the silenced receptor can restore TRAIL sensitivity. 
Whereas mice lacking TRAIL are viable, both caspase 8 and FADD are crucial to 
embryonic development and normal lymphocyte proliferation (103). These findings make 
complete loss of expression of these proteins less likely than loss of TRAIL death receptors. 
MiRNAs are a family of small (18-2Snt) non-coding RNAs that regulate protein 
expression at a post-transcriptional level via binding to specific mRNAs. Recently, several 
screens have been performed to identify miRs that are involved in TRAIL signaling and 
sensitivity in cancer (104,105). One of these screens identified miRs that regulate expression 
of DISC components (105). miR-14S and -216 were predicted to target DR4 and DRS, 
while FADD was a predicted target of MiR-182 and -96 (105). Although these studies are 
preliminary, miRNAs affecting DISC components could constitute interesting markers for 
TRAIL death receptor-mediated sensitivity and/or drug targets in the future. G I DISC component polymorphisms and functionality 
Besides loss of DR4 or DRS expression in tumor cells, alterations in the TRAIL death 
receptor gene sequences might play a role in TRAIL sensitivity (see Table 2). 
In hematological tumors, a variant of DR4 with a single-nucleotide polymorphism 
within the extracellular cysteine-rich domain was associated with several types of cancer, 
including CLL and mantle cell lymphoma (MCL) (106). This is particularly interesting 
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer since TRAIL-induced apoptosis was shown to depend on DR4 in CLL cells (107). Several other polymorphisms leading to codon changes, often found in the DD or the cysteine-rich domain of DR4 or DRS, have also been associated with enhanced risk for MCL and B-cell lymphoid neoplasms (108). Since these cancers could, in part, develop due to inefficient TRAIL receptor-mediated signaling, they might also respond poorly to TRAIL death receptor-targeted therapies. In solid tumors, two missense polymorphisms potentially affecting TRAIL binding were found to co-segregate in the extracellular domain of DR4 in primary NSCLC, gastric adenocarcinoma and in head and neck squamous cell cancer (HNSCC). These polymorphisms were also present in matched normal tissues and therefore do not constitute mutations per se. However, the frequency of being homozygous for these two polymorphisms was increased in the cancer samples compared to matched controls, suggesting a predisposition to cancer (109). Polymorphic alterations in DR4, mostly in the extracellular cysteine-rich domain of the receptor, were increased in osteosarcoma, but also in prostate cancer metastases (110,111). DRS mutations were found in HNSCC, NSCLC, breast cancers, hepatocellular carcinomas and gastric cancers, often in the exon coding for the DD (exon 9) (112-116) (Table 2). In metastatic breast cancers, Shin et al. found at least four DRS mutations that interfere with apoptosis transduction in metastatic lesions, while three other mutations were both present in the primary tumors and in the metastatic lesions (116). Lack or truncation of the DD of DRS was reported in a sporadic colon cancer patient with liver metastasis and in the RT4 bladder cancer cell line, respectively (118-119). Several of the DR4 and DRS mutations have been found in conserved hydrophobic residues and charged amino acids of the DD in cancer cells (113) where they hampered efficient DISC recruitment of F ADD and caspase 8 (120). Bin et al. recently tested four additional point mutations frequently found in the DD of DRS in cancer cells (121). Although his-tagged TRAIL could still bind to mutated TRAIL death receptors, efficient DISC formation was hindered, and TRAIL sensitivity was decreased. His-tagged TRAIL treatment did not induce formation of inactive wild type DR4/mutant DRS heterotrimers. It is therefore unclear why excess concentrations of his-tagged TRAIL could not restore TRAIL sensitivity by activating the functional DR4. Although this could be partially due to competition between the overexpressed mutant DRS and endogenous DR4, it is interesting that TRAIL signaling was less hampered by DRS loss than by DRS mutations. Only DR4-selective agonists could overcome the effects of mutations in DRS and induce apoptosis. Given the presence of TRAIL death receptor mutations in circa 10% of human tumors, prior screening could therefore be critical for the choice of ligands. Furthermore, although the negative effects of DR4 or DRS mutations on DISC formation have been described, the consequences on TRAIL receptor-mediated pro-survival signaling still need to be addressed. 
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Table 2 I Mutations found in DR4 and DRS in various cancers. 
Tumor Patients (n) Mutations Patients (n) Mutations observed in Reference 
type screened for observed. in screened for DRS 
DR4 mutations DR4 Oocation) DRS mutations Oocation) B-NHL 117 2 (00) 117 6 (4 different mutations (117) in the DD, 1 truncating mutation before the DD) 
HNSSC n.d. n.d. 60 2 (DD, incl. 1 germline (114) truncating mutation) NSCLC n.d. n.d. 104 11 (10 in the DD, 1 in (113) intro 8) Breast 57 3 (DD) 57 4 (2 DD + 2 in DD flanking (116) cancer regions) Gastric n.d. n.d. 43 3 (115) cancer n.d. n.d. 100/DD"' 1 (DD) (112) incl. 40/entire None additional (112) gene 
Legends: not determined (n.d.), head and neck squamous cell cancer (HNSCC), non-small cell lung cancer (NSCLC), B-cell non-Hodgkin's lymphoma (B-NHL), hepatocellular cancer (HCC). * Only the DD-coding region was analyzed. 
It should also be noted that some rare polymorphisms and mutations have been reported 
in the genes coding for caspase 8 and FADD (122,123). In comparison, DR4 and DRS gene 
alterations have been found in a significant number of tumors. Without screening options 
to determine functionality of either DR4 or DRS, a combination of DR4 and DRS-specific 
ligands might be a strategy to increase the likelihood of activating the TRAIL death 
receptor(s) and prevent eventual decoupling effects due to the presence of a non-functional 
receptor. H I Death receptor-selective TRAIL variants 
As it has been shown that in CLL cells TRAIL specifically signal through DR4 (107), the 
generation of TRAIL variants with a higher affinity for DR4 and/or DRS has raised interest 
in order to enhance DISC formation. Several DR4- and DRS-selective TRAIL variants were 
designed using computational design (124-126). Two DR4-selective forms of TRAIL were 
generated with a single amino acid mutation at position 218 from asparagine to either 
histidine or tyrosine in the receptor binding domain. Binding assays revealed that both DR4-
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer selective forms had a decreased affinity for DRS and TRAIL decoy receptors as compared to normal TRAIL, while their affinity for DR4 was unchanged. The DR4-selective TRAIL variants effectively induced apoptosis in cell lines that specifically signal via DR4 whereas almost no apoptotic effect was induced in cells expressing exclusively DRS. However, the DR4- selective variants were less effective in DR4-responsive cells when compared to TRAIL (124). Therefore, new TRAIL variants with increased affinity to both DR4 and DRS were designed, by replacing glycine-131 by lysine or arginine (126). The efficacy of these TRAIL variants was compared to the efficacy of TRAIL in a panel of cell lines that signal TRAIL induced apoptosis via DR4, DRS or both receptors, and demonstrated an increased apoptotic effect in all cell lines regardless of their TRAIL death receptor signaling status 
(126). Using the same computational design, van der Sloot et al. generated a DRS-selective TRAIL variant with mutations D269H and E19SR, resulting in largely reduced affinity for DR4, less affinity to TRAIL decoy receptors, but higher affinity for DRS. This DRS-selective variant induced more apoptosis than TRAIL in colon carcinoma, ovarian carcinoma and chronic myeloid leukemia (CML) cells, while DR4-selective cells were only sensitive to TRAIL (125). Upon combination with cisplatin, the DRS-selective TRAIL variant showed enhanced anti-tumor efficacy as compared to rhTRAIL both in vitro and in a bioluminescent ovarian cancer xenograft model (97). Kelley et al. generated TRAIL death receptor-selective TRAIL mutants using a phage display approach (127). The DR4-binding TRAIL mutants carried an Y189A mutation and had increased affinity for DR4, while binding to DRS was undetectable. Mutations Q193K and Q193R in TRAIL proved to be important for its affinity for DRS. In apoptosis assays, the DR4-selective mutants were less potent as compared to flag-tagged TRAIL in lung carcinoma cells, whereas the DRS-selective mutants retained their apoptosis-inducing ability. However, the potency of the DR4-selective mutants was not verified in cell lines exclusively expressing DR4. Macfarlane et al. (128) demonstrated that the DR4-selective variants described be Kelly et al. (127) did not induce apoptosis in Ramos cells, which were previously shown to signal via DR4 (107). This strengthens the possibility that the mutations in the DR4-selective TRAIL variant caused a loss in apoptotic potency. Therefore, the authors synthesized several new DR4-selective TRAIL mutants. One TRAIL variant with five mutations (Q193S, N199V, K201R, Y213W, and S21SD) induced less apoptosis in DRS-positive Jurkat cells as compared to TRAIL, while its DR4-specific activity in Ramos cells was preserved. In addition, primary CLL and MCL cells were sensitive to treatment with the DR4-selective variant. DISC-IPs in cells treated with this variant demonstrated enhanced recruitment of FADD and caspase 8 to the DISC, as compared to DISC-IPs after TRAIL exposure. This suggests that specific activation of the dominantly signaling TRAIL death receptor by a selective TRAIL mutant results in enhanced DISC formation and apoptosis induction as compared to the use of TRAIL that binds both TRAIL death receptors. 
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It is currently not possible to determine which TRAIL death receptor predominantly 
transduces the apoptosis signal in a given primary tumor. However, the development 
of DR4- and DRS-selective TRAIL variants opens ways to circumvent the TRAIL decoy 
receptors and warranty activation of the dominant TRAIL death receptor when used in 
combination. I I TRAIL death receptor-specific agonistic antibodies 
In addition to the receptor-selective TRAIL variants, DR4- and DRS-specific agonistic 2 
antibodies have been developed. One important difference between the agonistic 
antibodies and rhTRAIL is the extended serum half-life of the antibodies in men, which is 
around 2-2.5 weeks whereas it is 25 min for rhTRAIL (129,130). 
HGS-ETRl (mapatumumab) is the only anti-DR4 antibody currently in clinical 
development, while five anti-DRS antibodies are being tested, namely HGS-ETR2 
(lexatumumab), Apomab (PRO9S780), 1RA-8 (CS-1008), AMG6S5 and LBY135. These 
agonistic antibodies effectively induced apoptosis in a broad panel of cancer cell lines, 
without toxicity to normal hepatocytes (131-139). Cross-linking of the anti-DRS antibodies 
was either required (1RA-8), or beneficial (HGS-ETR2 and Apomab) for their apoptotic 
effect in vitro (132,137,138). Apomab, 1RA-8 and LBY13S were shown to inhibit tumor cell 
growth in xenograft mice models (137-140). 1RA-8 also induced cell death in ex vivo tissue 
slice models with primary human ovarian and cervical cancer tissue (141,142). 
Combination of chemotherapeutic drugs with the TRAIL death receptor-specific 
agonistic antibodies or TRAIL variants may show whether a drug specifically sensitizes 
cells via DR4 or DRS. Bortezomib was combined in vitro with both HGS-ETRl and 
HGS-ETR2 which resulted in additive or synergistic effects on (apoptotic) cell death in 
leukemic and lymphoma cells (133,136). Bortezomib treatment also sensitized a panel of 
NSCLC cells to both HGS-ETRl and HGS-ETR2, while cells were resistant to treatment 
with the antibodies alone. Remarkably, bortezomib only induced expression of DRS while 
DR4 levels remained the same. Sensitization to HGS-ETRl can thus not be attributed to 
DR4 upregulation (143). The effect of radiation on the sensitivity for different antibodies 
was also investigated. In colon carcinoma cell lines, increased sensitivity to HGS-ETRl 
and HGS-ETR2 was seen following irradiation (134). In cervical cell lines, radiation was 
found to sensitize cells to TRAIL via DR4, while radiation sensitized cells to both DR4 
and DRS antibodies (63). In addition, cervical and breast cancer cells were successfully 
sensitized to the anti-DRS antibody 1RA-8 in vitro as well as in vivo (144,145). Doxorubicin 
was shown to sensitize primary lymphoma cells to both HGS-ETRl and HGS-ETR2 in 
vitro, and breast cancer cells to 1RA-8 in vitro as well as in vivo (133,144). These examples 
of studies combining different drugs or radiation with agonistic antibodies against DR4 or 
DRS further suggest that the observed sensitization is not TRAIL death receptor specific. 
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer TRAIL death receptor-specific antibodies are currently under investigation in several phase 1 and 2 clinical trials, as single agents or in combination with various chemotherapeutics (129,130,146-160). Tumor responses were observed in 3 out of 40 extensively pretreated NHL patients (one complete and two partial responses) on anti-DR4 antibody (151). The antibodies are well-tolerated, also when combined with chemotherapy, and may be particularly interesting when used in combination with other anti-tumor agents. An overview of the anti-DR4 and anti-DRS agonistic antibodies under clinical investigation, and of particular interest in combination with other anti-tumor agents, was recently presented by Oldenhuis et al. (14). 
J I Regulation of TRAIL death receptor-mediated apoptotic signaling at the cell membrane The caspase cascade can be strongly influenced by membrane-proximal events, independent of TRAIL death receptor or caspase 8 expression levels. Several factors contributing to efficient DISC recruitment and apoptosis have been described. 1 I DR4 and DRS aggregation promotes DISC formation TRAIL death receptors can trimerize independently of the presence of TRAIL (161), but stimulation by oligomers of at least 3 ligands is required for DISC activation (21). Unlike TRAIL, anti-DR4 or anti-DRS agonistic antibodies bind only two receptor subunits and as a consequence these ligands possess different abilities to trigger TRAIL death receptor oligomerization. A study by Chuntharapai et al. established that mouse anti-human DR4 antibodies require cross-linking to be effective in a variety of cancer cell lines in vitro (162). In vivo, these antibodies demonstrated efficacy in different human xenograft mouse models, even in absence of the exogenous cross-linking agents that are essential for their activity in vitro. These results support the existence of an endogenous oligomerization mechanism, which based on in vitro and in vivo experiments are independent of both the antibody-dependent cell-mediated cytotoxicity and the complement-dependent cytotoxicity (139,162). Remarkable discrepancies have been found between DR4 and DRS requirement for ligand-induced aggregation. DRS only responded to membrane-bound or cross-linked soluble flag-tagged TRAIL, whereas soluble flag-tagged TRAIL (sTRAIL) was sufficient to induce DR4-mediated apoptosis (163,164). Not all TRAIL preparations require aggregation to activate DRS since rhTRAIL can stimulate this receptor without cross-linking (125,165). However, the results obtained with sTRAIL suggest that ligand aggregation is more important for DRS than for DR4. It is noteworthy that the potency of sTRAIL, anti-DR4 and anti-DRS antibodies was enhanced upon ligand pre-aggregation, which indicates that aggregation can be beneficial to signaling via both DR4 and DRS (163). The superior 30 
Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer importance of ligand cross-linking for DRS compared to DR4 was further demonstrated with anti-TRAIL death receptor agonistic antibodies. Apoptotic signaling could only be initiated by cross-linked anti-DRS antibodies in CLL cells, whereas anti-DR4 antibodies induced apoptosis in absence of cross-linking. Accordingly, TRAIL-induced apoptosis signaling was predominantly mediated by DR4 in these cells (166). It is remarkable that HGS-1R2J, an anti-DRS agonistic antibody, induced apoptosis in absence of cross­linking (direct agonist) and was more efficient than its cross-linking-dependent agonist counterpart HGS-E1R2 in a xenograft model. This indicates that binding to specific sites in the extracellular domain of DRS can induce sufficient aggregation (167). Unfortunately, no clinical trials have been reported for HGS-TR2J (http://clinicaltrials.gov/ct2/home). Finally, the possibility that excessive aggregation might enhance toxicity in normal cells should be further evaluated in order to design optimal therapeutics. His-tagged and flag-tagged TRAIL, crosslinked or not with an antibody, tend to aggregate as opposed to non-tagged soluble trimeric forms such as LZ- or rh-TRAIL. The presence of aggregates that would induce excessive aggregation of DR4 and DRS could explain the toxicity of these tagged forms of TRAIL toward normal cell types as opposed to stable TRAIL trimers (25,165,168). In addition to the epitopes recognized by the anti-DR4 or anti-DRS antibodies, studies have shown that the antibody isotypes should also be taken into account in vivo. Because of the strong aggregating properties of these isotypes, IgM and IgG3 antibodies raised against CD9S exhibited liver toxicity (13). Murine IgG2a isotype antibodies have been reported to be more potent than murine IgGl isotype antibodies for inducing complement-dependent death receptor oligomerization in vivo (169). Although both murine anti-DR4 isotypes exhibit similar apoptosis induction in vitro, mouse IgGl anti-human DR4 antibodies are unexpectedly more effective in human xenograft mouse models than the IgG2 variants 
(162). Altogether, these findings highlight the need for further studies on the contribution of the immune response to the potency of the various isotypes targeting the same TRAIL death receptor in vivo. Although aggregation of the TRAIL death receptors can be induced via ligand binding, various drugs have also been shown to stimulate receptor aggregation. The bile acid glycochenodeoxycholic acid (GCDCA) increased DRS expression and aggregation in a punctuated pattern in a hepatocellular cancer cell line but this was not seen for DR4. These changes were associated with an increase in TRAIL sensitivity (170). Similarly, LY303Sll, an inactive analogue of the phosphoinositide-3 kinase (PI3K) inhibitor LY294002, induced ligand-independent oligomerization of DRS in high molecular weight DRS complexes (200-400 kDa) and stimulated TRAIL-induced apoptosis. Imaging by confocal microscopy showed a more patchy distribution of DRS in LY303511-treated cells, which was coupled to higher FADD and caspase 8 recruitment at the DISC (171). 
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2 I Lipid raft localization stimulates TRAIL death receptor aggregation The presence of TRAIL death receptors in lipid rafts on the cell membrane constitutes another essential mechanism for efficient TRAIL signaling. The term "lipid rafts" typically refers to insoluble detergent (often Triton X-100)-resistant membrane domains rich in sphingomyelin, sphingolipids and cholesterol (172-174). Proteins involved in various cellular signaling pathways, notably Src kinases, have been shown to distinctively associate with these lipid rafts, facilitating signal modulation (172,175). Numerous studies performed over the past 10 years have indicated that translocation of CD9S into lipid rafts is very important for its ligand sensitivity since it promotes receptor clustering and aggregation (176). Recent evidence now indicates that membrane rafts also play a crucial role in the regulation of TRAIL-induced cell death. TRAIL, alone or in combination with several chemotherapeutic agents, stimulates DISC formation by relocating DISC proteins into lipid rafts (Table 3). Most studies have shown that lipid raft disruption leads to a loss of the sensitizing effects of these chemotherapeutic drugs, or to a general loss of TRAIL sensitivity. Work by Song et al. revealed that DISC formation could also take place in non-raft fractions. However, the importance of the lipid rafts for effective TRAIL death receptor signaling was highlighted by the fact that their disruption with methyl-�-cyclodextrin (M�CD) inhibited both caspase 8 cleavage and TRAIL-induced cell death in TRAIL-sensitive cells. Furthermore, in TRAIL-resistant NSCLC cells, TRAIL failed to recruit caspase 8 and FADD into lipid rafts, suggesting that lipid raft localization correlates with functional DISC formation (75). Although the molecular mechanisms behind TRAIL death receptor clustering into lipid rafts are not yet entirely clear, an intricate signaling cascade has already been established (see Figure 1). TRAIL stimulates accumulation of arachidonic acid by inducing release of reactive oxygen species (ROS) (186). This event induces translocation of acid sphingomyelinase (ASM) to the plasma membrane and activation of this enzyme, leading to ceramide production. Ceramide-rich caveolae are subsequently formed within the outer leaflet of the plasma membrane (183,186). These membrane domains promote DRS clustering and thereby enhance TRAIL sensitivity (183,186). Transient release of ceramide and clustering of DRS were seen in different types of ASM-positive cells, including cancer cells but not in ASM-negative splenocytes (186). The importance of this initial redox mechanism is supported by the fact that its inhibition by antioxidants such as N-acetylcysteine or Tiron blocks both ASM activation and TRAIL-induced apoptosis (186). Cyclooxygenase-2 (COX-2), which uses acid arachidonic as a substrate, prevents arachidonic acid accumulation, activation of ASM and TRAIL-induced apoptosis. Downregulation of COX-2 or addition of exogenous C16-ceramide can recapitulate these sensitizing effects, while inhibition of ASM with imipramine or lipid raft destruction with M�CD abolishes DRS clustering in ceramide-rich domains (183). These findings underscore the importance of ASM-dependent lipid raft formation for TRAIL sensitivity. 
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer Table 3 I TRAIL receptors and lipid rafts. Agents promoting DR4/DR5 lipid rafts localization Edelfosine, perifosine Doxorubicin Resveratrol Depsipeptide rhTRAIL, cisplatin Apo-2L/IRAIL + TRAIL enhancer ( crosslinker) Quercetin DuP-697, acid arachidonic Roscovitine, TRAIL Oxaliplatin Agent inhibiting DR4/DR5 lipid raft localization DISC proteins recruited to the lipid raft fraction Lipid raft Cell type Reference muker MCD, filipin DR4/DRS, FADD, caspase 8 GMl Multiple myeloma (177) DRS Ceramide Lymphoma (178) nystatin nystatin M�CD n.d. nystatin M�CD, imipramine cells, T splenocytes DR4/DRS, caspase 8, Caveolin-2 Colon FADD cancer DR4/DRS Lek Prostate cancer DR4/DRS, FADD, Caveolin-1 NSCLC caspase 8 DRS, caspase 8 Caveolin-1 Glioma DR4/DRS, FADD, Caveolin-1 Colon caspase 8 cancer DR4/DRS, FADD, Ceramide, Colon caspase 8 caveolin-1, cancer flotilin M�CD, DRS, FADD, caspase n.d. Breast imipramine 8 cancer nystatin DR4/DRS Ceramide Ga.smc cancer (179) (180) (75) (181) (182) (183) (184) (185) 
Legends: not determined (n.d.), nystatin (cholesterol-sequestering agent), depsipeptide (FR901228, HDAC inhibitor), methyl-cyclodextrin (MCD, cholesterol-depleting agent), methyl-!3-cyclodextrin {Ml3CD, cholesterol-depleting agent), filipin (cholesterol-sequestering agent), edelfosine and perifosine (synthetic alkyl-lysophospholipids), ganglioside (GMl), imipram.ine (acid sphingomyelinase inhibitor). Martin et al. raised the possibility that type I and type II cells might have different lipid raft localization patterns. In type I cells, DRS and the DISC components were pre-existent within lipid rafts at the plasma membrane. In type II cells, pre-incubation with DuP697 was required for these proteins to colocalize. Interestingly, it was shown in glioma cell lines that TRAIL-induced translocation of DR4 or DRS concomitantly stimulates TNF-Rl and CD9S translocation into lipid rafts, suggesting a possible cross-modulation of these receptors (181). 
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Upon binding of TRAIL to its TRAIL death receptors, little pro-apoptotic DISCs are formed. However, a 
rapid release of ROS causes arachidonic acid accumulation, which itself induces translocation of ASM to 
the plasma membrane and stimulates ASM activity. This leads to the production of sphingolipid ceramide 
in the outer leaflet of the cell membrane, initiating formation of ceramide-rich caveolae. These membrane 
structures, also called lipid rafts, promote aggregation of the TRAIL receptors. TRAIL death receptor 
aggregation within lipid rafts induces more efficient DISC formation, caspase cleavage and higher levels 
of apoptosis. Antioxidants such as N-acetylcysteine and Tiron can inhibit ROS production and lipid rafts 
formation. COX-2, by inhibiting the accumulation of arachidonic acid, inhibits acid sphingomyelinase activity 
as well as consequent TRAIL receptors aggregation in lipid rafts and apoptosis. TRAIL receptor aggregation 
and apoptosis can also be inhibited by imipramine, an ASM inhibitor. Lipid rafts can be disrupted by the 
cholesterol depleting agent �-MCD. Conversely, inhibition of COX-2 or addition of exogenous C16-ceramide 
stimulates TRAIL-induced apoptosis. Drug-induced lipid raft localization of TRAIL death receptors may not always contribute to the observed TRAIL sensitization. In breast cancer cells, the cyclin-dependent kinase 2 inhibitor roscovitine increased the amounts of procaspase 8, FADD and DRS in the lipid raft fraction, DISC formation was enhanced, and cells were sensitized to TRAIL. However, lipid raft localization did not seem to contribute to the sensitizing effect of roscovitine as 
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neither the cholesterol disrupting agent M�CD nor the ASM inhibitor imipramine were 
able to protect cells from the TRAIL-sensitizing effect of roscovitine (184). Importantly, 
predominant localization of DR4 or DRS outside of lipid rafts can induce pro-survival 
signals, thereby adding even more complexity. In 1RAIL-resistant NSCLC cell lines, 
TRAIL treatment only resulted in activation of the nuclear factor-kB and the extracellular 
signal-regulated kinase 1/2 (ERKl/2) survival pathways. In these 1RAIL-resistant cells, 
DR4 and DRS were primarily located outside of the raft fractions. Recruitment of Receptor­
interacting protein (RIP) and FLIP at the DISC played a crucial role in both DISC assembly 
in the non-raft fraction and downstream stimulation of the survival pathways (75). 
Interestingly, although extensive data have been collected on the relation between lipid 
raft localization of TRAIL death receptors and apoptotic signal transduction, little is known 
about the recruitment of 1RAIL decoy receptors to the lipid rafts, and its consequences 
for apoptosis. In various cell types, including cancer cells, DcRl and DcR2 were mostly 
found in lipid rafts, where they competitively inhibited 1RAIL binding to the 1RAIL 
death receptors and consequently decreased 1RAIL sensitivity (32). The influence of the 
lipid rafts on this decoupling effect of 1RAIL decoy receptors has yet to be evaluated in a 
non-overexpression model. Future experiments are needed to determine whether 1RAIL 
sensitizers directing DR4 and DRS to membrane rafts also have stimulating effects on DcRl 
and DcR2, which could at the same time dampen the pro-apoptotic effects of these drugs. 
If so, DR4- or DRS-specific agonists might potentially circumvent this problem. 
TRAIL death receptor localization seems to be regulated in a receptor-specific and cell­
specific manner. Many studies have focused on DRS, and have shown that signaling via 
this receptor depends on lipid raft localization. Type I cells, characterized by efficient DISC 
formation, tend to show more frequent 1RAIL death receptor co-localization within lipid 
rafts than type II cells. Many cytotoxic agents that enhance TRAIL sensitivity stimulate 
the recruitment of DISC proteins to membrane rafts. It is noteworthy that within this new 
research field, the markers used to define membrane rafts often differ between studies. 
Results obtained following lipid raft isolation may depend largely on the type and 
concentrations of detergent used to extract the lipidic detergent-resistant fractions (187). 
Considering the exciting discoveries made during the last few years, further studies on the 
relationship between DISC formation, lipid rafts and the kinases found in these rafts are 
warranted. Upcoming studies should now greatly benefit from recent efforts to establish 
a consensus definition for these membrane rafts, for instance assessed by the Keystone 
symposium on lipid rafts and cell function (188). 
3 I Receptor internalization hampers TRAIL death receptor-mediated apoptosis 
Receptor internalization plays a crucial role in TNF family member receptor signaling 
since this event is required for both TNF-Rl- and CD9S-mediated apoptotic signalling 
(189,190). Studies on the importance of TRAIL death receptor internalization have also been 35 2 -
Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer performed, with contrasting conclusions compared to TNF-Rl and CD9S. TRAIL death receptor internalization, which was shown to be clathrin-dependent, does not seem to be necessary for TRAIL-induced apoptosis (191). In fact, caspase 8 cleavage was slightly enhanced when 1RAIL death receptor internalization was blocked (191,192). TRAIL death receptor stimulation was found to disrupt the endocytosis machinery, possibly amplifying caspase cleavage at the DISC (191). In addition, it has been suggested that clathrin­independent mechanisms may also participate in TRAIL death receptor internalization 
(192). These substantial discrepancies between CD9S ( or TNF-Rl) and TRAIL death receptor internalization are intriguing, and constitute one of the most striking differences between these pathways. In addition to TRAIL-induced internalization, TRAIL death receptors can also undergo constitutive endocytosis as part of a desensitizing mechanism, in leukemia as well as colon and breast cancer cells (98,100,193). This downregulation of the 1RAIL death receptor was clathrin-dependent. Both TRAIL death receptor expression and TRAIL sensitivity could be restored by a general endocytosis inhibitor, phenylarsine oxide (PAO), by an inhibitor of clathrin-mediated apoptosis, chlorpromazine, and by specific gene silencing of either adaptator protein 2 or clathrin (100). DR4 was found to be internalized at a higher frequency than DRS despite similar mRNA and protein levels, which suggests an important role for DR4 endocytosis in 1RAIL resistance (98,100,193). K I Post-translational modifications of the DISC components While the contribution of TRAIL death receptor upregulation to TRAIL sensitivity enhancement in response to chemotherapeutic drugs is still debated, it is clear that the caspase 8/FLIP ratio is one of the key factors influencing TRAIL sensitivity. Now, numerous post-translational modifications of the DISC proteins are also emerging as important mechanisms regulating TRAIL sensitivity in cancer cells (see Figure 2 and 3). 
1 I TRAIL death receptor O-glycosylation facilitates receptor aggregation In connection with TRAIL death receptor aggregation, post-translational modifications of DR4 and DRS such as receptor glycosylation have been shown to affect TRAIL signaling, thereby affecting TRAIL sensitivity (see Figure 2). 0-linked glycosylation involves the binding of glycosyl groups to serine and threonine side chains that can improve ligand binding and membrane protein activation (194). Wagner et al. nicely demonstrated that specific 0-glycosyltransferases were overexpressed in cancer tissue as compared to normal tissue and that their expression correlated with TRAIL sensitivity (38). Expression of the 0-glycosylation initiating enzyme GALNT14 was correlated with TRAIL sensitivity in pancreatic carcinoma, NSCLC cells and melanoma cells. In colon carcinoma, expression of GALNT3 and of the 0-glycan-processing enzymes FUT 3 and FUT 6 correlated with TRAIL sensitivity. Inhibition of 0-glycosylation enzymes by benzyl-a-G alNAc decreased TRAIL-
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer induced apoptosis. SiRNA against GALNT14, GALNT3, FUT3, and FUT6 also reduced TRAIL sensitivity while overexpression of GALNT14 increased DISC formation and sensitized cells to TRAIL. Mass spectrometry of the extracellular domain of DRS indicated that DRS could be a direct target of GALNT14. It was suggested that O-glycosylation modulates TRAIL sensitivity by inducing TRAIL death receptor aggregation, thereby promoting DISC formation and caspase 8 activation (38). 











DR4 j \ DR4/DR5 � DRS 
Figure 2 I The "good" DISC. Several events contribute to optimal caspase 8 cleavage at the DISC. In TRAIL-sensitive cells, TRAIL receptor­specific agonists bind to their cognate TRAIL receptor trimers, inducing their aggregation in lipid rafts. In this figure, DR4 and DRS specifically designate homotrimers, while DR4/DR5 refers to either type of trimer, including possible heterotrimers. Modified forms of the TRAIL death receptors such as O-glycosylated TRAIL death receptors, S-nitrosylated DR4 or S-palmitoylated DR4 are more prone to aggregation and initiation of DISC formation. The SRP protein complex is involved in stabilizing DR4 at the cell membrane, which increases its sensitivity to DR4-specific agonists. Upon TRAIL death receptor stimulation, FADD is recruited to the TRAIL death receptor trimers, leading to caspase 8 recruitment and its cleavage into an active pl8 cytoplasmic fragment. DISC formation and stability can be increased by IG20pa binding, PKG'>­or ROCK-dependent signals, thereby increasing caspase 8 processing. Caspase 8 cleavage is also enhanced by CUL3- and RBX-1-dependent polyubiquination of caspase 8, which allows p62 binding, triggering both caspase 8 aggregation and auto-proteolytic cleavage of this protein. 
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Figure 3 I The ilbad" DISC. 
Efficient DISC formation can be inhibited by numerous mechanisms in TRAIL-resistant cells. The soluble 
receptor to TRAIL (OPG) or the membrane DcRl/DcR2 can prevent TRAIL binding to the TRAIL death 
receptors and/ or formation of pro-apoptotic membrane complexes ("Good" DISCs). DcR2 notably forms 
heterotrirners with DRS. DRS can be directly ubiquitinated and targeted to the proteasome for degradation. 
Some mutations found in the TRAIL death receptors hamper efficient TRAIL binding or FADD recruitment. 
DISC formation is less efficient in absence of TRAIL death receptor recruitment to the lipid rafts. If, however, 
DISC formation is to take place outside of the lipid rafts, non-functional complexes ("Bad" DISCs) are formed 
and stimulate pro-survival pathways. FADD recruitment to the TRAIL death receptor can be inhibited by 
PKC-, ERKl/2- and CK-dependent signals. Several proteins and proteins complexes can be recruited to the 
DISC, preventing caspase 8 cleavage and/or stimulating pro-survival pathways. The list of such proteins and 
protein complexes includes FLIP, RIP, PED/PEA-15 and the TRAIL death receptor-capping DDX3/clAP-1/ 
GSK-3 complex. Recruitment to FADD of PED/PEA-15 is positively regulated by its double-phosphorylation, 
under the influence of Akt, CAMK2 and PKC signaling. MADD binds to the TRAIL death receptor and 
prevents auto-proteolytic cleavage of caspase 8. Phosphorylation of caspase 8 by Src kinase also prevents its 
cleavage at the DISC. CARPs, namely CARPI and CARP2, are ubiquitin-ligase proteins that promote caspase 
8/10 ubiquitination and block proteolytic processing of these caspases. Conversely, A20 binds caspase 8, 
thereby preventing its pro-apoptotic polyubiquitination by CUL3 and caspase 8 auto-proteolytic processing. 2 I DR4 S-nitrosylation stimulates caspase 8 cleavage 
S-nitrosylation refers to the covalent binding of a nitrogen monoxide group to a reactive 
thiol cysteine. This emerging post-translational protein modification regulates a wide range 
of signal transduction mechanisms, including apoptosis (195). DR4 but not DRS was found 
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer to be S-nitrosylated following treatment with the nitric oxide- donor nitrosylcobalamin (NO-Cbl), a pro-drug based on vitamin B12 (see Figure 2). Site-directed mutagenesis identified the amino-acid 336 as the S-nitrosylated cysteine residue in DR4. Proliferation assays established that the DR4 C336A mutant was less sensitive to NO-Cbl or TRAIL than other point mutants or vector-transfected cells, and showed reduced caspase 8 activation following NO-Cbl treatment. Since endogenous DR4 S-nitrosylation was not detected in any of the three types of cancer cell lines tested, further experiments are needed to evaluate the extent of these findings in both normal and cancer cells (196). 
3 I S-palmitoylation of DR4 promotes its oligomerization The reversible attachment of a palmitate to a cysteine residue, a process also known as S-palmitoylation, can induce lipid raft localization of membrane receptors (197). Rossin et al. showed that DR4 was partially palmitoylated within a cysteine triplet near its transmembrane domain (see Figure 2). Palmitoylation of DR4 was required for its constitutive lipid raft localization and homo-oligomerization. In an overexpression system, only palmitoylated DR4 could hetero-oligomerize with DRS. DRS itself lacks the cystein triplet and accordingly was not found to be palmitoylated. Pre-treating cells with the palmitate analog 13-oxypalmitate or the cholesterol-depleting agent cholesterol oxydase hampered DR4 constitutive lipid raft localization, decreased TRAIL-induced DISC formation and subsequently inhibited apoptotic cell death. Stimulation of the intrinsic apoptotic pathway with staurosporine in combination with cholesterol oxydase did not induce cell death. This suggests that cholesterol oxydase specifically affects the extrinsic pathway of apoptosis. Site-directed mutagenesis from cysteine to serine confirmed the C261-3S cysteine triplet to be critical to TRAIL-induced caspase 8 cleavage (198). 
4 I Caspase 8 phosphorylation prevents its cleavage at the DISC Caspase 8 activity can be inhibited by phosphorylation of its tyrosine-380 by Src kinase (see Figure 3). TRAIL-resistant DLDl cells transfected with a plasmid coding for a non­phosphorylatable caspase 8 mutant were more sensitive to TRAIL than their counterparts transfected with the wt caspase 8 gene. In support of these findings, the Src inhibitor PP2 increased TRAIL-induced caspase 8 cleavage and apoptosis in several cell lines, independent of TRAIL death receptor upregulation (199). Importantly, the combination of TRAIL and PP2 was not toxic toward primary hepatocytes (200). Src levels are high in lipid rafts and these rafts have been shown to influence TRAIL death receptor aggregation and DISC formation. It remains to be tested whether Src kinase-dependent caspase 8 phosphorylation is increased in lipid rafts. 
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5 I FLIP phosphorylation lowers its affinity for the DISC In addition to caspase 8 phosphorylation, FLIP phosphorylation has also been described. The bile acid GCDCA did not affect protein expression of DISC components in hepatocellular cancer cells. However, pre-treatment with GCDCA increased caspase 8 and 10 recruitment at the TRAIL-DISC by phosphorylating both FLIP1 . and the short isoform (FLIPJ thereby lowering their affinity for FADD (see Figure 3). These effects could be prevented by the PKC inhibitor chelerythrine, suggesting an involvement of this pathway in regulating phosphorylation of the FLIP isoforms and their translocation to the TRAIL-DISC (201). Surprisingly, the authors did not discuss whether the increase in DISC formation could also be attributed to the higher clustering of DRS seen upon GCDCA treatment as reported in one of their earlier publications (170,201). 
6 I DISC protein ubiquitination differentially regulates DISC composition DRS can be ubiquitinated, and its stability increased, by the proteasome inhibitor bortezomib, leading to higher TRAIL sensitivity (202) (see Figure 2). Although both FLIP isoforms can be ubiquinated, FLIPs was shown to be more prone to ubiquitination than FLIP 1. and consequently exhibits a shorter half-life (203). Peroxisome-activated receptor y (PPAR-y) ligands and 2,5-dimethyl-celecoxib, a derivative of the COX-2 inhibitor celecoxib without COX-2 inhibitory activity, triggered ubiquitination of FLIP, induced degradation of both isoforms and sensitized various tumor cells to 1RAIL (204,205). The effects of the PPAR-y ligands seemed PPAR-y-independent (205). In a yeast two-hybrid screen, two caspase 8- and 10-associated RING proteins (CARPs) with E3 ubiquitin ligase activity were identified by McDonald and El-Deiry (206). CARPl and CARP2 interact with caspase 8 and 10 prodomains via their RING domain, which promotes their ubiquitination and subsequent proteasomal degradation. Downregulation of CARPl and CARP2 sensitized colon and lung cancer cells to TRAIL-induced apoptosis by increasing cleavage of caspase 8/10. It is noteworthy that CARP downregulation did not modulate the basal expression levels of caspase 8/10. CARPl and CARP2 were upregulated in various cancer cell lines, and in a number of primary tumors compared to normal tissue. In a recent publication, Jin et al. uncovered a novel mechanism of caspase 8 (but not caspase 10) polyubiquitination, with opposite consequences for apoptosis initiation (207). In 1RAIL-sensitive cells of various origins, TRAIL death receptor stimulation leads to DISC formation and translocation into lipid rafts, where a cullin-based E3 ligase (CUL3) interacted with caspase 8 and induced a ring-box 1 (RBXl)-dependent polyubiquination of caspase 8. The presence of polyubiquitin in the C-terminal region of caspase 8 triggered recruitment of the ubiquitin-binding protein p62, which targeted DISC caspase 8 to ubiquitin-rich foci. Aggregation of caspase 8 in these high molecular weight structures promoted auto-proteolytic cleavage and the release of active caspase 8 into the cytoplasm, leading to executioner caspases activation and ultimately apoptosis. Using tandem mass spectrometry on purified high molecular 
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weight DISC fractions, the authors also identified a caspase 8-bound deubiquitinase named 
A20, overexpression of which could prevent CUL3-induced caspase 8 ubiquitination and 
caspase 8 activity (see Figure 2). Caspase 8 ubiquitination thus appears to be a tightly 
regulated process involving several non-canonical DISC proteins. Downstream of the 
DISC in the TRAIL apoptotic pathway, Bcl-2 family proteins and executioner caspases are 
also regulated by ubiquitination (208,209). Altogether, changes in the balance between pro­
and anti-apoptotic factors may account for the potent effects of proteasome inhibition on 
DISC formation and TRAIL sensitivity. L I Influence of survival pathways on DISC formation 
Beyond their role in cell cycle regulation, metabolism and cell differentiation, survival 
pathways can modulate TRAIL death receptor-mediated apoptosis. Studies show that 
numerous survival pathways are stimulated by the TRAIL apoptotic pathway, potentially 
initiating feedback loop mechanisms (36,210). It is now clear that survival pathways can 
also directly influence the apical events of DISC formation (Figure 2 and 3). Since these 
signals are primarily mediated by kinases, the effects can occur without changing the 
cytoplasmic protein levels of DISC proteins (211-213). The frequent enrichment of kinases at 
the membrane, particularly within lipid rafts, supports the possibility that close proximity 
might facilitate modulation of TRAIL death receptor-mediated signaling by these kinases. 
1 I The pro- and anti-DISC effects of protein kinase C 
Protein kinase C (PKC) describes a group of 12 lipid-dependent serine/threonine (S/T) 
kinases that regulate growth and differentiation. Stimulating this pathway with the 
PKC activator phorbo 12,13-dibutyrate (PDBu) inhibited caspase 8 cleavage in response 
to TRAIL treatment in Jurkat cells. This decrease in TRAIL sensitivity was partly due to 
PKC-induced activation of the MAPK pathway (214). Meng et al. further demonstrated 
that caspase 8 cleavage was inhibited following treatment with the PKC activator phorbol 
12-myistate 13-acetate (PMA) in type II cell lines from different tumor types. This was 
caused by disruption of FADD recruitment at the DISC (215). Similar results were obtained 
in the cervical cancer cell line Hela, where PKC stimulation using PMA could prevent 
FADD recruitment to the TRAIL death receptors (216) (see Figure 3). This strongly indicates 
that PKC can exert inhibitory effects on DISC formation in several cell types. The unique 
phosphorylation site of FADD (Serine-194) has been shown to regulate its non-apoptotic 
functions (217). It is therefore unlikely that the increase in FADD recruitment at the DISC 
seen upon PKC stimulation is caused by a PKC-dependent phosphorylation of FADD itself. 
Studies specifically focusing on the b isoform of PKC have led to opposite discoveries 
regarding the regulation of DISC assembly by PKC. Sandra et al. showed that the b isoform 
of PKC could accelerate caspase 8 cleavage at the DISC following a positive feedback 
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer loop possibly involving the mitochondria. This feedback loop was initiated by a rapid production of diacylglycerol following TRAIL treatment, which induced activation of PKC b and its relocation to the mitochondria, in a caspase-independent manner (218). Although the precise mechanism between this activation of PKC b and the increase in caspase 8 cleavage is unknown, a Rho kinase (ROCK)-dependent contraction of myosin light chains has been shown to promote initiator caspases binding to FADD following PKC activation (219) (see Figure 2). A better knowledge of the properties of the different isoforms would facilitate the development of specific PKC inhibitors which would not inhibit both the anti­and pro-apoptotic forms. 
2 I The ERKl/2 signaling pathway inhibits caspase 8 cleavage The ERKl/2 or MAPK pathway is an important cell survival pathway involved in carcinogenesis. This pathway has also been shown to inhibit TRAIL sensitivity at the DISC (see Figure 3). Frankel et al. found that the cytoplasmic domain of DR4 but not DRS was constitutively phosphorylated by p42MAPKtERK2 in unstimulated peripheral blood lymphocytes (220). This suggests the possibility for a direct regulation of DR4 activity by the ERK pathway. In activated T-cells, the MAPK/ERK signaling abrogated TRAIL-induced apoptosis upstream of caspase 8 and the mitochondrial amplification feedback loop (221). Similarly, MAPK kinase 1 (MEKKl) inhibition in Hela cells enhanced TRAIL-induced apoptosis while expression of a constitutively active (CA) MEKKl could protect cells from TRAIL death receptor-mediated apoptosis. TRAIL-induced caspase 8 processing was inhibited in cells expressing CA-MEKKl. Interestingly, TRAIL death receptor stimulation induced ERKl/2 activation, which appeared 5 min after treatment and lasted for about 1 h, thereby suggesting the involvement of this pathway in a negative feedback loop at the DISC (222). 
3 I The anti-DISC effects of active CKia and CK2a Casein kinase I a. isoform (CKia) and protein kinase CK2a, formerly known as casein kinase 2 (CK2a.), are serine/threonine kinases which can modulate DISC formation (see Figure 2). In colon cancer and pediatric rhabdomyosarcoma cell lines, TRAIL sensitivity dramatically increased upon inhibition of CKI with CKI-7 or of CK2 with 5,6-dichlorobenizimidazole (DRB). Formation and stability of the TRAIL-DISC were increased following CKI inhibition, while CK2 inhibition with DRB increased both TRAIL-induced caspase 8 recruitment at the DISC and TRAIL-induced apoptosis (223-225). Caspase 8 cleavage can be enhanced following feedback activation from executioner caspases downstream of the mitochondria such as caspase 6 (226). Blockade of the mitochondrial amplification pathway using Bcl-2 or Bcl-xL overexpression did not hamper caspase 8 cleavage in presence of TRAIL together with CKI or CK2 inhibitors. This confirms that CKs can modulate caspase 8 cleavage at the DISC itself. Active casein kinases such as CKI might inhibit TRAIL-induced apoptosis 
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by phosphorylating the TRAIL death receptor, thereby blocking FADD recruitment at the 
DISC (223-225). M I DISC regulation by recruitment of additional proteins 
Beyond the DISC components discussed earlier in this review, several other non-canonical 
proteins have been found to interact with the DISC at the membrane, where they either 
positively or negatively influence efficient DISC formation, caspase 8 cleavage and 
consequent apoptosis. A schematic representation of the recruitment of these pro- and anti­
apoptotic proteins to the DISC is given in Figure 2 and 3, respectively and the mechanisms 
are discussed more extensively below. 
1 I PED/PEA-15 blocks caspase 8 cleavage at the DISC 
Phosphoprotein enriched in diabetes/ phosphoprotein enriched in astrocytoma-15 kDa 
(PED/PEA-15) belongs to the category of non-canonical DISC proteins. Like FADD, FLIP 
and caspase 8, PED/PEA-15 possesses a death effector domain but no caspase-like domain. 
Hao et al. showed that PED/PEA-15 expression was about two times higher in TRAIL­
resistant compared to TRAIL-sensitive glioma cell lines (227). PED/PEA-15 was not found 
in the TRAIL-DISC of three TRAIL-resistant primary gliomas (77). Overexpression of 
PED/PEA-15 in TRAIL-sensitive glioma cell lines blocked the TRAIL apoptotic pathway 
while a PED/PEA-15 anti-sense approach restored TRAIL sensitivity in TRAIL-resistant 
gliomas (227). PED/PEA-15 exists in three isoforms, namely an unphosphorylated, a singly­
phosphorylated and a doubly-phosphorylated form. Calcium/calmodulin-dependent 
protein kinase II (CaMK2) or Akt phosphorylate PED/PEA-15 at serine-116 (228-230), thereby 
facilitating the second phosphorylation at serine-104 by PKC (231,232). Only the double 
phosphorylated form, present exclusively in TRAIL-resistant glioma cells, was found to 
be recruited to the TRAIL-DISC where it blocked caspase 8 activation (230) (see Figure 
3). Inhibition of CaMK2 with the broad-spectrum CaMK inhibitor KN-93 decreased PED/ 
PEA-15 phosphorylation, thereby restoring caspase 8 cleavage and apoptosis in gliomas 
(230). Inhibition of Akt or PKC also hindered PED/PEA-15 phosphorylation, its recruitment 
at the DISC and restored TRAIL sensitivity in glioma cell lines (227,229). These results are 
consistent with the role of PED/PEA-15 as a common target for multiple survival pathways, 
allowing these pathways to modulate TRAIL-induced apoptosis directly at the DISC. 
2 I Blockade of DISC formation by the DDX3/GSK3/cIAP-1 capping complex 
Li et al. described a novel protein specifically involved in acquired resistance to TRA-8, an 
agonistic anti-DRS antibody. DDX3, a member of the DEAD-box RNA helicase family, was 
endogenously associated with DRS. Upon stimulation of the TRAIL-sensitive breast cancer 
cell line MDA-MB-231 with TRA-8, DDX3 was cleaved and an active DISC was formed. 
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Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer In the TRA-8-resistant daughter cell line, the TRA-8 antibody failed to induce cleavage of DDX3. FADD and caspase 8 were not recruited to DRS, suggesting a role for DDX3 in inhibiting this process. Resistance to the anti-DRS antibody could be reversed by several chemotherapeutic agents, including doxorubicin, which restored FADD recruitment and cleavage of both DDX3 and caspase 8 (233). DDX3, together with GSK3 and cIAP-1, formed a capping complex at the DISC that counteracted TRAIL death receptor-mediated apoptosis (see Figure 3). Additionally, DDX3 and cIAP-1 were also recruited to the DISC in both sensitive and resistant cells following TRAIL death receptor stimulation but cleavage and inactivation of this capping complex was only induced in TRAIL-sensitive cells. In various cell lines, inhibition of GSK3 with compounds such as lithium was found to promote TRAIL death receptor-mediated apoptosis by increasing DISC formation (234). Altogether, these findings are particularly relevant in view of the numerous GSK3 inhibitors and IAP small molecule antagonists that are currently in clinical development (209,235). 3 I The pro- and anti-DISC properties of the various IG20 gene family isoforms The insulinoma-glucagonoma clone 20 (IG20) gene is frequently overexpressed in cancer and encodes several splice variants with various effects on cell proliferation and drug sensitivity (236). The IG20 pro-apoptotic (IG20pa) splice variant was shown to directly interact with both DR4 and DRS (237) but not with FADD (238) (see Figure 2) . Cancer cells transfected with IG20pa displayed a higher recruitment of FADD and caspase 8 to DR4 and DRS in response to TRAIL treatment, and were also more sensitive to this ligand (237,239). The precise mechanism behind this DISC-enhancing effect is unknown, but IG20pa is most likely recruited to the TRAIL death receptors via its C-terminal 70 amino-acid death domain homology region (237). Unlike the IG20pa variant, the MAPK-activating death domain protein (MADD) splice variant of IG20 is a negative regulator of caspase 8 activation at the DISC (see Figure 3). Downregulation of endogenous MADD alone resulted in spontaneous apoptosis via ligand­independent caspase 8 cleavage at the DISC, and also increased TRAIL sensitivity. MADD binds to the TRAIL death receptors but not to FADD or caspase 8 itself, and although it does not prevent DISC assembly, MADD inhibits caspase 8 cleavage at the DISC (240,241). In Kaposi's sarcoma cells, MADD could be downregulated with the antineoplastic drug and TRAIL sensitizer actinomycin D (242,243). These results further confirm that versatile mechanisms regulate TRAIL sensitivity at the DISC itself. 4 I Regulation of cell membrane DR4 levels by the signal recognition particle complex In search for proteins differentially regulating DR4- and DRS-mediated apoptosis in cancer cells, Ren et al. tested an arrayed library of siRNAs in combination with DR4- or DRS-specific antibodies, in HCTlS colon cancer cells (244). Several proteins were identified as pro- and anti-apoptotic for DR4- and/or DRS-mediated signaling. The authors found 44 
Chapter 2 I Turing on TRAIL death receptor apoptosis in cancer that expression of the signal recognition particle (SRP) complex was essential for DR4-mediated sensitivity (see Figure 2). Downregulation of the 54-kDa or 72-kDa (SRP54 or SRP72) subunits of the SRP complex decreased cell sensitivity to TRAIL and to anti-DR4 antibody, but not to anti-DRS antibody. Effects of SRP54 or SRP72 siRNAs on TRAIL sensitivity were also seen in cervical and pancreatic cell lines. The SRP complex is notably involved in the sorting process of nascent membrane proteins (245,246), which can be linked to the finding that cell membrane DR4 levels decreased upon inhibition of SRP54 or SRP72 expression (244). In addition to the studies on DR4 epigenetic silencing and endocytosis mentioned earlier in this review, these results support the hypothesis that cell membrane DR4 downregulation contributes to TRAIL resistance. N I Conclusions So far, much focus has been placed on finding ways to modulate pro- and anti-apoptotic protein expression to enhance TRAIL-induced apoptosis. The efficacy of such combinations in vitro and in xenograft models is unquestionable, and preliminary clinical data are encouraging. However, to fully exploit the apoptotic effect of any such combination treatment, there should be more insight in the mechanisms regulating TRAIL sensitization, DISC formation and caspase 8 activation. In view of the vast range of potential targets offered and rapidly accumulating data, the use of post-translational approaches to regulate the TRAIL-induced apoptotic cascade is also suggested. Furthermore, although DR4 and DRS agonists both transduce apoptosis, extensive data suggests that DR4- and DRS­mediated signaling cascades are fine-tuned by different mechanisms. Even more so than TRAIL, receptor-selective agonists such as anti-DR4 or anti-DRS antibodies or receptor­specific TRAIL variants are targeted therapies that necessitate screening for the presence of functional TRAIL death receptor in addition to screening for other DISC components. Elucidating potential DR4- or DRS-specific effects of novel and existing chemotherapies will be crucial to fully exploit the clinical potential of these TRAIL death receptor-selective agonists. In the meantime, the best strategy may be to combine these chemotherapies with dual targeting of both DR4 and DRS, using either TRAIL or a combination of DR4- plus DRS-selective agonists. Acknowledgements Supported by grants RUG 2005-3361, RUG 2005-3365 and VU 2006-3567 from the Dutch Cancer Society, the EU FP6 program LSHC-CT-2006-037686 and TI Pharma T3.112 45 
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Abstract 
Drug resistance is a major problem in ovarian cancer. Triggering apoptosis using death 
ligands such as tumor necrosis factor related apoptosis inducing ligand (TRAIL) might 
overcome chemoresistance. We investigated whether acquired cisplatin resistance affects 
sensitivity to recombinant human (rh) TRAIL alone or in combination with cisplatin in an 
ovarian cancer cell line model consisting of A2780 and its cisplatin-resistant subline CP70. 
Combining cisplatin and rhTRAIL strongly enhanced apoptosis in both cell lines. CP70 
expressed less caspase 8 protein, while mRNA levels were similar compared to A2780. Pre­
exposure of particularly CP70 to cisplatin resulted in strongly elevated caspase 8 protein and 
mRNA levels. Caspase 8 mRNA turnover and protein stability in the presence or absence 
of cisplatin did not differ between both cell lines. Cisplatin-induced caspase 8 protein levels 
were essential for the rhTRAIL-sensitizing effect as demonstrated using caspase 8 siRNA 
and caspase-8 overexpressing constructs. c-FLIP and p53 siRNA experiments showed that 
neither an altered caspase 8/c-FLIP ratio nor a p53-dependent increase in DRS membrane 
expression following cisplatin were involved in rhTRAIL sensitization. In conclusion, 
cisplatin enhances rhTRAIL-induced apoptosis in cisplatin resistant ovarian cancer cells 
and induction of caspase 8 protein expression is the key driver of rhTRAIL sensitization. 
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Chapter 3 I Drug-induced caspase 8 upregulation Introduction In ovarian cancer, the majority of tumors acquire drug resistance. Response rates to first­line platinum-based therapy are more than 80%, but most patients with advanced disease will finally relapse and die because of acquired drug resistance (1). Chemoresistance is attributed to numerous mechanisms, which can be broadly divided into decreased DNA damage response via p53 and increased cell survival, mainly through defects in apoptosis 
(2). A meta-analysis showed that aberrant p53 status results in a worse 5 year survival for ovarian cancer patients (3). Triggering apoptosis directly via the extrinsic apoptotic pathway might circumvent escape mechanisms developed by cancer cells. Especially the recombinant human (rh) form of the death ligand tumor necrosis factor related apoptosis inducing ligand (TRAIL) is considered to be interesting for clinical use because of its ability to induce apoptosis in several types of cancer cell lines and xenografts (4-6). Preliminary data from a phase I trial with rhTRAIL showed no major toxicity (7). TRAIL induces apoptosis by binding to death receptor 4 (DR4) and DRS (6). Binding to these DRs causes receptor trimerization and recruitment of the adaptor protein Fas associated death domain (FADD). This in tum recruits caspase 8, resulting in the formation of the death inducing signaling complex (DISC) (8). Binding of caspase 8 to the DISC causes its activation (9), with subsequent activation of effector caspases 3, 6 and 7, which will execute apoptosis. The cellular FLICE-inhibitory protein (c-FLIP), which is vastly homologous to caspase 8 but lacks enzymatic activity, can also associate with the DISC, blocking activation of caspase 8 through competition for binding sites. It has also been stated that c-FLIP may act as an activator of caspase 8 under specific circumstances (10,11). In addition, the intrinsic apoptotic pathway can be activated by caspase 8 through cleavage of the BH3-only protein Bid that triggers perturbation of the mitochondria by Bax and Bak and finally activation of caspase 9 and effector caspases (12). Numerous studies have demonstrated that drug resistance in cancer cells including ovarian cancer cells, could be prevented or overcome by combining rhTRAIL with chemotherapeutics (13). In a previous study, we showed that cisplatin can sensitize ovarian cancer cells to rhTRAIL-induced apoptosis in vitro as well as in a bioluminescent ovarian cancer xenograft model (14). The described mechanisms involved in modulation in ovarian cancer cells were established by comparison of cell lines with different background and sensitivity-patterns, which impede establishment of causal relationships. Therefore, we investigated in an isogenic model of cisplatin resistance the molecular determinants for rhTRAIL sensitivity, the mechanism of synergy between cisplatin and rhTRAIL and the role of functional p53 in this synergy. 
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Chapter 3 I Drug-induced caspase 8 upregulation Materials and Methods 
Cell lines The ovarian cancer cell lines A2780 and its 5-fold cisplatin resistant subline CP70, which carry wild type and functional p53, were a kind gift from Dr Hamilton (Fox Chase Cancer Center, Philadelphia, USA) (15). Cisplatin resistance in CP70 can partly be explained by an increased DNA repair mechanism and a higher intracellular glutathione content 
(16). Cells grew as monolayers in RPMI 1640 (Life Technologies Breda, the Netherlands), supplemented with 10% heat inactivated foetal calf serum (FCS) (Bodinco BV, Alkmaar, the Netherlands) and 0.lM L-glutamine. Cell lines were cultured in a humidified atmosphere with 5% CO2• 
Cytotoxicity assay The microculture tetrazolium assay was used to measure cytotoxicity as described earlier 
(14). Treatment consisted of continuous incubation with cisplatin (Pharmacochemie BV, Haarlem, the Netherlands) or rhTRAIL (produced as described earlier (17)) for 96 h. The mean ICS0 +/- standard deviation was determined in three experiments each performed in quadruplicate. 
Determination of apoptosis In 96-well plates cells were incubated with either rhTRAIL, cisplatin or both. The cells were exposed to cisplatin for 4 h, washed with phosphate buffered saline (PBS: 6.4 mM Na2HPO4; 1.5 mM KH2PO4; 0.14 mM NaCl; 2.7 mM KCI; pH=7.2) twice and incubated in regular culture medium. 20 h after administration of cisplatin, rhTRAIL was added for 4 h. Following rhTRAIL treatment, nuclear chromatin was stained with acridine orange to identify apoptosis by fluorescence microscopy. 
SDS-polyacrylamide gel electrophoresis and Western blotting Cells were treated with rhTRAIL and/or cisplatin as described above. Treatment with the proteasome inhibitor MG132 (Calbiochem, the Netherlands) (0.5 µM) lasted 24 h and rhTRAIL was added for the last 4 h. The caspase inhibitor I (zVAD) (Calbiochem, the Netherlands) was added 2 h before MG132. Cycloheximide (CHX) (Sigma-Aldrich, Zwijndrecht, the Netherlands) exposure was performed as indicated. After treatment, total cell lysates were generated and Western blotting was performed as described previously 
(14), using the following primary antibodies: FADD- and XIAP (Transduction Laboratories, Alphen a/d Rijn, the Netherlands), Bax, Bak, Bcl-2, -Bcl-X51L and p53-DO-1 (Santa Cruz, Heerhugowaard, the Netherlands), caspase 9 and Cipl/Wafl (p21) (BD Biosciences, Alphen a/d Rijn, the Netherlands), caspase 8 and cleaved caspase 3 (Cell Signaling, Leusden, the Netherlands) .  The Bid- and FLIP NF6 antibodies were kindly provided by Dr J Borst (the Netherlands Cancer Institute, Amsterdam, the Netherlands) and Dr ME Peter (The 
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Chapter 3 I Drug-induced caspase 8 upregulation Ben May Institute for Cancer Research, Chicago, IL) respectively. Secondary antibodies conjugated with horseradish peroxidase were obtained from DAKO (Glostrup, Denmark). Equal protein loading was confirmed by �-actin (ICN Pharmaceuticals, Zoetermeer, the Netherlands). Visualization was performed with BM Chemiluminescence Blotting Substrate (POD) or LumiLight Plus Western Blotting Substrate (Roche Diagnostics, Almere, the Netherlands). 
Flow cytometry Cells were harvested using trypsin and washed once with cold PBS. Cells were subsequently washed twice with cold PBS containing 2% FCS and 0.1 % sodium azide and incubated with phycoerythrin (PE)-conjugated mouse monoclonal antibodies against DR4, DRS, decoy receptor 1 (DcRl) and DcR2. Mouse PE-labelled IgGl and IgG2B were used as isotype controls. All PE-labeled antibodies were purchased from R&D Systems (Oxon, UK). Receptor membrane expression was analyzed using a flow cytometer (Epics Elite, Coulter-Electronics) and is shown as mean fluorescent intensity (MFI) of all analyzed cells. 
RNA interference and gene transfection Small interfering RNAs (siRNAs) were synthesized by Eurogentec (Seraing, Belgium). The double-stranded c-FLIP siRNA was 5'GAGGUAAGCUGUCUGUCGG-dTdT3' (sense) and 5'CCGACAGACAGCUUACCUC-dTdT3' (antisense). P53 siRNA 5'GCAUG­AACCGGAGGCCCAU-dTdT3' (sense) and 5' AUGGGCCUCCGGUUCAUGC-dTdT3' (anti-sense) was designed according to Martinez et al (18). Oligonucleotides specific for luciferase mRNA served as a negative control (19). Caspase 8 siRNA 5'CUACCA­GAAAGGUAUACCU-dTdT3' (sense) and 5' AGGUAUACCUUUCUGGUAG-dTdT3' (anti-sense) was designed according to Chun et al. (20) and negative control siRNA from Eurogentec was used. Subconfluent cells were incubated in unsupplemented Optimem® medium and transfected with siRNA (up to 133 nM) using Oligofectamine® reagent according to the manufacturer's protocol (Invitrogen, Breda, the Netherlands). For the caspase 8 over-expression experiments, cells were transfected with pcDNA3-FLICE (a gift from J. Borst) using Fugene. The next day, cells were treated with cisplatin and/or rhTRAIL as described above, harvested and used for protein isolation, cytospins, FACS experiments, and/or an apoptosis assay. Cytospins were immunohistochemically stained for caspase 8 as described earlier (21). 
Real Time RT-PCR Total RNA was isolated by guanidine isothiocyanate-phenol-chloroform extraction with TRizol® (Invitrogen, Breda, the Netherlands) and purified using the RNeasy mini Kit and on-column DNase I digestion (Qiagen, Leusden, The Netherlands) according to the manufacturer's instructions. cDNA was synthesized from 1600 ng purified RNA as described 
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by the manufacturer's protocol (Life Technologies, Breda, the Netherlands) using oligo 
(dT)ll primers and MMLV transcriptase. Real Time RT-PCR was performed in 96-wells 
plates on a MyiQ® real time detection system (BioRad) with GAPDH as housekeeping 
reference gene. Primer sequences of caspase 8 were S'GGAGCTGCTCTTCCGAATTA 3' 
(forward) and S'GCAGGTTCATGTCATCATCC 3' (reverse) and those of GAPDH were 
S'CACCACCATGGAGAAGGCTGG 3' (forward) and S'CCAAAGTTGTCATGGATGACC 
3' (reverse). Amplification of the samples in triplicate was carried out in a final reaction 
volume of 25 µL, containing lx iQ™ SYBR Green Supermix (Bio-Rad), 5 µM of each 
primer and 5 µL cDNA (1:50). The thermocycling program used for each real-time RT-PCR 
consisted of an initial 3 min denaturation at 95°C, followed by 40 cycles of 15 s denaturation 
at 95°C, 20 s primer annealing at the primer specific Tann and 30 s fragment elongation at 
72°C. A melting curve was obtained at the end of each 40 cycles of amplification in order 
to determine the presence of a unique reaction product. To determine RT-PCR efficiency 
and initial starting quantity of the samples, a standard curve was generated using samples 
from a 1:3 dilution series of total starting cDNA. 
Statistical analysis 
All experiments were performed at least three times on different occasions. Analysis 
included double-sided nonpaired Student's t-test. A P-value < 0.05 was considered 
significant. 
Results 
Combination of cisplatin and rhTRAIL causes enhanced induction of apoptosis 
A2780 was moderately sensitive to cisplatin treatment for 96 h, with an IC50 of 2.6 µM in 
a survival assay. CP70 was 5-fold resistant to cisplatin, with an IC50 of 14.7 µM (Figure 
lA). CP70 was rhTRAIL resistant and A2780 was moderately sensitive, as the IC50 was not 
reached using up to 0.25 µg/ml in a survival assay for 96 h (Figure lB). Based on previous 
data, cells were treated for 4h with cisplatin, recovered for 20 h, and treated with rhTRAIL 
for 4 h for the apoptosis assay (14). rhTRAIL (0.25 µg/ml) induced moderate levels of 
apoptosis in A2780, ~ 20%, whereas CP70 was not sensitive to rhTRAIL. Combination of 
cisplatin with rhTRAIL enhanced apoptosis in both cell lines, with ~ 80% apoptosis in 
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Figure 1 I Resistance to cisplatin causes cross-resistance to rhTRAIL. Combination therapy 
overcomes resistance. 
(A) Survival after 96 h exposure to 0 µM - 25 µM (A2780) or 0 µM - 100 µM (CP70) cisplatin and (B) survival after 96 h exposure to 0 µg/ml - 0.25 µg m1-1 rhTRAIL as measured by cytotoxicity assays. (C) To determine apoptosis induction, cells were treated for 4 h with cisplatin (2.5 µM, 10 µM and 30 µM) after which cisplatin was washed away. 20 h later the cells were treated for 4 h with 0.25 µg/ml rhTRAIL. Apoptosis was determined with acridine orange staining. Apoptosis in the combinations marked with * was significantly enhanced (P < 0.05) over apoptosis after single agent treatment. Data represent the mean ± SD of at least three independent experiments. 
The resistant cell line CP70 has reduced caspase 8 protein levels 
To determine which cellular characteristics could account for the different sensitivity 
patterns to rhTRAIL, key components of the TRAIL signaling pathway were analyzed. 
Membrane expression of DR4 and DcRl were almost undetectable in both cell lines. DcR2 
expression was similar, whereas DRS was increased in CP70 (MFI = 120 ± 31) versus A2780 
(MFI = 53 ± 26) (Figure 2A). Western blot analysis showed similar expression of FADD, 
c-FLWu c-FLWs, caspases 9 and 3, Bid, Bax, Bak, Bcl-2, Bel-XL XIAP levels in A2780 and 
CP70. Remarkably, caspase 8 levels were lower in CP70 than in A2780 (Figure 2B). 
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Hf Figure 2A-B I Cellular characteristics involved in sensitivity to rhTRAIL. Cisplatin can induce caspase 8 protein in the low caspase 8 expressing CP70. 
(A) Basic levels of TRAIL receptor membrane expression in A2780 and CP70 as determined by FACS analysis. Receptor expression is expressed as mean fluorescence intensity (MFI). (B) Western Blot analysis of basic protein expression levels of key determinants of the TRAIL pathway in A2780 and CP70. 
Cisplatin induces upregulation of caspase 8 protein Next, we evaluated the effect of cisplatin on TRAIL-receptor expression and the effect of different regimens on cleavage of caspases 8 and 9. Cisplatin did not affect DR4 and DcRl levels. DcR2 was moderately upregulated, but DRS was strongly induced upon exposure to cisplatin in both cell lines (Figure 2C). In response to cisplatin, moderate activation of caspase 8 was induced in A2780. rhTRAIL alone induced mild activation of caspases 8 and 9, whereas upon combination treatment both caspases were strongly activated. In CP70, cisplatin induced upregulation of procaspase 8 levels. Rh TRAIL induced a slight activation of caspases 8 and 9, while the combination of cisplatin and rhTRAIL resulted in strong activation of both caspases (Figure 2D). 
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rhTRAIL + + + + + + 0.25 (tJg/ml) Figure 2C-D I Cellular characteristics involved in sensitivity to rhTRAIL. Cisplatin can induce caspase 8 protein in the low caspase 8 expressing CP70. (C) The effect of cisplatin on DRS expression in both cell lines. Flow cytometry was performed 24 h after 4 h incubation with cisplatin. (D) Western blot analysis of caspase 8 and caspase 9 after exposure to cisplatin and rhTRAIL. A2780 and CP70 were incubated with 2.5 µM or 30 µM cisplatin during 4 h, after which the cells were washed. 20 h later unexposed or cisplatin exposed cells were treated during 4 h with 0.25 µg/ ml rhTRAIL. !3-actin serves as a loading control. The blots are representative for at least three independent experiments. Caspase 8 protein levels affect rhTRAIL-induced apoptosis Since caspase 8 protein levels are reduced in CP70 compared to A2780, we examined the importance of caspase 8 protein levels for rhTRAIL-sensitivity following cisplatin pre­treabnent. Efficient downregulation of caspase 8 with siRNA strongly reduced apoptosis induction following treabnent of A2780 and CP70 with rhTRAIL alone and combined with cisplatin (Figure 3A). In caspase 8 siRNA transfected cells, combined treabnent with cisplatin and rhTRAIL minimally induced caspase 8 and 3 activation, while in negative control siRNA transfected cells strong activation of both caspase 8 and 3 was observed (Figure 3B). It can be noticed that caspase 3 levels are also slightly upregulated following cisplatin in both cell lines (Figure 3B). A role for caspase 3 in rhTRAIL-sensitization 
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can therefore not be excluded. However, the importance of caspase 8 levels was also 
demonstrated by transient upregulation of caspase 8 in CP70 that enhanced apoptosis 








Q. 20 � 
0 
0 1 0  20 
cisplatin (µM) 
A2780 
. .  - . . 
30 
CP70 
80 -+- neg c siRNA - rhTRAIL 
-- neg c siRNA + rhTRAIL 
l so · A- casp 8 siRNA + rhTRAIL 
-� 40 a 
: 20 




Caspase a l::: =-=-==-=::=-=-======:::::I I';::=-===-=-=========. 
p1 8 :==========::::: 
Caspase J I- - - - ------f j--- -- ----1 
Cleaved caspase 3 I . • 1 1  I 




+ + - + + 
+ + - + + ------
Neg c siRNA Caspase 8 siRNA 
+ - + - + + 
- + + - + + 
Neg c siRNA Caspase 8 siRNA 
Figure 3A-B I Caspase 8 downregulation inhibits cisplatin and rhTRAIL-induced 
apoptosis, while caspase 8 upregulation augmented apoptosis induction. 
A2780 and CP70 were transfected with siRNA against caspase 8 or negative control siRNA (A,B). CP70 cells 
were transiently transfected with a caspase 8 construct (C,D). 48h after transfection, cells were treated with 
30 µM cisplatin or medium control for 4 h, after which all cells were washed with PBS. Following 16 h of 
recovery, cells were treated with 0.25 µg/ml rhTRAIL or medium control for 4 h. (A) Apoptosis induction was 
determined by AO. Caspase 8 siRNA strongly reduced apoptosis induction by rhTRAIL and cisplatin in both 
cell lines. (B) Caspase 8 and 3 expression was determined using Western blot analysis. The exposure time of 
the caspase 8 blot of CP70 was increased compared to the blot of A2780. p-actin serves as a loading control. 
The blots are representative for at least three independent experiments. 
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Figure 3C-D I Caspase 8 downregulation inhibits cisplatin and rhTRAIL-induced 
apoptosis, while caspase 8 upregulation augmented apoptosis induction. (C) Cytospins were generated and stained for caspase 8 and show increased caspase 8 levels following transfection. (D) Apoptosis induction following cisplatin and rh1RAIL was determined by AO. Caspase 8 upregulation increased apoptosis induction by rh1RAIL alone and by rhTRAIL in combination with cisplatin. 
Cisplatin increases caspase 8 mRNA levels We investigated the mechanism causing reduced basal caspase 8 protein levels and cisplatin-induced caspase 8 upregulation in CP70. Basal caspase 8 mRNA levels were slightly higher in CP70 than in A2780. Exposure to cisplatin resulted in 1.5 fold induction of caspase 8 mRNA in both cell lines (Figure 4A). Possible differences in mRNA stability over time and in response to cisplatin were determined using actinomycin D. Caspase 8 mRNA degradation in the absence or presence of cisplatin was not different between A2780 and CP70 (P = 0.35) (Figure 4B). These results show that cisplatin does not influence caspase 8 mRNA degradation, indicating that the induction of mRNA is caused by increased transcription. 
Caspase 8 protein translation is reduced in CP70 The similar caspase 8 mRNA expression, while basal caspase 8 protein levels were different suggest possible changes in caspase 8 protein translation or degradation. Cells were exposed to the proteasome inhibitor MG132 in order to test whether increased proteasomal degradation causes the reduced caspase 8 protein levels in CP70. MG132 treatment induced upregulation of active caspase 8, leading to concomitant synergy with rhTRAIL (Figure 4C). To prevent caspase 8 activation by MG132 treatment, cells were co-incubated with the caspase inhibitor zVAD for 24 h, which did not lead to a change in full length caspase 8 levels (Figure 4D). CHX exposure for up to 24 h slightly affected caspase 8 levels in 
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both cell lines, while caspase 8 degradation was not different between A2780 and CP70 
(Figure 4E). These results show that not caspase 8 protein stability but rather a decreased 
translation of caspase 8 mRNA is causing the reduced caspase 8 expression in CP70. 
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Figure 4A-B I Stability of caspase 8 mRNA or protein does not differ between A2780 
and CP70. Differences in caspase 8 protein levels in CP70 are due to changes in protein 
translation. 
(A) rnRNA expression of caspase 8 was determined with quantitative RT-PCR after exposure to 30 µM 
cisplatin, 0.25 µg/ml rhTRAIL or the combination in both cell lines. Cells were incubated for 4 h with cisplatin, 
after which the cells were washed and total RNA was isolated 20 h after cisplatin exposure. Total RNA was 
isolated 4 h after exposure to rhTRAIL. Quantitative RT-PCR was carried out on cDNA with the SYBR Green 
method. Quantification was performed with the standard curve method with GAPDH as reference. Basic 
mRNA levels between A2780 and CP70 were not different. Cisplatin induced caspase 8 mRNA 1 .5 fold. (B) 
To assess caspase 8 mRNA stability, cells were exposed to 30 µM cisplatin for 4 h or left untreated. Hereafter, 
all conditions were washed with PBS and received new medium, followed by addition of 5 µg/ml Act D. 
Total RNA was extracted at the time of Act D addition (t = 0 h) and at the indicated time points. Quantitative 
RT-PCR was performed as in (A). Data represent the mean ± SD of at least three independent experiments. 
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Figure 4C-D I Stability of caspase 8 mRNA or protein does not differ between A2780 
and CP70. Differences in caspase 8 protein levels in CP70 are due to changes in protein 
translation. 
(C) A2780 and CP70 were exposed to 0.5 µM of the proteasome inhibitor MG132 for 24 h. The following day 
either rhTRAIL was added the last 4 h of incubation, or the cells were left untreated. Then cells were lysed 
and subjected to immunoblot analysis with caspase 8 and 3 antibodies. (D,E) A2780 and CP70 were treated 
with 0.5 µM MG132 for the indicated time points in the presence of 50 µM of z-VAD and lysed or treated 
with 20 µg/ml CHX for the indicated time points and lysed. Following SOS/PAGE immunoblotting was done 
with caspase 8 antibodies. !3-actin serves as a loading control. All immunoblots are representative for at least 
three independent experiments. 
Increased caspase 8 but not the caspase 8/c-FLIP ratio is involved in the response to 
cisplatin and rhTRAIL in CP70 
Difference in caspase 8/c-FLIP ratio between A2780 and CP70 might contribute to resistance 
in CP70. However, efficient downregulation of both c-FLIPL and c-FLIP5 with siRNA did 
not lead to increased apoptosis after either treatment regimen, and did not affect caspase 
8 cleavage (Figure SA). Downregulation even led to a significant decrease in apoptosis in 
CP70 (Figure SB). These results indicate that solely the elevated caspase 8 level is involved 
in the onset of apoptosis after combination treatment in CP70. Moreover, c-FLIP even 
promotes caspase 8 activation in these cells. 
P53 causes cisplatin-induced DRS expression but is not involved in rhTRAIL 
sensitization 
As pS3-induced upregulation of DRS is frequently described to be instrumental in the 
synergistic effect between chemotherapeutics and rhTRAIL (22), we asked whether the 
synergistic effect of cisplatin and rhTRAIL was pS3 dependent. PS3 was efficiently and 
functionally downregulated using siRNA in A2780 and CP70 as shown by the decreased 
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luc p53 Figure 6A-B I P53 causes cisplatin-induced DRS expression but is not required for rhTRAIL sensitization of A2780 and CP70. A2780 and CP70 were transfected with siRNA against p53 or luciferase and were 24 h later exposed to 30 µM of cisplatin during 4 h, after which all cells including those not exposed to cisplatin, were washed. The next day the cells were treated with 0.25 µg/ml rh1RAIL for 4 h. (A) Subsequently, Western blotting of p53 and p21 levels was performed on the lysates. !3-actin serves as a loading control. (B) A small fraction of the same cell suspension used for Western blot was plated in a 96-wells plate and apoptosis levels were determined with acridine orange apoptosis assays. After downregulation of p53, a significant increase in apoptosis occurred in CP70 after treatment with rh1RAIL. 
expression of p21 (Wafl/Cipl), a transcriptional target of pS3 (Figure 6A). In response to 
cisplatin, pS3 levels rose slightly in pS3-suppressed cells, but the levels remained far below 
those in the untreated luciferase siRNA transfected cells. Apoptosis induction (Figure 
6B) and activation of caspases 8, 9, and 3 (Figure 6C) were not affected by pS3 siRNA. 
Following pS3 downregulation, basal DRS membrane expression maintained unchanged, 
whereas cisplatin-induced DRS membrane expression was effectively suppressed in A2780 
and CP70 (Figure 6D). These results show that pS3-dependent upregulation of DRS is not 
involved in the synergy between cisplatin and rhTRAIL. In addition, DISC-IP using a DRS 75 3 
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antibody following cisplatin treatment showed that DISC-formation is not impeded in 
CP70 ( data not shown). 
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Figure 6C-D I P53 causes cisplatin-induced DRS expression but is not required for 
rhTRAIL sensitization of A2780 and CP70. (C) Cleavage patterns of caspase 8, caspase 9 and caspase 3 was determined on lysates after transfection with siRNA against luciferase and p53 as indicated above. The exposure time of the caspase 8 blot of CP70 was increased compared to the blot of A2780. !3-actin serves as a loading control. All blots are representative for at least three independent experiments. (D) 24 h after siRNA transfection, the cells were exposed for 4 h to 2.5 µM, 10 µM and 30 µM cisplatin, after which all cells were washed. The next day cells were harvested and analysed for DRS expression by flow cytometry. DRS expression is represented as mean fluorescence intensity (MFI). Data represent the mean ± SD of at least three independent experiments. 
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Chapter 3 I Drug-induced caspase 8 upregulation Discussion In the present study we show that the cellular caspase 8 protein level is an important determinant of sensitivity to rhTRAIL-induced apoptosis in an isogenic ovarian cancer cell line model of acquired cisplatin resistance. Combination of cisplatin and rhTRAIL effectively induced apoptosis, with cisplatin-induced caspase 8 protein expression being the key driver of sensitization to rhTRAIL in CP70. The central role of caspase 8 was further indicated by our observation that cisplatin-induced DRS upregulation was not an important sensitizing factor. Since caspase 8 mRNA levels do not differ significantly between A2780 and CP70, the low caspase 8 protein levels in CP70 are likely to be caused by decreased translation of caspase 8 protein rather than decreased transcription through methylation or genetic alterations that occur in neuroblastoma (23,24) and in other solid tumors (25,26). Increased caspase 8 protein degradation in CP70 was ruled out, as the effect of inhibition of protein synthesis and proteasomal degradation on caspase 8 levels was not different between A2780 and CP70. Translational and post-translational modifications are important drivers of the expression levels and activity of key proteins in the regulation of cell survival and apoptosis such as p53 (27), p73 (28), XIAP and AP AF-1 (29). Recently, attention has been drawn to microRNAs (miRNAs) as important regulators of translation and mRNA stability (30). Deregulation of several miRNAs was described for ovarian cancer and an important role for miRNAs in cisplatin and TRAIL resistance was shown in ovarian and lung cancer respectively (31,32). In melanoma cells an inducible post-translational modification of mRNA contributed to TRAIL resistance, where cytosolic proteins could suppress DRS protein expression by binding to the 3' -untranslated region of DRS-mRNA (33). These studies support our hypothesis that a post-transcriptional mechanism is involved in the low expression of caspase 8 in CP70. The fact that most prominently in CP70 caspase 8 translation could be enhanced by cisplatin exposure argues in favor of a reversible block of translation. Low caspase 8 levels were previously shown to contribute to rhTRAIL­resistance in several cell line models and tumors (34,35). Concerning the role of caspase 8 and the death receptor pathway in chemotherapy induced cell death conflicting reports have been published. Death receptor dependent and independent activation of caspase 8 was involved in the response to different chemotherapeutic drugs (36-38). In addition, resistance to these drugs through defects in the extrinsic pathway further supported the involvement of this pathway in chemotherapy induced cell death (37,39). Besides the differential expression of caspase 8 we found no other proteins that could account for the difference in TRAIL sensitivity between A2780 and CP70. As caspase 3 was slightly upregulated in both cell lines following cisplatin, a role for caspase 3 and hence also XIAP can not be completely ruled out (40). However, basal caspase 3 levels did not differ between the two cell lines, excluding caspase 3 as a determinant for the difference in rhTRAIL sensitivity. A reduced caspase 8/c-FLIP ratio can result in resistance to death 77 3 
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receptor signaling (41,42), whereas an increased caspase 8/c-FLIP ratio in the DISC can cause 
sensitization to rhTRAIL by chemotherapeutics (43,44). In our cell lines, downregulation 
of c-FLIP did not increase apoptosis induction. In the resistant CP70, downregulation of 
c-FLIP even resulted in a significant drop in apoptosis levels after exposure to cisplatin 
and rh1RAIL. This suggests that c-FLIP acts as a pro-apoptotic protein in CP70 and 
that the caspase 8 level is the most important determinant for rhTRAIL sensitivity. 
Although extensive literature exists on the anti-apoptotic function of c-FLIP, a role of 
c-FLIP in activation of caspase 8 was also reported (11,10). It is postulated that the c-FLIP L 
concentration at the DISC determines whether caspase 8 activation or inhibition occurs 
(10,45). Thus, it can be reasoned that the caspase 8-activating function of FLIP applies to 
A2780 and CP70, especially when low caspase 8 levels are present and heterodimerization 
can occur more easily than homodimerization. 
Upregulation of DR4 or DRS, which can occur in a pS3-dependent or -independent 
manner in response to chemotherapeutics (46,47), is often described as a key event in the 
synergistic effect between chemotherapeutics and rhTRAIL (22). Here, we show that the 
increase of death receptors after chemotherapy treatment might just be an epiphenomenon, 
instead of a key event in modulation of rh1RAIL-induced cell death by chemotherapeutics. 
Downregulation of pS3 did not affect apoptosis induction in either cell line, whereas the 
substantial increase of DRS after treatment with cisplatin was almost completely abrogated 
by pS3 downregulation. It has been shown that pS3 is required for cisplatin-induced 
apoptosis either via pS3-dependent ubiquitination of FLIP or pS3-induced XIAP and Akt 
downregulation when used as a single agent (40,48). These results may explain why CP70 
has reduced caspase-8 levels compared to A2780. However, in our experiments we have 
chosen to use cisplatin in a short treatment setting. This was followed by a short treatment 
with TRAIL, and we have demonstrated that upon combination of cisplatin and rhTRAIL, 
pS3 is no longer required for apoptosis induction. 
Conclusively, these results show that cisplatin enhances rhTRAIL sensitivity in both 
cisplatin sensitive and resistant cells. Induction of caspase 8 protein expression is the key 
driver of rh1RAIL sensitization. 
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Abstract 
Tumor cell selective activation of apoptosis by recombinant human TNF-related apoptosis­
inducing ligand (rhTRAIL) is enhanced through co-activation of pS3 by chemotherapeutic 
drugs. This often involves pS3-dependent increases in DRS expression. The novel 
anticancer agent nutlin-3 provides a promising alternative for pS3 activation as it disrupts 
the interaction between the negative feed-back regulator MDM2 and pS3. Here, we 
examined whether nutlin-3 could enhance apoptosis induction by rhTRAIL and the DRS­
selective rhTRAIL variant D269H/E19SR in a panel of wild type pS3-expressing ovarian, 
colon and lung cancer cell lines. Nutlin-3 dose dependently enhanced pS3, p21, MDM2 and 
DRS surface expression. Although nutlin-3 alone did not induce apoptosis, it preferentially 
enhanced D269H/El9SR-induced apoptosis over rhTRAIL. The mechanism of sensitization 
was further investigated in ovarian cancer models. Combination treatment potentiated 
the cleavage of caspases 8, 9, 3, and PARP. PS3 and MDM2 siRNA experiments showed 
that this enhanced apoptotic effect was mediated by wild type p53 activation due to 
disruption of the MDM2-mediated pS3 inhibition. In agreement with this, OVCAR-3 cells 
harboring mutant pS3 could not be sensitized to TRAIL death receptor-induced apoptosis 
with nutlin-3. Addition of the DNA damaging chemotherapeutic drug cisplatin to the 
combination further increased the levels of both wild type pS3 and DRS and enhanced 
rhTRAIL and D269H/E195R induced-apoptosis. In ex vivo tissue slices of primary human 
ovarian cancers, the combination of D269H/E195R with nutlin-3 and cisplatin also 
massively induced caspase 3 activation and apoptosis. 
In conclusion, nutlin-3 is a potent enhancer of rhTRAIL- and especially D269H/E19SR­
induced apoptosis. Combined use with cisplatin further enhances apoptosis induction. 
Since at least SO% of cancers carry wild type p53 we propose that this combination could 
provide an effective treatment for these cancers. 
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Chapter 4 I Preferential D269H/El95R sensitization by nutlin-3 over rhTRAIL Introduction 
Cancer remains one of the leading causes of death in developed countries and cancer 
mortality is expected to continue to rise globally, so new drugs are urgently required. 
An abundance of cancer drugs, often molecularly targeted and rationally designed, are 
currently becoming available for use in the clinic. Many of the newly developed targeted 
drugs will exert only modest activity when applied alone and will be more effective when 
combined with other drugs. Examination of rationalized combinations and optimizing 
their antitumor activity is therefore highly relevant to improve therapy. 
An example of a drug with clear preclinical activity and modest activity in the clinic 
is recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL). It can bind to 
pro-apoptotic TRAIL death receptors, designated death receptor DR4 or TRAIL-Rl and 
DRS or TRAIL-R2, leading to selective apoptosis induction in tumor cells, while leaving 
normal cells unharmed (1-5). DR-specific agonistic antibodies and rhTRAIL variants have 
been generated to specifically target one TRAIL death receptor to enhance efficacy (6-14). 
For example, E19SR/D296H, a DRS-selective variant of rhTRAIL, has increased affinity 
for DRS and was a more effective apoptosis-inducer as compared to rhTRAIL in various 
cell lines and in a bioluminescent xenograft model of ovarian cancer (9,15). The efficacy of 
rhTRAIL-induced apoptosis can be further enhanced by a rational combination of drugs 
targeting complementary apoptotic pathways (15-17). 
RhTRAIL activates the extrinsic apoptotic pathway in which binding to DR4 and DRS 
results in the formation of the death-inducing signaling complex (DISC), com prizing of Fas 
associated death domain (FADD) and caspase 8 (18). Following DISC formation, caspase 
8 is cleaved leading to either direct activation of caspase 3 or engagement of the intrinsic 
(mitochondrial) apoptotic pathway via Bid cleavage leading to caspase 3 activation and 
eventually to apoptosis. Chemotherapeutic drugs and radiation, in general, induce the 
intrinsic apoptotic pathway that involves DNA damage-induced activation of signaling 
proteins including the tumor suppressor protein pS3. P53, an important transcription 
factor, subsequently triggers cell cycle arrest and/or apoptosis via p53-mediated release 
of apoptotic factors from the mitochondria leading to cleavage of caspases 9 and 3 (19,20). 
Combination of rhTRAIL with chemotherapeutic drugs thus results in simultaneous 
activation of the extrinsic and intrinsic apoptotic pathways leading to strong apoptosis in 
tumor cells in pre-clinical models (16). However, in the clinic the phase 2 randomized studies 
showed not yet an clear advantage of the addition of rhTRAIL or death receptor-targeting 
antibodies to chemotherapy (21,22). Therefore, an even more pronounced exploitation 
of the intrinsic pathway might be relevant. In this respect the recently developed drug 
nutlin-3 is of interest. Nutlin-3 is a small molecule that binds MDM2, which is a negative 
feed-back regulator of p53 activity by forming a complex with p53. In addition, MDM2 
in complex with p53 can induce proteasomal degradation of p53. Disruption of the 
MDM2-p53 interaction by nutlin-3 results in accumulation of p53 in the absence of DNA 
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Chapter 4 I Preferential D269H/E195R sensitization by nutlin-3 over rhTRAIL damage. Nutlin-3 effectively induced p53 levels in a panel of cancer cell lines carrying wild type p53, resulting in apoptosis or cell cycle arrest in vitro as well as in vivo (23-26). Nutlin-3 is currently in early clinical development and might especially be of interest for the 50% of the tumors that carry wild type p53 (27,28). In the present study, we have used nutlin-3 as a novel approach to activate p53 and the intrinsic apoptotic pathway in a panel of wild type p53-expressing human cancer cell lines. Next, we explored the effect of combining nutlin-3 and extrinsic apoptotic pathway activation by rhTRAIL. We compared the apoptosis-inducing ability of rh1RAIL versus the DRS-selective rh1RAIL variant D269H/El95R when combined with nutlin-3. Finally, a novel living ex-patient model of primary human ovarian cancers was included to test functionality of these combinations in a clinically more relevant context. 
Materials and Methods Reagents Rh1RAIL and D269H/E195R were produced as described earlier (9). Nutlin-3 was purchased from Cayman Chemical and caspase inhibiter 1 (zVAD-FMK) from Calbiochem. Cell Culture The human ovarian cancer cell line A2780 was kindly provided by Dr T.C. Hamilton (Fox Chase Cancer Center, Philadelphia, Pennsylvania). The human H460 non small cell lung cancer, the human Lovo colon cancer, and the human OVCAR-3 ovarian cancer cell lines were purchased from American Type Culture Collection. A2780, H460 and Lovo carry wild type p53, while OVCAR-3 carries mutant p53. A2780 was cultured in RPMI 1640 (Invitrogen), supplemented with 10% heat inactivated fetal calf serum (FCS) (Bodinco BV), and 0.1 M L-glutamine, H460 and Lovo in RPMI 1640, supplemented with 10% heat inactivated FCS, OVCAR-3 in DMEM high glucose (Invitrogen), supplemented with 10% heat inactivated FCS and 0.lM L-glutamine. All cell lines grew as monolayers and were cultured in a humidified atmosphere with 5% CO2_ Cytotoxicity assay Themicroculturetetrazolium assay was used to measure cytotoxicity. Cell lines were cultured in HAM/F12 and DMEM medium, supplemented with 20% FCS and 0.1 M L-glutamine. Following 96 h treatment, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide (MTT)-solution at a concentration of 5 mg/ml (Sigma-Aldrich) was added and formazan production was measured as described previously (29). Cell survival was defined as the growth of treated cells compared to untreated cells and was determined in three experiments with each performed in quadruplicate. 86 
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Determination of apoptosis Cells were seeded in 96-well plates and treated as indicated. Following treatment, apoptosis was identified by staining nuclear chromatin with acridine orange. Apoptosis was defined by the appearance of apoptotic bodies and/or chromatin condensation by fluorescence microscopy and was expressed as the percentage of apoptotic cells in a well. All experiments were performed at least three times. 
Western blot analysis Cells were seeded in 6-wells plates and treated as indicated. Following treatment, cells were harvested at indicated time points by treatment with trypsin for 5 min at 37°C and washed twice with cold PBS. Cells were lyzed for 30 min on ice with M-PER lysis buffer (Pierce) supplemented with protease inhibitor followed by centrifugation (10 min 10,000 g, 4°C). Subsequently, protein concentrations were determined using a Bio-Rad DC protein assay according to the manufacturers' protocol (Bio-Rad) and cell lysates were diluted to 1 µg/µl with 2 x SDS Sample buffer (50 mM TrisHCl, pH 6.8, 4% SDS, 10% glycerol, 10% 2-B-mercaptoethanol, 0.002% bromophenol blue) and boiled for 5 min. Total cell lysates were size fractionated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto activated polyvinylidene difluoride membranes (Millipore BV). After blocking for 1 h in Tris-buffered saline (mM Tris-HCI, 137 mM NaCl) supplemented with 5% milk powder (Fluka) and 0.05% Tween-20 (Sigma-Aldrich), immunodetection of the protein of interest was performed according to the manufacturer's protocol. The following antibodies were applied: caspase 3 (9662), cleaved caspase 3 (9661), caspase 8 (9746), caspase 9 (9502), PUMA (4976), DRS (3696) (all from Cell Signaling), p53 (DO-1, Santa Cruz), p21/wafl (OP64), MDM2 (Ab-1) (both from Calbiochem), noxa (ALX-804-408, Alexis), DRS (ALX-210-743-c200, Alexis) and PARP (11 835 238 001, Roche Diagnostics). The Bid antibody was kindly provided by Prof. Dr. J Borst (the Netherlands Cancer Institute, Amsterdam, the Netherlands). Binding of these antibodies was determined using horseradish peroxidase (HRP)-conjugated secondary rabbit anti-mouse, and goat anti-rabbit antibodies (DAKO). Visualization was performed with LumiLight Plus Western Blotting Substrate (Roche Diagnostics). Equal protein loading was confirmed by immunostaining with �-actin antibody (ICN Pharmaceuticals). All experiments were performed at least three times. 
Flow cytometry Cells were seeded in 6-wells plates and treated as indicated. After treatment, cells were harvested at indicated time points by treatment with cell dissociation buffer (Gibco, Invitrogen, Breda, the Netherlands) for 5 min at 37°C and washed twice with cold PBS supplemented with 2% FCS and 0.1 % sodium azide. The following antibodies were used to determine TRAIL receptor membrane expression: TRAIL-RI (HSlOl), TRAIL-R2 (HS201), 87 4 
Chapter 4 I Preferential D269H/E195R sensitization by nutlin-3 over rhTRAIL TRAIL-R3 (HS301), TRAIL-R4 (HS402) (All purchased from Alexis) and phycoerythrin (PE) conjugated goat anti-mouse. Mouse IgG (DAKO) was used as isotype control. TRAIL receptor membrane expression was analyzed using a flow cytometer (Epics Elite, Coulter­Electronics) and is shown as mean fluorescent intensity (MFI) of all analyzed cells from at least three separate experiments. 
RNA interference Small interfering RNAs (siRNAs) specific for p53, MDM2, and Bid were designed. The double stranded sequences were: 5' AAGACUCCAGUGGUAAUCUAC-dTdT3' (sense) and 5'GUAGAUUACCACUGGAGUCUU-dTdT3' (anti-sense) for p53, 5' AAGCCAUUGCUUUUGAAGUUA-dTdT3' (sense) and 5'UAACUUCAAAAGCAA­UGGCUU-dTdT3' (anti-sense) for MDM2, and 5'GAAUAGAGGCAGAUUCUGA­dTdT3' (sense) and 5'UCAGAAUCUGCCUCUAUUC-dTdT3' (anti-sense) for Bid. Cells were seeded in 6-wells plates. The next day, the subconfluent cells were incubated in unsupplemented Optimem® medium and transfected with 133 nM p53, MDM2, Bid, or negative control siRNA (Eurogentec) using Oligofectamine® reagent according to the manufacturer's protocol (Invitrogen). 24 h after siRNA treatment, cells were seeded for apoptosis assays or Western blot analysis and treated as indicated. 
Tissue collection for ex vivo tissue slice experiments Epithelial ovarian cancer tissue samples were obtained from patients undergoing primary surgery at the UMCG. All histological subtypes were included in the study. All patients gave written informed consent. Tumor specimens obtained from ovaries or omentum were placed on ice cold medium (DMEM high glucose (Invitrogen) supplemented with 10% FCS, 1 % penicillin/streptomycin, 2.5 µg/ml amphotericin B, and 50 µg/ml gentamicin) immediately following surgical resection. Specimens were assessed for adequacy based on size and tissue consistency and were used for the experiment within a few hours. 
Preparation and incubation of tissue slices Cores of 5 mm were prepared manually from the obtained tumor specimen, embedded in agarose and placed in a Krumdieck Tissue Slicer (Alabama Research and Development). Slicing was performed under buffered conditions in ice-cold oxygen-saturated Krebs­Henseleit buffer (KHB) (25 mM glucose (Merck), 25 mM NaHCO3 (Roth), 10 mM HEPES (Roth), pH 7.4). Tissue slices of approximately 200-300 µm thickness and a wet weight of 10-14 mg were generated using standard settings (cycle speed setting 30; interrupted mode) and collected in ice-cold KHB. Within 1 h after slicing, 3 slices were fixed in formalin to serve as O h  controls and the other slices were incubated individually in 6-wells plates in oxygen-saturated medium (DMEM high glucose (Invitrogen) supplemented with 10% FCS, 1 % penicillin/streptomycin, 2.5 µg/ml amphotericin B, and 50 µg/ml gentamicin). 
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Plates were placed in plastic containers allowing constant gassing with carbogen and 
incubated at 37°C, while gently shaking (30). Depending on the number of slices that could 
be obtained, drug combinations were added in triplicates as indicated after 1 h incubation. 
Following 24 h treatment, slices were fixed in 1 ml formalin and paraffin embedded. 
4 µm sections were cut from the paraffin embedded slices and mounted on APES coated 
slides, deparaffinized by standard procedure and were hematoxylin-eosin (H&E) stained. 
Apoptosis was cytomorphologically scored based on H&E stainings as described earlier 
(31). 
Immunohistochemistry 
Sections were immunohistochemically stained for cleaved caspase 3 with a polyclonal 
rabbit anti cleaved caspase 3 antibody (3661, Cell Signaling) as described previously (31). Results 
Nutlin-3 increased p53, p21, MDM2 protein levels, and DRS surface expression 
We used wild type p53 expressing human cancer cell lines from different tumor types 
to assess the effect of nutlin-3. The A2780 ovarian cancer, Lovo colon cancer, and H460 
non small cell lung cancer cell lines were treated for 24 h with increasing concentrations 
of nutlin-3 after which p53, p21 and MDM2 protein levels were determined. Nutlin-3 
dose dependently enhanced p53, p21 and MDM2 levels, which indicates transcriptional 
activation of p53 due to the effective disruption of the MDM2-p53 interaction (Figure 
lA). Next, we investigated whether nutlin-3 affected expression of DRS, a transcriptional 
target of p53 (32). Indeed, DRS protein levels were increased upon nutlin-3 treatment in 
these cell lines (Figure lA). Moreover, DRS membrane expression of all cell lines increased 
upon treatment with increasing concentrations of nutlin-3. DR4 membrane expression 
remained stable in H460 and decreased in Lovo. A2780, however, did not express DR4 (15). 
Membrane levels of decoy receptor 2 (DcR2) remained stable in all cell lines and decoy 
receptor 1 (DcRl) levels were not detected (Figure 18). 
Nutlin-3 preferentially enhanced apoptosis induction by D269WE195R over rhTRAIL 
We examined whether enhanced p53 and DRS expression by nutlin-3 sensitized cells to 
rhTRAIL and D269H/E195R. Therefore, A2780 cells were treated for 24 h with nutlin-3 
and rhTRAIL or D269H/El95R was added in the last 4 h of treatment. H460 and Lovo cells 
were exposed to nutlin-3 and D269H/E195R concomitantly for 24 h. In each of these cell 
lines, nutlin-3 alone was not an effective apoptosis inducer. A2780 cells were modestly 
sensitive to rhTRAIL with ~5% apoptotic cells, whereas D269H/El95R was more potent 
with ~20% apoptotic cells. The sequential combination of nutlin-3 and rhTRAIL or D269H/ 
E195R strongly enhanced apoptosis to ~20% and ~60% apoptotic cells, respectively. In 
H460 and Lovo, rhTRAIL alone induced more apoptosis than D269H/El95R alone (~30% 89 4 
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Figure 1 I Nutlin-3 treatment induced upregulation of p53, p21, MDM2 and DRS (membrane) 
expression. 
(A) Treatment of A2780, H460, and Lovo with increasing concentrations of nutlin-3 for 24 h resulted in a 
dose-dependent upregulation of p53, MDM2, p21, and DRS protein levels as determined by Western blotting. 
(B) DR4, DRS and DcR2 membrane expression levels were measured using FACS analysis demonstrating 
that nutlin-3 enhanced DRS levels dose-dependently, while DcR2 remained unchanged. In H460 and Lovo, 
DR4 levels decreased upon treatment. DcRl was not detected. Presented data are representative for at least 3 
independent experiments and mean MFI levels are shown ±SD. 
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Figure 2 I Nutlin-3 enhanced apoptosis induction by rhTRAIL and especially D269H/E195R. 
(A) Pre-treatment of A2780 cells for 20 h with increasing concentrations of nutlin-3 followed by addition of 
rhTRAIL or D269H/El95R for 4 h dose-dependently increased the percentage of apoptotic cells in particular 
when using D269H/El95R. Combined treatment for 24 h dose-dependently sensitized H460 and Lovo to 
rhTRAIL and D269H/El95R-induced apoptosis. Apoptosis was determined using an acridine orange assay. 
(B) Combination treatment with nutlin-3 (24 h} and rhTRAIL or D269H/El95R (4 h) resulted in caspase 
activation and PARP cleavage, with strongest activation following nutlin-3 and D269H/El95R. (C) Apoptosis 
induction by the combination was completely blocked by 1 h pre-treatment with ZVAD-FMK (50 µM). 
Presented data are representative for at least 3 independent experiments. 
Nutlin-3 combined with rhTRAIL or D269H/E195R enhanced caspase-dependent 
apoptosis 
The mechanism of enhanced apoptosis induction following combination treatment was 
further analyzed in ovarian cancer models. Hence, the effect of single and combined 
treatment regiments on apoptosis at the level of caspases 8, 9, 3, and PARP cleavage was 
examined in A2780 cells. Treatment with nutlin-3 (24 h) or rhTRAIL (4 h) did not induce 
caspase or PARP cleavage. D269H/E195R (4 h) induced mild cleavage of caspase 8, caspase 
9, caspase 3, and PARP. Clearly, cleavage of all three caspases and PARP was strongly 
induced upon combined nutlin-3 and D269H/El95R treatment, and somewhat less with the 
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Chapter 4 I Preferential D269H/El 95R sensitization by nutlin-3 over rhTRAIL combination of nutlin-3 and rhTRAIL (Figure 2B). Apoptosis induction by the combination was caspase dependent, as 1 h pre-incubation with the broad-caspase inhibiter zVAD-FMK (50 µM) prior to the addition of rhTRAIL or D269H/E195R completely prevented apoptosis induction (Figure 2C). The sensitizing effect of nutlin-3 was dependent on the disruption of the MDM2-p53 interaction To exclude p53-independent effects of MDM2 that have been described (33), MDM2 was downregulated using siRNA inA2780 cells. Effective downregulation of MDM2 resulted in enhanced apoptosis induction by rhTRAIL and D269H/El95R to a similar extent as nutlin-3-induced sensitization (Figure 3A). As expected, nutlin-3 did not enhance apoptosis in the MDM2-suppressed cells. Next, we assessed whether the apoptosis stimulating effect of nutlin-3 was p53-dependent using p53 siRNA. Apoptosis levels following nutlin-3 and rhTRAIL or D269H/El95R in p53-depleted cells were significantly lower at every concentration of nutlin-3, confirming p53 dependency (Figure 3B). Upon treatment with nutlin-3, OVCAR-3 cells carrying mutant p53 were not sensitized to rhTRAIL or D269H/El95R, while pre-treatment with cisplatin increased the apoptotic effect of both ligands (Supplementary figure lA, B). Together, these results indicate that disruption of the MDM2-p53 interaction by nutlin-3 leading to p53 activation is the main mechanism underlying sensitization for rhTRAIL and D269H/E195R. Moreover, the sensitizing effect of cisplatin appears to involve a p53-independent mechanism. Nutlin-3 in combination with rhTRAIL or D269H/E195R induced Bid-mediated apoptosis In order to investigate whether nutlin-3 activated the intrinsic apoptotic pathway, we examined the effect of nutlin-3 on protein levels of PUMA and Noxa, known to be regulated by p53. PUMA levels were not affected by nutlin-3 and Noxa levels even decreased in A2780 (Figure 4A). Next, Bid was silenced with selective siRNA to block caspase 8-mediated activation of the intrinsic apoptosis pathway following rhTRAIL treatment. Efficient down-regulation of Bid (Figure 4C) completely prevented apoptosis induction by rhTRAIL alone or the combination of rhTRAIL and nutlin-3 (Figure 4B). Bid down-regulation also blocked D269H/El95R-induced apoptosis either alone or in the presence of nutlin-3 (Figure 4B). The reduction in apoptosis in Bid siRNA-treated cells compared to negative control siRNA-treated cells was reflected in the strong reduction in cleavage of caspases 3 and 9. Cleavage of caspase 8, however, was hardly affected by Bid downregulation, indicating that caspase 8 activation was not due to a functional feedback of caspase 3/9 (Figure 4C). Together, this indicates that nutlin-3 sensitizes A2780 cells to rhTRAIL and D269H/E195R by enhanced caspase 8 activation facilitating truncated Bid-dependent activation of the intrinsic apoptotic pathway. 92 
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Figure 3 I The sensitizing effect of nutlin-3 on rhTRAIL- or D269H/E195R-induced apoptosis 
was exerted via a specific block of the MDM2 - p53 interaction. A2780 cells were transfected with MDM2 or p53 specific siRNAs and 48 h after transfection, cells were treated with the nutlin-3 and rhTRAIL or D269H/E195R combinations. Apoptosis induction was determined by acridine orange. (A) MDM2 was effectively silenced (right panel) and caused sensitization of cells to rh1RAIL and D269H/El95R, while the sensitizing effect of nutlin-3 was abrogated (left panel). (B) P53 was effectively silenced (right panel) and decreased the sensitizing effect of nutlin-3 at different concentrations (left panel). 
Cisplatin augmented nutlin-3-induced p53 activation and DRS-mediated apoptosis 
Platinum-based chemotherapy forms the standard of care for ovarian cancer. Therefore, 
we examined whether cisplatin could further enhance the effect of nutlin-3 in combination 
with rhTRAIL and D269H/El95R. A2780 cells were pre-treated for 4 h with cisplatin, 
washed and further incubated for 16 h with nutlin-3 to allow maximal p53 induction 
following cisplatin-induced DNA damage. In A2780, 1 mM of cisplatin was sufficient to 
induce p53, rendering cells more susceptible to nutlin-3 treatment, as demonstrated by a 
stronger induction of p53, p21, and MDM2 compared to single treatment with nutlin-3 or 
cisplatin (Figure SA). Notably, although p53-induction is far more pronounced following 
cisplatin as opposed to nutlin-3 treatment, the level of p21 and MDM2 induction is similar. 93 4 
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nutlin-3 (µM) Figure 4 I Nutlin-3 in combination with rhTRAIL or D269H/E195R induced Bid-mediated apoptosis. 
(A) Cells treated for 24 h with increasing concentrations of nutlin-3 hardly affected PUMA expression and 
caused a decrease in Noxa protein levels. (B) Silencing of Bid by siRNA completely attenuated the sensitizing 
effect of nutlin-3 on rh1RAIL-induced apoptosis (left panel). Nutlin-3-dependent sensitization for D269H/ 
E195R was not completely blocked under these conditions (right panel). (C) Bid downregulation inhibited 
caspase 3 and caspase 9 cleavage as induced by combined treatments. Cleavage of caspase 8 was not affected. Low concentrations of cisplatin (0.1-2.5 µM) combined with 10 µM nutlin-3 additively increased DRS membrane expression levels as compared to single agent-induced effects, while DcR2 levels remained unchanged (Figure 5B). Next, we examined whether cisplatin enhanced the apoptotic effect of nultin-3 and rhTRAIL or D269H/El95R. Sequential treatment with cisplatin and nutlin-3, as described before, did not induce apoptosis, while nutlin-3 enhanced apoptosis induction by D269H/E195R and rhTRAIL (4 h). A low dose of cisplatin (1 µM) only sensitized A2780 to D269H/E195R, but not to rhTRAIL. Triple combination of nutlin-3 and cisplatin with D269H/El95R was more potent than with rhTRAIL (Figure SC). A higher dose of cisplatin (10 µM) was required to sensitize cells to rhTRAIL and showed additively enhanced apoptosis levels upon triple combination (Supplementary figure 2). Cell survival was also measured following 96 h combined 
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Figure 5 I Cisplatin treatment enhanced the sensitizing effect of nutlin-3 and D269H/E195R­
dependent apoptosis. 
A2780 cells were pre-treated for 4 h with low doses of cisplatin, and after removal of cisplatin treated with 
nutlin-3 over night. (A) P53, p21 and MDM2 levels were examined using Western blotting. This showed that 
cisplatin (10 µM) combined with nutlin-3 (10 µM) induces a massive upregulation of these proteins. (B) DRS 
and DcR2 membrane expression levels were determined by FACS analysis and showed that low doses of 
cisplatin combined with nutlin-3 (10 µM) enhanced DRS levels when compared to nutlin-3 alone. DcR2 levels 
however, remained unchanged. (C) rhTRAIL or D269H/El95R was added for 4 h following treatment with 
cisplatin (1 µM) and nutlin-3 (10 µM), and apoptosis levels were examined with acridine orange. At this low 
dose, cisplatin additively sensitized A2780 cells to combined nutlin-3 and D269H/El95R exposure. (D) Cell 
survival was measured using an MIT assay following 92 h continuous treatments. Nutlin-3 in combination 
with D269H/El95R more potently inhibited cell survival compared to the combination with rhTRAIL (upper 
panel). Addition of cisplatin to the nutlin-3/rhTRAIL combination resulted in an additive inhibitory effect on 
cell survival, while the combination of cisplatin, nutlin-3 and D269H/El95R resulted in a more than additive 
effect (lower panel). 
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treatment. This showed that nutlin-3 in combination with D269H/El95R more potently 
inhibited cell survival than nutlin-3 combined with rhTRAIL (Figure 5D upper panel). 
An additive decrease in cell survival was observed upon combined cisplatin, nutlin-3 
and rhTRAIL treatment, while the combination of cisplatin, nutlin-3 and D269H/El95R 
resulted in a more than additive effect (Figure 5D lower panel). 
Normal colon epithelial cells were not affected by combination of nutlin-3, cisplatin 
and rhTRAIL or D269H/E195R 
We tested the possible apoptotic effects of the triple-combination on the normal colon 
epithelial cell line NCM460. No significant activation of apoptosis was observed following 
24 h treatment with all three drugs, indicating tumor cell selective activity of the triple­
combination without harming normal cells (Figure 6). 
control clsplatin + nutlin-3 + 
rhTRAIL 
clsplatln + nutlln-3 + 
D269H/E195R 
Figure 6 I Cisplatin, nuUin-3 and rhTRAIL or D269H/E195R did not induce apoptosis in 
normal colon epithelial cells. Normal colon epithelial NCM460 cells were pre-treated with cisplatin (10 µM) for 4 h, after which cisplatin was removed and cells were exposed to nutlin-3 (10 µM) for 16 h, followed by addition of rhTRAIL or D269H/E195R (0.1 µg/ml) for 24 h. Cells were stained with acridine orange. Hardly any apoptotic cells were observed following treatment with all three regimens. 
Combining nutlin-3, cisplatin and D269H/E195R massively induced apoptosis in a 
novel living ex-patient model of primary human ovarian cancers 
Finally, we evaluated whether our treatment modalities were effective in inducing 
apoptosis in primary ovarian tumor tissue cultured as ex vivo tissue slices. Depending 
on size of the specimen, variable numbers of slices were generated using the Krumdieck 
tissue slicer and treated for 24 h with treatment regimens as indicated. Apoptosis scoring 
based on H&E staining showed excellent cell viability following 24 h incubation. In a pilot 
experiment, D269H/El95R treatment induced more apoptosis compared to rhTRAIL (data 
not shown). Therefore, in the subsequent experiments, slices were treated with D269H/ 
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E195R, not with rh1RAIL. Single treatment with D269H/El95R, cisplatin or nutlin-3 
resulted in low apoptotic levels. Combination treatment resulted in more apoptotic cells. 
Upon combination of all three drugs, massive apoptosis induction occurred (Figure 7 A). 
Next, we stained serial slides with H&E and for active caspase 3 (Figure 7B, C). Active 
caspase 3 levels correlated with the observed apoptosis levels based on H&E staining 
as demonstrated by strong positive staining upon combination of drugs. In the triple 
combination active caspase 3 staining was less prominent, which is probably related to the 
late apoptotic stage of cells as reflected by the highly condensed nuclei in the H&E staining. 
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Figure 7 A I Combination of nutlin-3, cisplatin and rhTRAIL or D269H/E195R massively 
induced apoptosis in an ex vivo tissue slice model of primary human ovarian cancer. Tissue slices from primary human ovarian cancer tissue were treated with the indicated combinations for 24 h. (A) Quantification of apoptosis levels based on H&E scoring of each separate experiment. Single drug treatment induced moderate levels of apoptosis, which were enhanced substantially upon combination treatment. Combination of cisplatin, nutlin-3 and D269H/E195R further enhanced apoptosis with apoptosis in over 80% of cells. 
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Figure 7B-C I Combination of nutlin-3, cisplatin and rhTRAIL or D269H/E195R massively 
induced apoptosis in an ex vivo tissue slice model of primary human ovarian cancer. 
Tissue slices from primary human ovarian cancer tissue were treated with the indicated combinations 
for 24 h. (B) H&E staining of a representative experiment showed excellent cell viability following 24 h 
incubation. Increased numbers of apoptotic cells can be seen following treatment with cisplatin (C) (10 µM), 
nutlin-3 (N) (20 µM), or D269H/E195R (DRS) (0.25 µg/ml). Combined treatment further enhanced number 
of apoptotic cells and combination of all three drugs showed massive apoptosis induction with almost no 
viable cells left. (C) Representative active caspase 3 staining corresponding with the H&E slides. The levels 
of active caspase 3 nicely correlate with the quantified number of apoptotic cells based on the H&E stainings. Discussion 
In the present paper, we showed that the MDM2 blocking agent nutlin-3 acts as an enhancer 
of TRAIL receptor-induced apoptosis in an MDM2-pS3 dependent manner. Moreover, 
the combination of nutlin-3 with the DRS-selective rhTRAIL variant D269H/E19SR was 
substantially more effective in inducing apoptosis than nutlin-3 combined with rhTRAIL. 
This was related to the nutlin-3 dependent increase in DRS expression. Adding cisplatin to 
the combination further enhanced apoptosis induction. Interestingly, the combination of 
D269H/El9SR, nutlin-3 and cisplatin massively induced apoptosis and caspase 3 cleavage 
in a novel living ex-patient model of primary human ovarian cancers. Since platinum-98 
Chapter 4 I Preferential D269H/El95R sensitization by nutlin-3 over rhTRAIL based chemotherapy is the cornerstone of ovarian cancer treatment, this illustrates the potential clinical relevance of our findings. Approximately half of all human tumors express wild type pS3, but these tumors often display a hampered pS3 function, due to enhanced levels of MDM2 in complex with pS3 (34). Via disruption of the MDM2-pS3 complex, nutlin-3 effectively induced pS3 levels in a panel of cancer cell lines carrying wild type pS3, resulting in apoptosis or cell cycle arrest in vitro as well as in vivo (23,26). Nutlin-3 hardly induced apoptosis in our panel of wild type pS3 cell lines, which has been observed by others as well in a subgroup of cell lines (26). Titis may be related to downstream defects in the pS3-dependent intrinsic apoptosis pathway (17). We and others found that nutlin-3 increases promoter activity and membrane expression of DRS (35,36). In lung and colon cancer cell lines, we actually observed that nutlin-3 decreased DR4 expression. Therefore, we explored the attractive strategy to combine nutlin-3 with drugs that induce apoptosis via the extrinsic pathway, such as rh1RAIL (35,36). To fully exploit the effect of nutlin-3 on DRS, we used a DRS­selective rhTRAIL variant with mutations D296H and E19SR (9,15,35,36). Indeed, nutlin-3 preferentially potentiated the effect of D269H/El9SR over rh1RAIL not only in ovarian cancer cells, but also in lung and colon cancer cells. Importantly, normal colon epithelial cells were not affected by the combination. D269H/El9SR has a higher affinity for DRS as compared to rhTRAIL, which may explain the increased efficacy of the combination with nutlin-3. This is supported by our finding that D269H/E19SR in combination with nutlin-3 more potently activated caspase 8-induced caspase 3 cleavage. DRS-specific targeting is an interesting anti-tumor strategy as combinations of various drugs such as proteasome inhibitors or cisplatin with rhTRAIL, more often upregulated DRS than DR4 (37). In addition, high DRS expression measured immunohistochemically in tumors of ovarian cancers patients correlated with poor patients survival and DRS was upregulated following chemotherapy (38,39). We showed earlier that cisplatin caused increased levels of pS3 and DRS membrane expression and enhanced rh1RAIL-induced apoptosis in ovarian cancer cell lines (15,40). Interestingly, cisplatin-induced pS3 expression was not required for DRS upregulation and rh1RAIL-sensitization (40). We also showed enhanced in vivo efficacy of D269H/E19SR over rhTRAIL in combination with cisplatin, using an orthotopic wild type pS3 A2780 bioluminescent xenograft model (15). However, tumor growth resumed upon discontinuation of combined treatment. Thus, more potent combinations are warranted. In order to benefit from the putative difference in pS3 activation via cisplatin-induced DNA-damage versus nutlin-3, we included cisplatin in the ovarian cancer cell models. In contrast to cisplatin, nutlin-3 enhances pS3 levels without genotoxic effects (34). Accumulation of unphosphorylated pS3 functions equally well as a transcription factor compared to DNA-damage induced phosphorylated pS3, as reflected in the nutlin-3-induced DRS upregulation (41). Upon combination of cisplatin and nutlin-3, massive pS3 induction occurred, resulting in strong upregulation of p21, MDM2, and DRS. 99 4 
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As a consequence, nutlin-3 rendered cells more susceptible for cisplatin combined with 
D269H/El9SR. 
The in vitro results were translated into a novel living ex vivo patient model of ovarian 
cancer. This model might be physiologically more relevant over in vitro cell line models 
and primary tumor cell cultures, as it takes tumor-stroma interactions into account. 
Moreover, heterogeneity of individual tumors and between the tumors can be evaluated. 
In concordance with our in vitro data, D269H/E19SR was more potent than rhTRAIL as a 
single agent and in combination with cisplatin. Previously, the anti-DRS antibody TRA-8 
effectively induced apoptosis was further enhanced in combination with chemotherapeutic 
drugs including cisplatin in a similar ex vivo model of ovarian cancer (42,43). Fascinatingly, 
we showed in the present study that D269H/E19SR in combination with nutlin-3 enhanced 
apoptosis in the ex vivo patient model. Adding cisplatin to the combination resulted in 
massive apoptosis induction as reflected in active caspase 3 staining and H&E staining. 
In contrast to our in vitro data, the combination of nutlin-3 and cisplatin showed 
increased apoptotic effects compared to single treatment in the ex vivo ovarian cancer 
patient model. This combination showed additively enhanced apoptotic effects in vitro 
in wild type pS3 expressing testicular germ cell cancer, neuroblastoma and leukemia cells 
(44-47) . Interestingly, nutlin-3 also enhanced chemotherapy-induced apoptosis in mutant 
pS3 expressing cancer cells of various origins via activation of E2Fl, thus extending the 
applicability of the combination to both wild type and mutant pS3 cancer cells (48). Nutlin-3 
is currently under clinical investigation in hematological malignancies and solid tumors 
(28). Combining nutlin-3 with cisplatin in a subsequent trial may be of interest. 
In conclusion, the present study demonstrates that nutlin-3 and cisplatin strongly 
potentiate DRS-mediated apoptosis. This offers a new strategy for effective (ovarian) 
cancer treatment using DRS targeting agents. Acknowledgments 
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Supplementary figure 1 I Nutlin-3 did not sensitize mutant p53 expressing OVCAR-3 cells to 
rhTRAIL or D269H/E195R. (A) Increasing concentrations of nutlin-3 (24 h) did not enhance apoptosis induction by rTRAIL or D269H/ E195R in OVCAR-3 cells, which express mutant p53. (B) Cisplatin did enhance rhTRAIL- and D269H/El95R­induced apoptosis in OVCAR-3 cells. 
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Supplementary figure 2 I Cisplatin did sensitize A2780 to the combination of nutlin-3 and 
rhTRAIL. Cisplatin (10 µM, 4 h) did additively enhance apoptosis induction by nutlin-3 (16 h) and rhTRAIL (4 h). 104 
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Chapter 5 I IR-signaling protects cancer cells against TRAIL DR-induced apoptosis Abstract 
Recombinant human (rh)TRAIL induces apoptosis in human cancer cells. However, 
resistance to rhTRAIL is frequently observed. This can be due to pro-survival signals that 
counteract rhTRAIL-induced apoptosis. The insulin-like growth factor (IGF) system is 
an important prosurvival signaling pathway that is also involved in energy metabolism 
in tumors. In the present study, we investigated whether inhibition of IGF-lR and 
insulin receptor (IR) signaling affects rhTRAIL sensitivity in a panel of ovarian and lung 
cancer cells lines with variable rhTRAIL- and chemo-sensitivity. Small interfering RNA 
(siRNA)-mediated downregulation of IR but not IGF-lR strongly enhanced rhTRAIL­
induced apoptosis, as reflected by strong cleavage of caspases and PARP. IR knockdown 
sensitized cells for both DR4 (4C7) and DRS (D269H/El9SR)-selective rhTRAIL variants. IR 
downregulation increased pS3 protein levels, enhanced DRS membrane expression, and 
decreased cellular glucose uptake. PS3 siRNA experiments showed pS3 dependency of 
the enhanced apoptotic effect. To mimic IR knockdown-induced glucose deprivation, cells 
were treated with 2-deoxy-glucose (2-DG). Similar increases in pS3 and DRS expression 
and augmented death receptor-mediated apoptosis were detected. 
In conclusion, IR, but not IGF-lR downregulation strongly enhanced TRAIL death 
receptor-mediated apoptosis via a diminished glucose uptake in chemo- and rhTRAIL 
sensitive and resistant cell lines. These data provide a new rationale for combination 
therapy of rhTRAIL with IR targeted agents or glycolysis inhibitors such as 2-DG. 
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Chapter 5 I IR-signaling protects cancer cells against TRAIL DR-induced apoptosis Introduction Ovarian cancer is the most lethal type of gynecological cancer in the Western world. Although initial response rates to platinum-based chemotherapy are over 80%, 5-year survival of advanced stage ovarian cancer patients is only 15-25%. This is due to chemo­resistance (1,2). Non small cell lung cancer (NSCLC) represents 80% of all lung cancers and is the most common cause of cancer death, with an overall 5-year survival rate of only 6.6% in advanced disease. Standard chemotherapy shows limited efficiency in NSCLC patients (3,4). More effective treatment strategies are therefore urgently required in both cancer types. Recombinant human TNF related apoptosis inducing ligand (rhTRAIL) is a member of the TNF family and an interesting tumor-specific agent (5-7). Phase 1 studies showed that rhTRAIL (Apo2L/dulanermin) can be administered safely as a single agent and in combination with chemotherapeutic agents (8,9). RhTRAIL binds to five receptors; two death receptors (DRs) DR4 and DRS, two decoy receptors (DcRs) DcRl and DcR2, and one soluble receptor osteoprotegerin (OPG). Binding of rhTRAIL to the DRs causes receptor trimerization and initiates the formation of the death inducing signaling complex (DISC), which activates the caspase cascade resulting in apoptosis (10,11). Resistance to rhTRAIL occurs in approximately 50% of all tumor cell lines (12,13). To overcome resistance, rhTRAIL has been combined with various chemotherapeutic drugs to maximize efficacy in vitro and in vivo (13,14). These combinations are potent in the pre-clinical setting. However, recent preliminary randomized phase II data showed no clear additive effects of several combinations in patients (15,16). Possible mechanisms for TRAIL resistance include growth factor-induced survival signaling via protein kinase B (PKB/ Akt) and the mitogen-activated protein kinase (MAPK) signaling pathways (17). The insulin-like growth factor (IGF) system is important for the regulation of cellular proliferation and energy metabolism (18). The IGF system comprises three ligands IGF-I, IGF-11, and insulin and three transmembrane receptors IGF-receptor I (IGF-lR), IGF-2R and the insulin receptor (IR) (19). Numerous malignancies overexpress IGF-I, IGF-11, IGF­lR and IR, while expression of IGF-2R, a scavenger of IGF-11 as it lacks an intracellular signaling domain, is reduced (20-23). The IR and IGF-lR are the main signaling receptors and are highly homologous in their tyrosine kinase domains. Both homodimers and IGF­lR/lR hybrid receptors are formed, which have different ligand affinities (24,25). Ligand binding to dimerized receptors induces receptor-autophosphorylation. Subsequently, IR substrates (IRS 1-4) are recruited, which activates the phosphatidylinositol-3-kinase (PI3K) and MAPK signaling pathways (19,20,26). Deregulation of the IGF axis contributes to carcinogenesis which makes it an attractive target for (combination) therapy (27). Until now, the focus of IGF axis targeting for cancer therapy development has been on the IGF­lR. Interestingly, despite the large homology, the IR has a distinct role in glucose uptake compared to IGF-lR, as Akt activation upon ligand binding to the IR results in translocation 
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Chapter 5 I IR-signaling protects cancer cells against TRAIL DR-induced apoptosis of glucose transporters to the cell membrane, allowing glucose uptake (28). Tumor cells display increased glucose uptake compared to normal cells due to the strongly enhanced aerobic glycolysis, which is known as the Warburg effect (29). This may involve IR signaling 
(23). We recently showed with DNA expression arrays of ovarian carcinomas from 157 patients that deregulation of the IGF axis influenced survival of ovarian cancer patients (30). In the present study, we therefore investigated whether specific downregulation of IGF­lR or IR enhanced DR-induced apoptosis in a panel of wild type p53 expressing ovarian cancer and NSCLC cell lines. To analyze DR-specific effects, we examined the effect of three different rhTRAIL variants, namely rhTRAIL, the DR4-selective rhTRAIL variant 4C7, and the DRS-selective variant D269H/El95R (31,32). We also investigated whether the effect of IR and IGF-lR downregulation on DR-induced apoptosis was related to changes in cellular glucose metabolism. 
Materials and Methods 
Reagents RhTRAIL, D269H/El95R and 4C7 were produced as described earlier (32,31). 2-Deoxy-D­glucose (2-DG) and insulin were obtained from Sigma-Aldrich (Sigma-Aldrich Chemie BV) .  Recombinant human IGF-1 and IGF-II were purchased from R&D Systems. 
Cell culture The ovarian cancer cell line A2780 and its 75-fold cisplatin resistant sub cell line C30 were kindly provided by Dr Hamilton (Fox Chase Cancer Center, Philadelphia). Cisplatin resistance in C30 is partially due to an increased DNA repair mechanism and a higher intracellular glutathione content (33,34). The ovarian cancer cell line TOV21G and NSCLC cell lines H460 and A549 were purchased from American Type Culture Collection (ATCC) (35). All cell lines carry wild type and functional p53. A2780 and C30 were cultured in RPMI 1640 (Invitrogen), supplemented with 10% heat inactivated fetal calf serum (FCS) (Bodinco BV) and 0.1 M L-glutamine. TOV21G was grown in 1:1 mixed DMEM high glucose and Ham (Invitrogen), supplemented with 10% heat inactivated FCS. H460 and A549 were grown in RPMI 1640, supplemented with 10% heat inactivated FCS. All cell lines grew as monolayers and were cultured in a humidified atmosphere with 5% CO2. 
Drug exposure Cell lines were treated with the rhTRAIL variants in various concentrations and time courses, dependent on their known sensitivity to rhTRAIL (35,36). A2780 and C30 were treated with 0.1 µg/ml for 4 h, TOV21G with 0.25 µg/ml for 24 h, H460 with 0.01 µg/ml for 24 h, and A549 with 0.1 µg/ml for 24 h. To investigate caspase and PARP cleavage, H460 cells were exposed to rhTRAIL variants for 4 h. For the glucose deprivation experiments, 
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all cell lines were exposed to 2-DG for 48 h. In A2780 and C30, the rhTRAIL variants were 
added during the final 4 h of 2-DG treatment and in TOV21G and H460, the rh1RAIL 
variants were added during the final 24 h of 2-DG treatment. 
RNA interference 
Small interfering RNAs (siRNAs) specific for IR, IGF-lR, and p53 were designed. The 
double stranded sequences were: 5'GGCUCCUUCGGCAUGGUGUAU-dTdT3' (sense) 
5' AUACACCAUGCCGAAGGAGCC-dTdT3' (anti-sense) for the IR, 5' GCCGAUG­
UGUGAGAAGACC-dTdT3' (sense) and S' GGUCUUCUCACACAUCGGC-dTdT3' 
(anti-sense) for the IGF-lR, and S'AAGACUCCAGUGGUAAUCUAC-dTdT3' (sense) and 
5'GUAGAUUACCACUGGAGUCUU-dTdT3' (anti-sense) for p53. Cells were seeded in 
6-wells plates. The next day, the subconfluent cells were incubated in unsupplemented 
Optimem® medium and transfected with 133 nM IR, IGF-lR, p53, or negative control 
siRNA (Eurogentec) using Oligofectamine® reagent according to the manufacturer's 
protocol (Invitrogen). In order to combine siRNAs targeting different mRNAs, cells were 
transfected with 100 nM of each siRNA sequence. 24 h after siRNA treatment, cells were 
seeded for an apoptosis assay, 2-[18F]-fluoro-2-deoxy-D-glucose uptake analysis, Western 
blot analysis and/or FACS analysis and treated as indicated after another 24 h. 
Determination of apoptosis 
Cells were seeded in 96-well tissue-culture plates and treated as indicated. Following 
treatment, apoptosis was identified by staining nuclear chromatin with acridine 
orange. Apoptosis was defined by the appearance of apoptotic bodies and/or chromatin 
condensation by fluorescence microscopy and was expressed as the percentage of apoptotic 
cells in a well. All experiments were performed at least three times. 
Western blot analysis 
Cells were seeded in 6-wells plates and treated as indicated. Following treatment, cells 
were harvested at indicated time points by treatment with trypsin for 5 min at 37°C and 
washed twice with cold phosphate buffered saline (PBS). Preparation of total cell lysates 
and Western blot analysis was performed as described previously (36). Immunodetection 
of the protein of interest was performed according to the manufacturer's protocol. The 
following primary antibodies were applied: IGF-lR (3027), IR (3025), phospho-IGF-IR(Tyr 
1135/1136)/IR(Tyr1150/1151) (3024), caspase 3 (9662), cleaved caspase 3 (9661), caspase 8 
(9746), caspase 9 (9502) (all from Cell Signaling), p53 (DO-1, Santa Cruz), DRS (ALX-210-
743-c200, Alexis), DR4 (1139, Prosci) and PARP (11 835 238 001, Roche Diagnostics). Binding 
of these antibodies was determined using horseradish peroxidase (HRP)-conjugated 
secondary rabbit anti-mouse, goat anti-rabbit, and rabbit anti-goat antibodies (all from 
DAKO). Visualization was performed with LumiLight Plus Western Blotting Substrate 
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(Roche Diagnostics). Equal protein loading was confirmed by immunostaining with f3-actin 
antibody (ICN Pharmaceuticals). All experiments were performed at least three times. 
Flow cytometry 
Following treatment, cells were harvested with cell dissociation buffer (Gibco) for 5 min at 
37°C and washed twice with cold PBS supplemented with 2% FCS and 0.1 % sodium azide. 
The following antibodies were used to determine TRAIL receptor membrane expression: 
TRAIL-Rl (HS101), TRAIL-R2 (HS201), TRAIL-R3 (HS301), TRAIL-R4 (HS402) (All 
purchased from Alexis) and phycoerythrin (PE) conjugated goat anti-mouse. Mouse IgG 
(DAK:O) was used as isotype control. TRAIL receptor membrane expression was analyzed 
using a flow cytometer (Epics Elite, Coulter-Electronics) and is shown as mean fluorescent 
intensity (MFI) of all analyzed cells from at least three separate experiments. 
2-[18F]-fluoro-2-deoxy-D-glucose uptake 
Following transfection with the indicated siRNAs in triplicates, glucose uptake was 
analyzed using 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG), as described previously (37). 
Cells were washed twice with PBS and resuspended in 1 ml PBS per well. Subsequently, 
1 MBq [18F]FDG was added to each well and cells were incubated for 1 h at 37°C to allow 
[18F ]FDG uptake. After incubation, cells were washed twice with PBS to remove excess [18F] 
FOG, harvested using trypsin and radioactivity was measured using a calibrated well­
type LKB-1282-Compu-gamma system (LKB Wallac). [18F]FDG uptake was defined as the 
percentage of [18F]FDG reference samples. Results 
IGF-ligands induced receptor phosphorylation in ovarian cancer and NSCLC cell lines 
To examine responsiveness of the IGF system, we stimulated a wild type p53 expressing 
cell line panel comprising the intermediately rhTRAIL sensitive A2780 and C30 (a cisplatin 
resistant derivative of A2780) and rhTRAIL resistant TOV21G ovarian cancer cell lines 
and the rhTRAIL sensitive H460 and rhTRAIL resistant A549 NSCLC cell lines with IGF-I, 
IGF-11 and insulin. Cells were serum starved overnight and subsequently stimulated with 
50 nM ligand for 30 min. In the ovarian cancer cell lines all three ligands induced IR / 
IGF-lR phosphorylation. In the NSCLC cell lines only IGF-I and IGF-TI induced receptor 
phosphorylation, while insulin had no effect (Figure 1). 
110 
Chapter 5 I IR-signaling protects cancer cells against TRAIL DR-induced apoptosis 
A2780 
C IGF-I IGF-1I INS 
C30 
C IGF-I IGF-11 INS 
TOV21G 
C IGF-1 IGF-11 INS 
plR / IGF-1 R I ::::· =================::::: ::=================::::: ::::=================::::: 
P-actin l ..-. � ,... �, ,,.....-.-� 1 1 ------
H460 
C IGF-I IGF-11 INS 
A549 
C IGF-I IGF-11 INS 
Figure 1 I IGF-ligands induced receptor phosphorylation. IR / IGF-lR phosphorylation following stimulation of A2780, C30, TOV21G, H460, and A549 with IGF-I, IGF­II or insulin (INS) (50 nM). Cells were serum starved overnight and stimulated subsequently for 30 min. All three ligands induced receptor phosphorylation in the ovarian cancer cells lines, while only IGF-I and IGF-II induced phosphorylation in the NSCLC cell lines. 
Downregulation of IR but not IGF-lR strongly enhanced DR-induced apoptosis We designed receptor specific siRNAs to downregulate each receptor and subsequently examine the effect on DR sensitivity in our cell line panel. Effective and specific IR downregulation strongly enhanced apoptosis induction by rhTRAIL, 4C7 and D269H/ E19SR in all cell lines examined (Figure 2A, B). In contrast, IGF-lR downregulation did not affect DR-induced apoptosis and even seemed to protect cells against apoptosis induction. Interestingly, IR downregulation alone induced mild apoptosis in A2780, C30 and H460, and even more apoptosis in AS49. There was no difference in the apoptosis enhancement between rhTRAIL and rhTRAIL variants, indicating that the sensitization was not DR­selective. IGF-lR siRNA induced receptor-specific downregulation in all cell lines except for H460, where it also affected IR expression (Figure 2B). In order to investigate the underlying mechanism of the DR-sensitizing effect, expression levels of several pro-apoptotic proteins were examined following IR and IGF­lR downregulation. Expression levels of Bak, Bax, Bim, FADD, FLIP and the inhibitors of apoptosis (IAP), XIAP, cIAP-1 and cIAP-2, were not affected (data not shown). Interestingly, pS3 protein levels strongly increased in all cell lines following IR but not IGF-lR downregulation (Figure 2B). As DR4, DRS and DcR2 are transcriptional targets of pS3 (38-41), we next examined whether IR and IGF-lR siRNA affected 1RAIL-receptor membrane expression. A2780 and C30 do not express DcRl or DR4 (42). In all cell lines, DRS membrane expression increased following IR siRNA, while DcR2 expression remained stable. In contrast, IGF-lR downregulation did not affect DRS membrane expression. 
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Chapter 5 I IR-signaling protects cancer cells against TRAIL DR-induced apoptosis DcRl was not detected in TOV21G, H460 or A549. IR downregulation increased apoptosis induction by both D269H/El95R and 4C7 in TOV21G, H460 and A549, while DR4 was not increased following downregulation of either IGF-R (Figure 2C). These results indicate that an increase in DR4 membrane expression is not required for the sensitizing effect of IR downregulation on 4C7-induced apoptosis. 
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Figure 2C I Effective downregulation of IR strongly enhanced DR-induced apoptosis, p53 
protein levels, and DRS membrane expression. (C) DRS membrane expression is increased upon downregulation of IR, but not IGF-lR. DR4 membrane expression was not affected in TOV21G and A549 and even seemed to decrease in H460 following siRNA of each IGF-R. DcR2 expression was not affected in any cell line and DcRl was not detected. 
IR downregulation in combination with rhTRAIL (variants) induced enhanced 
cleavage of caspases 8, 9, and 3 and PARP Caspase cleavage was examined in H460 to analyze the mechanism of apoptosis induction by IR siRNA in combination with DR-targeting drugs. IR downregulation alone induced mild cleavage of caspase 8 and caspase 3, substantial cleavage of PARP, but no caspase 9 cleavage. Treatment with the rhTRAIL (variants) alone induced cleavage of all three caspases and PARP, with 4C7 being most effective. Upon combination of IR siRNA with the rhTRAIL (variants), strong enhancement of caspase 8, 9 and 3 as well as PARP cleavage observed. Notably, caspase 9 activation was predominantly induced via self-cleavage with a more distinct 35 kDa cleavage product than 37 kDa cleavage product. Results obtained for caspase and PARP cleavage correlated well with the level of apoptosis induction as measured by acridine orange (Figure 2A). IGF-lR downregulation did not induce any caspase cleavage. Combination with the rhTRAIL (variants) did not increase caspase or PARP cleavage (Figure 3). 113 5 
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Figure 3 I Cleavage of caspases 8, 9, and 3 and PARP following IR downregulation in 
combination with rhTRAIL (variants) in H460 cells. Combination of IR siRNA with the rhTRAIL (variants) (0.01 µg/ml, 4 h) resulted in strong caspase 8, 9 and 3 cleavage and in cleavage of PARP. Caspase and PARP cleavage was increased compared to single treatment with the rhTRAIL variants. Combination of IGF-lR with the rhTRAIL variants did not result in enhanced caspase or PARP cleavage. 
P53 was required for the enhanced apoptotic effect 
To investigate the role of p53 in apoptosis induction by IR downregulation and rhTRAIL 
(variants) in H460, both IR and p53 were efficiently downregulated using siRNA in H460 
(Figure 4A). While p53 downregulation did not affect apoptosis induction by rhTRAIL 
(variants), it completely blocked apoptosis induced by IR siRNA alone. IR siRNA treatment 
sensitized cells to rhTRAIL, 4C7 and D269H/El95R as shown above, which was reversed 
when combined with p53 downregulation. These results indicate that p53 was essential for 
the apoptosis enhancement, and p53 dependence was similar for DR4- and DRS-induced 
apoptosis (Figure 4B). 114 
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(A) P53 and IR were efficiently downregulated following combination of siRNAs in H460. The increased p53 levels after IR knockdown alone were repressed by p53 siRNA. (B) H460 cells were transfected with the combination of p53 and IR siRNA and subsequently treated with the rhTRAIL variants. P53 siRNA prevented apoptosis induction by IR siRNA alone. Following treatment with all three variants, the enhanced apoptotic effect as observed following IR downregulation was repressed by simultaneous downregulation of p53. Downregulation of p53 alone had no effect on apoptosis levels. 
IR downregulation inhibited glucose uptake of A2780, C30 and H460 Glucose uptake of cancer cells partially depends on insulin-induced signaling via the IR 
(23) and inhibition of the glucose uptake can cause p53 accumulation in these cells (43,44). To determine the effect of IR downregulation on the glucose uptake in A2780, C30 and H460 cells, we have measured [18F]FDG uptake. IR siRNA decreased [18F]FDG uptake by approximately 40% in all three cell lines, while IGF-lR siRNA did not affect [18F]FDG uptake in C30 and H460 but did reduced the uptake in A2780 cells by 20% (Figure 5). 
Glucose deprivation enhanced DR-induced apoptosis Next, we investigated whether the enhanced apoptotic effect of rhTRAIL (variants) following IR downregulation was due to reduced glucose uptake. Cells were deprived of glucose using 2-deoxy-D-glucose (2-DG) and DR-induced apoptosis was measured. 2-DG, a synthetic glucose analogue, is a competitive inhibitor of glucose metabolism that can not be metabolized (45). Increasing 2-DG concentrations up to 20 mM induced little apoptosis in the cell lines tested. However, upon combination with rhTRAIL, 4C7 (used for H460 and TOV21G) and D269H/El95R strong apoptosis induction was observed. The different rhTRAIL variants induced similar apoptosis levels of ~80% in H460 and TOV21G. InA2780 
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and C30, D269H/El95R did induce more apoptosis compared to rhTRAIL. Interestingly, 
glucose deprivation appeared to sensitize C30, the 75-fold cisplatin resistant subline of 
A2780, to apoptosis induction more effectively than A2780. This was indicated by the 
lower concentration of 2-DG (5 mM) that sensitized C30 cells for the most part to rhTRAIL 
and D269H/E195R, while in A2780 20 mM 2-DG was required to obtain the same effect. 
Remarkably, apoptosis levels following IR downregulation in combination with rhTRAIL 
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Figure 5 I IR downregulation inhibited glucose uptake of A2780, C30 and H460. Glucose uptake as measured using [18F]FDG in A2780, C30 and H460 48 h following IR downregulation was -40% lower. IGF-lR had no effect on glucose uptake of C30 and H460, and little effect in A2780. 
Glucose deprivation enhanced DR membrane expression and p53 protein levels 
Following IR downregulation, p53 protein levels as well as DRS membrane expression 
were increased. To further investigate the causal relation with glucose deprivation, p53 
and DRS levels were examined after 2-DG treatment in A2780, C30, TOV21G and H460 
cells. Similar to the effect of IR downregulation, p53 levels were increased in A2780, 
upon 2-DG treatment. DRS membrane expression levels decreased following 5 and 10 
mM 2-DG, and were back to basal level following 20 mM 2-DG. In C30, p53 upregulation 
was less pronounced, except following treatment with 10 mM 2-DG (Figure 6B). At this 
2-DG concentration, DRS membrane expression was also increased. Induction of p53 
was observed in H460 and TOV21G cells at the lowest 2-DG concentration, while DRS 
membrane levels were higher following increasing doses of 2-DG. Interestingly, in contrast 
to IR downregulation glucose deprivation resulted in enhanced DR4 membrane levels in 
H460 and TOV21G (Figure 6C). DcR2 levels remained stable in all cell lines. 
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Figure 6A I Glucose deprivation enhanced DR-induced apoptosis, p53 protein levels, and 
DRS membrane expression. (A) Decreased glucose uptake was mimicked using 2-DG treatment for 48 h. Increasing concentrations of 2-DG up to 20 mM strongly enhanced apoptosis induction by rhTRAIL, 4C7 and D269H/El95R in A2780 (0.1 µg/ml, 4 h), C30 (0.1 µg/ml, 4 h), H460 (0.01 µg/ml, 24 h) and TOV21G (0.25 µg/ml, 24 h). 
117 
5 














A2780 C30 H460 TOV21 G 
.... ..1 1-- -'  , ,  ...... ...., .... , ,  ---1 
4 1  1 1  .- - 1 1-............. __.d 
5 10  20 0 5 10  20 0 5 1 0  20 0 5 10  20 
A2780 






300 ■ DRS 
250 □ DcR2 
200 






5 10  
2-DG (mM) 
TOV21 G  
20 
JOO □ DR4 
250 ■ DRS 
C DcR2 
□ DR4 
100 ■ DRS 
80 a DcR2 
200 
i 1 so 
1 00 
50 
0---....... ---. ........ -................ --..... 






0 +--•o-....,_ ...... s._.,...,..... ... 1_0 ........ .,...._ .. 2.0........, 
2-DG {mM) 
Figure 6B-C I Glucose deprivation enhanced DR-induced apoptosis, p53 protein levels, and 
DRS membrane expression. 
(B) P53 protein levels, determined by Western blotting, were enhanced following increasing concentrations 
of 2-DG (48h) in A2780, H460 and TOV21G. In C30 p53 levels increased after 10 mM 2-DG. (C) DRS and DR4 
membrane expression, measured by FACS analysis, dose dependently increased in H460 and TOV21G upon 
treatment with 2-DG (48 h). 
Glucose deprivation in combination with rhTRAIL (variants) strongly enhanced 
cleavage of caspases 8, 9, 3 and PARP We sought to study the glucose deprivation-induced enhancement of apoptosis at the protein level in more detail. Cleavage of caspases and P ARP was measured following combination treatment of H460 cells. 2-DG alone did not induce any caspase or PARP cleavage. Exposure to the rhTRAIL variants alone induced mild cleavage of all three caspases and PARP with 4C7 being most potent. Upon combination, strong caspase and 
118 
Chapter 5 I IR-signaling protects cancer cells against TRAIL DR-induced apoptosis 
A H460 
Caspase a l 
p18 :=, 
============ 
Caspase 3 !.._ .._. ...,  
Cleaved caspase 3 I :============: 
Caspas• • 1 - - - - - --1 
:============: 
Bid 1---- - -...... - 1 
PARP I - I 
:============: 











100 a control 
C rhTRAIL 
■ 4C7 
� 80 a D269H/E195R 
.!!! 60 




04--__ ...._...,_....___ _ _._ _____ __ 
neg c siRNA IR siRNA IGF-1R siRNA 
D 
B H460-Bcl2 
IR I I :======== 
IGF-1R I ... I 
p53
1 � ......,. ----1 








100 a control 
�rJbT.fAIL 
�











Figure 7 I The intrinsic apoptosis pathway was essential for apoptosis induction by IR 
inhibition or glucose deprivation combined with rhTRAIL (variants). 
(A) Combination of 2-DG (10 mM, 24 h pre-treatment) and rhTRAIL, 4C7 or D269H/El95R (0.01 µg/ml, 4 h) induced strong activation of caspases 8, 3, and 9 and cleavage of PARP in H460. Single treatment with 2-DG did not induce any caspase or PARP cleavage. (B) IR and IGF-lR were downregulated efficiently in H460-Bcl2 cells. P53 protein levels were increased following IR siRNA, but not after IGF-lR siRNA. (C) Downregulation of IR and IGF-lR in H460 overexpressing Bcl2 did not increase apoptosis induction by rhTRAIL, 4C7 or D269H/El95R (0.1 µg/ml, 24 h). (D) Increasing the 2-DG dose (48 h) did not enhance apoptosis induction by rhTRAIL, 4C7 or D269H/E195R (0.1 µg/ml, 24 h) in H460 over-expressing Bcl2. 
PARP cleavage occurred, again most potently by 4C7 combined with 2-DG (Figure 7A). 
Similar to the IR siRNA experiments, caspase 9 seemed to be activated via self-cleavage as 
the 35 kDa cleavage product is the most prominent band. 
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IR downregulation or 2-DG treatment did not convert type II cells into type I cells The mitochondrial apoptosis pathway is instrumental for rhTRAIL induced apoptosis in H460 cells (type Il cells) (35). Therefore, we investigated whether activation of the mitochondrial apoptosis pathway was important for the sensitizing effect of both IR downregulation and glucose deprivation. To this end we used H460 cells over-expressing Bcl-2, an anti-apoptotic BH-3 only protein, in which the mitochondrial pathway is shut down completely (35,46). P53 levels increased upon IR downregulation in H460-Bcl2 (Figure 78). In parental H460 cells, apoptosis (~20% of the cells) was observed following treatment with IR siRNA alone, ~60% with 4C7 alone and ~80% upon combination of rhTRAIL (variants) with IR downregulation or glucose deprivation (See figures 2A and 6A). In H460-Bcl2 cells, IR downregulation, 2-DG, or rhTRAIL (variants) did not induce any apoptosis. Upon combination treatment, apoptosis levels did not exceed 20%, indicating that activation of the mitochondrial apoptosis pathway is essential for the enhanced apoptotic effect of IR downregulation or glucose deprivation on rhTRAIL (variants) sensitivity in H460 cells (Figure 7 C, D). Discussion In the present paper, we show that inhibition of the IR strongly enhanced TRAIL DR­induced apoptosis in several ovarian carcinoma and NSCLC cell lines. IR downregulation circumvented rhTRAIL-resistance, as demonstrated for rhTRAIL-resistant A549 cells. Moreover, IR downregulation in combination with DR-targeting drugs was also effective in cisplatin-resistant C30 cells. In contrast, IGF-lR inhibition had no effect or even prevented TRAIL DR-induced apoptosis in all cell lines used. Moreover, we provide evidence that the enhanced apoptotic effect following IR downregulation is related to a decrease in cellular glucose uptake and the induction of p53. Traditionally, the focus of inhibition of the IGF axis has been on targeting IGF-lR. Anti­IGF-lR targeting therapies are currently in various phases of clinical development (47,48). This approach which has a strong rationale based on preclinical data, is still controversial. In colon cancer patients for example, an IGF-lR antibody added to chemotherapy even had a detrimental effect on treatment outcome (49). Neglecting the potential to inhibit the IR probably reflects the concern of metabolic toxicity of this approach. However, this view might be reconsidered as there is mounting evidence that the IR plays a major role in tumor biology (22,27). For that reason, we specifically downregulated IR or IGF-lR to investigate their individual effect on TRAIL DR-induced apoptosis. To our knowledge, we are the first to describe that IR downregulation strongly enhanced TRAIL DR-induced apoptosis. In contrast, downregulation of the IGF-lR did not result in enhanced apoptosis induction, or even reduced apoptosis levels in some cell lines. A recent report from our group showed that inhibition of IGF-lR with the tyrosine kinase inhibitor (TKI) NVP-AEW541 inhibited 120 
Chapter 5 I IR-signaling protects cancer cells against TRAIL DR-induced apoptosis apoptosis induction by rhTRAIL in colon cancer cells (50). The IGF-lR inhibitor cyclolignan picropodophyllin (PPP) on the other hand, enhanced apoptosis induction by rhTRAIL in melanoma cell lines specifically expressing DRS (51). These data demonstrate that IGF-lR inhibition, similar to IGF-lR downregulation, does not always lead to enhanced apoptosis via both TRAIL-DRs. It is known for decades that insulin stimulates cancer cell proliferation in vitro (52). More recently, the importance of the IR was underscored in vitro and in vivo in a human xenograft mouse model. IR downregulation inhibited cancer cell proliferation, metastasis and vessel formation in breast cancer cells (53). In addition, specific IGF-lR inhibition increased insulin-induced IR-mediated phosphorylation of Akt and glucose uptake in breast cancer cells (54). Similar results were obtained in an in vivo mouse model of human pancreatic neuroendocrine cancer in which the IR enhanced tumor progression and induced resistance to IGF-lR targeted therapy (55). Given the fact that the IR and IGF­lR initiate similar signaling pathways and that compensating mechanisms have been described following targeting of a single receptor, co-targeting of the IR and IGF-lR is of potential interest (54-58). This can be achieved by combination of receptor specific agents, or by TKis that inhibit both receptors simultaneously. BMS-754807 and OSI-906, both dual IR/ IGF-lR targeting TKis, indeed effectively inhibited growth of various cancer cell lines and in human xenograft mouse models and are currently in early clinical development (59-63). Based on our current data it would be very interesting to consider the combination of dual IR/IGF-lR targeting TKis with DR-targeting apoptosis inducers for testing in the clinic. Especially since the enhanced apoptotic effect that we observed was not DR specific, this combination might be versatile. The inhibitory effect on DR-induced apoptosis following IGF-lR downregulation as we have shown, suggests that in some cancers specific IR inhibition might be beneficial over dual IR and IGF-lR inhibition. We showed that p53 protein levels strongly increased upon IR downregulation. P53 siRNA experiments demonstrated that the enhanced apoptotic effect was p53-dependent. As p53 negatively regulates both IR and IGF-lR expression levels, this may appear counterintuitive (64,65). However, IR knockdown presumably also affects p53 indirectly, since reduced IR signaling affected glucose uptake in our experiments. This is even further substantiated by our findings that glucose deprivation with 2-DG also resulted in increased p53 expression levels. P53 plays an important role in the regulation of cellular energy metabolism. Glucose deprivation-induced p53 activation and p53 dependent apoptosis induction have been described previously (43,44). Under conditions of low nutrient availability, p53 is activated and promotes oxidative phosphorylation over glycolysis via decreased glucose transporter expression, decreased IR expression and decreased glycolytic rate via TP53-induced glycolysis and apoptosis regulator (TIGAR), thus maximizing ATP production (for review see ref. (66)). Increased mitochondrial activity induced by p53 might also lead to increased activation of the mitochondrial apoptosis pathway. Previously, 
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Chapter 5 I IR-signaling protects cancer cells against TRAIL DR-induced apoptosis various combination strategies with rh1RAIL converted type II cells, i.e. depending on activation of the mitochondrial apoptosis pathway, into type I cells, i.e. directly activating caspase 3 sufficiently via caspase 8 (67-70). H460 is a type II cell line (35). Therefore, we used H460-Bcl2 cells and demonstrated that Bcl-2 overexpression completely blocked apoptosis. Although we found enhanced caspase 8 activation, these results demonstrate that the type II cell line H460 was not converted into a type I cell line following the combination of IR downregulation or glucose deprivation and rh1RAIL. Hence, both the death receptor and the mitochondrial apoptosis pathways were activated. In case of severe starvation, either autophagy or apoptosis can be induced as a cell survival or cell death mechanism respectively (66). In our experiments, the balance shifted towards apoptosis and not autophagy. To what extent p53 plays a role in this balance shift is unknown. However, apoptosis induction was not completely abrogated by p53 knockdown. This indicates that other proteins that contribute to apoptosis induction, for example AMPK, Mcl-1 or DRS are effected as well (71,72). Previously, 2-DG enhanced rh1RAIL-induced apoptosis via AMPK activation and Mcl-1 downregulation in leukemic and cervical cancer cell lines (71) and via DRS upregulation in melanoma cells (72). In our experiments, pAMPK decreased following IR downregulation and 2-DG treatment. We did not observe a consistent effect on Mcl-1 expression in our cell line panel (data not shown). Various drugs which exploit the Warburg effect are in different stages of development (73,74). As 2-DG is well tolerated in patients (75), our data provide a rationale to target glucose metabolism in combination with rh1RAIL-induced apoptosis, which is also able to enhance apoptosis induction in both cisplatin- and rhTRAIL resistant cell lines. Conclusively, the data presented here indicate that the IR and tumor cell metabolism are potential anti-tumor targets, especially when combined with JR.AIL DR-targeting agents. Acknowledgments This work was performed within the framework of Dutch Top Institute Pharma, project 'TNF ligands in cancer' project nr T3-112 and partly supported by grant RUG 2010-4603 of the Dutch Cancer Society. 
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Chapter 6 I Functional analysis of DRS isoforms Abstract TNF related apoptosis inducing ligand (rhTRAIL) is an interesting apoptosis inducing agent, due to its specificity against cancer cells. Binding of rhTRAIL to death receptor 4 (DR4) and death receptor S (DRS) initiates the formation of the death inducing signaling complex, leading tot apoptotic cell death. Two isoforms of DRS have been identified in humans, designated DRS(S) for the short isoform and DRS(L) for the long isoform, the latter containing 29 additional amino acids in the extracellular domain. The functionality of the isoforms remains unclear, including their binding affinities to rhTRAIL, rhTRAIL variants or agonistic DR antibodies. Specific targeting of either one of the DRS isoforms may improve apoptosis induction in tumor cells, providing a rationale to develop isoform selective agents. Therefore, the aim of this study was to investigate the functionality of the two DRS isoforms and to develop agonistic antibodies against DRS with isoform-specific binding characteristics. We showed that both isoforms were commonly expressed in a panel of 16 human cancer cell lines with similar isoform expression levels within each cell line. Chinese hamster ovary (CHO) cells were stably transfected with each individual human DRS isoform. In this model, we showed that both isoforms could bind rhTRAIL as well as D269H/El95R, a DRS-selective rhTRAIL variant. Additionally, both DRS(L) and DRS(S) are capable of initiating an apoptotic signal upon ligand binding. The 'agonistic' antibody against DRS that was developed, displayed binding to DRS as measured by ELISA. However, the antibody also had non-specific binding activity in CHO cells stably expressing human DRS(L) and DRS(S), and in DRS expressing human A2780 ovarian cancer cells. Moreover, the candidate DRS agonistic antibody failed to trigger apoptosis in A2780 cells or Colo205 colon cancer cells. In conclusion, we showed that the two DRS isoforms are commonly expressed in human cancer cell lines and bind rhTRAIL. We have provided data that the individual isoforms can induce an apoptotic signal. 
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Apoptosis is a highly regulated form of cell death that developed in multi-cellularorganisms 
to eliminate damaged or aged cells (1). Evasion of apoptosis was recognized as one of the 
hallmarks of cancer (2). As apoptosis results in the formation of apoptotic bodies that are 
cleared by the immune system without causing an inflammation response, induction of 
apoptosis has been an important strategy in anti-cancer treatment (3). However, acquired 
apoptosis resistance due to alterations in apoptotic protein expression profiles is a major 
problem. Therefore, it is of interest to develop new strategies to induce apoptosis in 
cancer cells. Recombinant human TNF related apoptosis inducing ligand (rhTRAIL), also 
known as Apo2L or dulanermin, is an attractive apoptosis inducing agent. It selectively 
induces apoptosis in cancer cells and is well-tolerated in patients (4-8). RhTRAIL is a type 
II trans-membrane protein that is expressed as a homotrimer (9,10). RhTRAIL binding to 
death receptor 4 (DR4 or TRAIL-Rl) and death receptor 5 (DRS or TRAIL-R2) results in 
receptor trimerization and initiates the formation of the death inducing signaling complex 
(DISC) (11). DISC formation activates the caspase cascade, resulting in apoptosis (12). The 
tumor-specific activity of rhTRAIL is a major advantage of rhTRAIL. However, rhTRAIL 
resistance has been reported frequently and recent results from randomized phase 2 trials 
show no beneficial effect of rhTRAIL addition to conventional chemotherapeutic treatment 
(13-16). To enhance the efficacy of apoptosis induction via the TRAIL death receptors (DRs), 
numerous combination studies with radiation and various chemotherapeutic agents have 
been performed and indeed show enhanced apoptotic effects in the pre-clinical setting 
(17). Another strategy to enhance apoptosis induction by rhTRAIL is the development of 
DR-selective rhTRAIL variants and agonistic antibodies to specifically target one TRAIL­
DR (18,19). For example, D296H/E195R, a DRS-selective variant of rhTRAIL, has increased 
affinity for DRS and was a more effective apoptosis-inducer as compared to rhTRAIL in 
various cell lines and in a bioluminescent xenograft human ovarian cancer model (20,21). A 
possible advantage of the DR-specific antibodies on the other hand, is the extended serum 
half-life compared to rhTRAIL, which is in humans around 2-2.5 weeks versus 25 min for 
rhTRAIL (16,22,23). Agonistic DR antibodies are currently under investigation in several 
phase 1 and 2 clinical trials, as single agents or in combination with chemotherapeutics. 
The antibodies are generally well-tolerated, also when combined with chemotherapy (for 
review see (24)). 
An overwhelming amount of research has been performed on rhTRAIL, the development 
of DR-specific targeting agents and their use as single agents or in combination treatments. 
However, the existence of and the role for the two isoforms of DRS are commonly ignored. 
Due to alternative splicing, two isoforms of DRS are expressed that differ in a 29 amino 
acid domain located extracellular in close proximity to the transmembrane domain of DRS 
(Figure lA) (25). These isoforms, designated DR5(S)/TRAIL-R2(S) for the short isoform 
and DR5(L)/TRAIL-R2(L) for the long isoform, are expressed in normal and tumor tissues 
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Chapter 6 I Functional analysis of DRS isoforms (25). Whether the two isoforms differ functionally is still unclear. We hypothesize that more knowledge concerning the functionality of the two DRS isoforms might provide the rationale for DRS isoform selective therapy. Therefore, the aim of this study was to investigate the functionality of the two DRS isoforms individually with respect to apoptosis signaling and binding affinities to rhTRAIL, rhTRAIL variants, and agonistic antibodies. In addition, we aimed to develop agonistic antibodies against DRS with isoform-selective binding characteristics. 
Materials and Methods 
Reagents RhTRAIL and D269H/E19SR were produced as described earlier (21). Cycloheximide (CHX) was purchased from Sigma-Aldrich. 
Cell culture The human ovarian cancer cell line A2780 was kindly provided by Dr Hamilton (Fox Chase Cancer Center, Philadelphia, Pennsylvania). A2780 was cultured in RPMI 1640 (Invitrogen), supplemented with 10% heat inactivated fetal calf serum (FCS) (Bodinco BV) and 0.1 M L-glutamine. The human colon carcinoma cell line Colo20S was purchased from ATCC. Colo20S was cultured in RPMI 1640, supplemented with 10% heat inactivated FCS. Both cell lines were cultured in a humidified atmosphere at 37°C with S% CO2• Culture medium for mouse El.4 BS cells and mouse B-cell culture consisted of DMEM/F12 HAM (Sigma) supplemented with 0.8% (v/v) Pen/Strep (Gibco), 1.25% {v/v) L-glutamine (Gibco), 0.5% {v/v) sodiumpyruvate (Gibco), 10% {v/v) bovine calf serum (Hyclone), 0.1 % {v/v) 2-mercaptoethanol (Gibco) and 5-10% (v/v) T-cell supernatant (produced by PMA/PHA stimulated human peripheral blood mononuclear cells). Basic culture medium for all other cell lines consisted of DMEM/F12 HAM (Gibco) supplemented with 0.8% (v/v) Pen/ Strep (Gibco). For hybridoma culture, this basic culture medium was supplemented with 0.5% (v/v) sodiumpyruvate, 0.1 % (v/v) 2-mercaptoethanol, 10% fortified bovine serum (Hyclone), 2% {v/v) hypoxantine/thymidine (ill) supplement (Gibco) and 2% (v/v) IL-6 containing supernatant produced by a human bladder carcinoma cell line T24 (T24-CM). In hybridoma selection medium, aminopterin was added by using 2% (v/v) HAT media supplement (Sigma) instead of ill-supplement. The Chinese hamster ovary (CHO) cell line and its sublines were cultured in basic culture medium supplemented with 5% {v/v) fortified bovine serum (Hyclone). For CHO­DRS cell lines, 10 µg/ml blasticidin (Invitrogen) was added. The mouse myeloma cell line SP2/0-Ag14 was cultured in basic culture medium supplemented with 0.5% (v/v) sodium pyruvate, 0.1 % (v/v) 2-mercaptoethanol and 10% fortified bovine serum. 
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RT-PCR Reverse transcriptase PCR (RT-PCR) was performed on RNA isolated from a panel of cell lines. RNA extraction, cDNA synthesis and GAPDH PCR were performed as previously described (26). DRS were designed according to Wang et al. (25) and were 5'-ACACA­GTGTGTCAGTGCGAAGAAGG-3' and 5' -CAGCGTCTCCAAGGCATCCA-3'. Primer sequences for GAPDH were S'CACCACCATGGAGAAGGCTGG 3' (forward) and S'CCA­AAGTTGTCATGGATGACC 3' (reverse). RT-PCR was performed as described previously (25). RT-PCR products were visualized by 1.5% agarose gel electrophoresis in lx Tris-Borate EDTA buffer. 
RNA interference Small interfering RNA (siRNA) specific for DRS was designed. The double stranded sequence was: 5'GACCCUUGUGCUCGUUGUC-dTdT3' (sense) 5'GACAACGAGCACAAGG­GUC-dTdT3' (anti-sense). Cells were seeded in 6-wells plates. The next day, the subconfluent cells were incubated in Optimem® medium and transfected with 133 nM DRS or negative control siRNA (Eurogentec) using Oligofectamine® reagent according to the manufacturer's protocol (Invitrogen). Twenty four h after siRNA treatment, medium was changed to RPMI supplemented with 10% FCS and after another 24 h, FACS analysis was performed. 
Flow cytometry Cells were harvested with trypsin for 5 min at 37°C and washed twice with cold phosphate buffered saline (PBS) supplemented with2% FCS and 0.1 % sodium azide. TRAIL-R2 (HS201) from Alexis was used as primary antibody to determine DRS expression and phycoerythrin (PE) conjugated goat anti-mouse as a secondary antibody. Mouse IgG (DAKO) served as isotype control. For the competition experiments, cells were incubated with 1 µg/ml rhTRAIL or D269H/E195R for 1 h on ice and washed twice prior to the incubation with the primary antibodies. DRS antibody (HS201) from Alexis, DRS antibody from eBioscience and an agonistic DRS antibody served as primary antibodies. PE conjugated goat anti­mouse and fluorescein isothiocyanate (FITC) conjugated mouse anti-human served as secondary antibodies. DRS membrane expression was analyzed using a flow cytometer (Epics Elite, Coulter-Electronics) and is shown as mean fluorescent intensity (MFI) of all analyzed cells from at least three separate experiments. 
Western blot analysis Cells were seeded in 6-wells plates and treated as indicated. Following treatment, cells were harvested at indicated time points by treatment with trypsin for 5 min at 37°C and washed twice with cold PBS. Preparation of total cell lysates and Western blot analysis was performed as described previously (26). Immunodetection of the protein of interest was 131 
Chapter 6 I Functional analysis of DRS isoforms performed according to the manufacturer's protocol. The following primary antibodies were applied: cleaved caspase 3 (9661), caspase 8 (9746) (both from Cell Signaling), and DRS (ALX-210-743-c200, Alexis). Binding of these antibodies was determined using horseradish peroxidase (HRP)-conjugated secondary rabbit anti-mouse, goat anti-rabbit, and rabbit anti-goat antibodies (all from DAKO). Visualization was performed with LumiLight Plus Western Blotting Substrate (Roche Applied Science). Equal protein loading was confirmed by immunostaining with �-actin antibody (ICN Pharmaceuticals). All experiments were performed at least three times. 
Determination of apoptosis Cells were seeded in 96-well tissue-culture plates and treated as indicated. Following treatment, apoptosis was identified by staining nuclear chromatin with acridine orange. Apoptosis was defined by the appearance of apoptotic bodies and/or chromatin condensation by fluorescence microscopy and was expressed as the percentage of apoptotic cells in a well. All experiments were performed at least three times. 
Production and purification of anti-DRS antibodies pSB6-hDRS-TVl, expressing DRS(L) and pSB6-hDR5-TV2, expressing DRS(S) were used to stably transfect CHO cells with each DRS isoform. CHO cells were FACS-sorted based on DRS expression as measured by DRS antibody (HS201) from Alexis and puromycin was used for positive selection. Antibodies were generated using pre-selection of B cells and the mini-electrofusion method (27,28). In short, 7-8 week old female BALB/C mice were immunized with gold bullets coated with DRS(L)- or DRS(S)-, mFLEX- and mGM-CSF­plasmids in a 2:1:1 ratio in both ears using a Helios Gene gun (BioRad). Immunization was performed with coated gold bullets every 3 weeks. One week after the second till fifth immunizations blood was drawn to examine serum antibody titres. Four days after the final boost, mice were sacrificed and erythrocyte-depleted spleen cell populations were prepared as described previously (29,28) and frozen at -140°C. Selection of specific B-cells was done by performing a cell-panning. Frozen splenocytes from two DRS(L) immunized mice were pooled and panning was performed on irradiated CHO-DRS(S) cells. After positive selection, antigen-specific B-cells were cultured as described (27). B-cell clones were selected and immortalised by mini-electrofusion to generate hybridomas. B-cells from one single well were fused (in duplo) with mouse myeloma SP2/0-Ag14 cells and limiting dilution series were performed to obtain stably growing clones, producing monoclonal antibodies. After each limiting dilution hybridoma cultures from wells with the highest cell-dilution, with the highest absorbance and best cell growth were selected for prolonged culture and storage. In total, only one monoclonal antibody­producing hybridoma was obtained from 12 electrofusions. 
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A small batch of antibodies was obtained by culturing the hybridoma in Hybridoma 
Serum Free Medium (SFM) complemented with Pen/Strep, 2% T24 and HT supplement 
for 8-10 days. After harsh centrifugation, supematants were concentrated using filter units 
(Millipore). Purification of the antibodies was performed with Protein A HP SpinTrap™ 
columns from GE Healthcare and binding buffer A, neutralization buffer C and elution 
buffer B2 (pH 2.5) from the Montage Antibody Purification Kit from Millipore. The 
antibody purification protocol was used as described in the Instructions for the Protein A 
HP Spintrap from GE Healthcare. Samples were diluted in a 1:1 ratio with binding buffer 
A before applying them to the SpinTrap columns. After purification, antibody solutions 
were desalted by applying them to a PD-10 desalting column. Final storage buffer of the 
antibodies was sodium acetate buffer (20mM pH of 5.5). Concentrations were determined 
by in duplo measurements on the Nanodrop. 
DR5 binding and blocking ELISA 
Mice sera, hybridoma supematants and commercial DR4 and DRS antibodies were tested 
for DRS and DR4 binding in an ELISA. Nunc Maxisorp 96/wells plates were coated with 
nothing, IgG-Fc, DR4/Fc, or DRS/Fe (R&D systems) overnight at 4°C. Plates were blocked 
with PBS/2% BSA for 2 h at RT, washed 3 times with PBS/0.05% Tween 20, and incubated 
with antibody, diluted in culture medium with 10% BCS for 1 h at 37°C. Antibodies used 
were hDRS.01, DR4 (HSlOl, Alexis) and DRS (HS201, Alexis). Following incubation, plates 
were washed 3 times with PBS/0.05% Tween 20 and bound antibodies were detected 
using goat-anti-mouse IgG-HRP (Southern Biotech) for 1 h at 37°C, washed 6 times, and 
visualized using OptiEIA TMB substrate (BD Bioscience). 
Results 
Alignment of DR4, DR5(L) and DR5(S) 
Alignment of DR4, DRS(L) and DRS(S) was performed to compare the structures of all 
TRAIL DRs. The alignment demonstrated that DRS(L) is the most aberrant receptor 
compared to DR4 and DR5(S) (Figure lB). 
Stable overexpression of human DR5(L) and DR5(S) in CHO cells 
In order to assess the functionality of the two DRS isoforms, a cell line model was developed 
consisting of CHO cells stably transfected with either human DRS(L) or DRS(S) (Figure 2). 
Notably, DRS(S) expression was lower compared to DRS(L) at the mRNA (Figure 2A) and 
protein (Figure 2B) level, while its membrane expression was higher (Figure 2C). 
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Figure 1 I Structure of DRS isoforms. (A) Two isoforms are expressed that differ with respect to a 29 amino acid stretch fragment located extracellular in close proximity to the transmembrane domain of DRS. (B) Alignment of all TRAIL DRs showed that DRS(L) differs most compared to both DR4 and DRS(S). Pink highlight: SNP location that has been described for DR4, yellow highlight: transmembrane domain. Binding of commonly expressed DR5(L) and DRS(S) to rhTRAIL 
The expression levels of the DRS mRNA isoforms were analyzed in 16 human cancer cell 
lines of various tumor types, including ovarian, colon, testis, breast and lung cancer. The 
CHO-DRS(L) or -DRS(S) overexpression model served as positive control. All cell lines 
expressed both isoforms, although the absolute DRS mRNA expression levels varied 
between the different cell lines. The expression levels of the two isoforms within each 
cell line were comparable (Figure 3A). Next, binding capacity of rhTRAIL to the DRS 
isoforms was examined by a competition assay for receptor binding. The DRS-selective 
rhTRAIL variant D269H/El9SR was also included, as it shows enhanced DRS binding 
properties compared to rh1RAIL (21). CHO-wild type (WT), CHO-DRS(L) and CHO­
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103  Figure 2 I CHO cell line model with specific overexpression of DRS(L) o r  DRS(S). 
(A) RT-PCR for CHO cells stably transfected with DR5(L) and DR5(S) demonstrated specific mRNA expression of negative control (CHO-WT), DR5(L) and DR5(S). (B) Western blot analysis of CHO cells stably transfected with DR5(L) and DR5(S) showed specific protein expression of each isoform. (C) FACS analysis of CHO cells stably transfected with DR5(L) and DR5(S) showed increased membrane expression of DR5(S) compared to DR5(L). the ligands to the DRS receptors, without inducing receptor internalization or apoptosis. Subsequently, FACS analysis was performed using different primary DRS antibodies in order to investigate whether competitive binding of rhTRAIL / D269H/El9SR prevented binding of the antibodies to the DRS isoforms. :MFI levels of CHO-DRS(L) and CHO­DRS(S) pre-incubated with rhTRAIL or D269H/E195R were largely reduced compared to untreated controls, indicating that rhTRAIL and D269H/El9SR block binding of all three DRS antibodies to the DRS isoforms. Competitive binding of rhTRAIL and D269H/ E19SR reduced binding of the DRS detecting antibodies to DRS(S) more than binding to 
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Figure 3 I DRS(L) and DRS(S) are both expressed in cancer cell lines and bind rhTRAIL. 
(A) RT-PCR for DRS(L) and DRS(S) in 16 different human cancer cells lines showed that both isoforms are generally expressed with similar mRNA expression levels in each cell line. 1. A2780 2. C30 3. CP70 4. SW948 5. SW250 6. Colo205 7. Lovo 8. TeraCP 9. MCF7 10. SKOV3 11. SKBR3 12. T47D 13 A549 14. SW1573 15. H460 16. Tera 17. CHO-WT 18. CHODRS(L) 19. CHO-DRS(S). (B) FACS analysis of CHO-DRS(L) (upper panel) and CHO-DRS(S) (lower panel) with or without pre-incubation of rhTRAIL or D269H/E195R showed that MFI levels decrease following pre-incubation, indicating that the DRS ligands compete with the different FACS antibodies for binding to both DRS(L) and DRS(S). The decrease in MFI was stronger in the CHO-DRS(S) cells. 
Functionality of DRS(L) and DRS(S) The ability of the DRS isoforms to initiate apoptosis was investigated. RhTRAIL, D269H/ E195R and an agonistic anti-DRS antibody were applied as single agents, but did not 
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Chapter 6 I Functional analysis of DRS isoforms induce any apoptosis (Figure 4). Next, cells were co-incubated with the protein translation inhibitor cycloheximide (CHX), a known enhancer of rhTRAIL-induced apoptosis, and different DRS-targeting agents for 6 h. CHX alone did not induce apoptosis in CHO­WT cells. Surprisingly, CHO-DRS(S) and CHO-DRS(L) cells were sensitive to CHX treatment with CHO-DRS(L) cells being the most sensitive. Upon combination with the DRS-targeting agents, still no apoptosis was observed in CHO-WT cells, while apoptosis levels in CHO-DRS(L) cells were slightly increased. In CHO-DRS(S) cells, combination with rhTRAIL only slightly enhanced apoptosis levels, D269H/El9SR was more effective, and the agonistic DRS antibody showed the largest effect at this concentration (Figure 4). Interestingly, apoptosis induction following the DR-ligands was similar in CHO-DRS{L), while DRS-selective targeting was more effective compared to rhTRAIL in CHO-DRS(S). Notably, DRS sensitivity of CHO-DRS(L) versus CHO-DRS(S) was related to the membrane expression levels of the DRS isoforms (see figure 2C). In conclusion, these data indicate that in this murine model, both human DRS(L) and DRS(S) are capable of initiating apoptotic signaling. 
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(A) CHO-WT, CHO-DRS(L), and CHO-DRS(S) cells were treated with rhTRAIL (0.25 µg/ml), D269H/El95R 
(0.25 µg/ml), or an agonistic DRS antibody (25 nM) in combination with CHX for 6 h. In CHO-WT cells, no 
apoptosis was induced. In CHO-DRS(L) single treahnent with CHX induced up to -20% apoptotic cells, 
and when combined with the different DR ligands, the percentage of apoptotic cells increased till -40 %. In 
CHO-DRS(S) CHX was less effective with -10% apoptotic cells. In combination with rhTRAIL, D269H/El95R, 
and an agonistic DRS antibody, the percentages of apoptotic cells were -20%, -30%, and -40% respectively. 
Development of DRS antibody To further investigate the functional properties of the DRS isoforms, we set out to develop agonistic antibodies against DRS(S) and DRS(L). A unique approach was used. Instead of injecting mice with recombinant human DRS protein/peptides, mice were immunized with plasmids encoding each isoform specifically. DRS-reactive B cells were isolated using 
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Chapter 6 I Functional analysis of DRS isoforms panning procedures on CHO-cells stably expressing DRS(S) or DR5(L). Bound B-cells were immortalized via mini-electrofusion as described previously (27). Only one hybridoma designated hDRS.01 was isolated and cell-panning selection experiments with CHO­DRS(L) and CHO-DRS(S) cells demonstrated that hDRS.01 was not DRS isoform specific. Binding of purified hDRS.01 to DRS was measured in an ELISA (Figure SA). Non-specific binding to the empty plate, IgG control and DR4/Fc coated wells was observed. Binding to DRS, however, was specifically increased compared to IgG (effective concentration (EC)50 0.01 versus 3.69), but the affinity was lower compared to the Alexis positive control DRS antibody (EC50 0.0022) (Figure SA). A DR4 antibody was also included in this ELISA as a control and did not bind to DRS/Fe (data not shown). DR5- specific and non-specific cell surf ace binding of hDR5.01 To test the specificity of the purified hDRS.01 antibody in an isogenic cell line model, CHO-WT, CHO-DRS(S) and CHO-DRS(L) cells were exposed to increasing antibody concentrations and binding was determined by FACS. Binding of hDRS.01 was compared to a commercially available primary antibody. The commercial antibody did bind only to CHO-DRS(L) and DRS(S) cells but not to the non-DRS expressing CHO-WT cells. In contrast, the hDR5.01 antibody did show binding to CHO-WT cells but higher MFI levels were observed for CHO-DRS(L) and CHO-DRS(S) cells, suggesting some selectivity. Specific binding of hDRS.01 to DRS expressing cells did not improve upon dilution of the antibody (Figure 5B). To confirm that hDRS.01 displays DRS-(in)dependent binding properties, antibody binding was examined in A2780 cells following DRS knockdown with siRNA. Indeed, DRS downregulation was confirmed using both a commercial antibody and hDRS.01. However, the commercial antibody showed a 4-fold reduction in binding to DRS knockdown cells, whereas only an approximately 40% reduction was observed with hDRS.01 (Figure SC). Taken together, these results indicate that hDRS.01 displayed DRS-specific and non-specific cell surface binding. HDR5.01 did not induce apoptosis in cancer cell lines To test whether hDRS.01 could initiate apoptosis in cancer cells, the colon carcinoma cell line Colo205 was treated with hDRS.01 and apoptosis induction was compared to the apoptosis-inducing efficacy of an agonistic DRS control antibody. Upon treatment with increasing concentrations of hDRS.01 up to 500 nM, no apoptosis was observed, while 1 nM of the agonistic DRS antibody was sufficient to induce 100% apoptotic cell death (Figure 6A). To examine whether hDRS.01 was able to trigger caspase activation, Colo205 cells expressing DR4 and DRS were treated with rhTRAIL and hDRS.01 and caspase cleavage was examined by Western blotting. While rhTRAIL treatment for 2 h induced strong cleavage of both caspase 8 and caspase 3, treatment with hDRS.01 for up to 24 h did not 
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Figure 5 I Purified hDRS.01 displays specific DRS binding. 
(A) An ELISA in which binding of hDRS.01 to DRS was measured. EC50 are indicated and were extrapolated 
from this ELISA. A-specific binding to the empty plate, IgG control and DR4 coating was shown. Binding to 
DRS was increased compared to IgG ( EC50 0.01 versus 3.69), but the affinity was decreased compared to the 
Alexis positive control (EC50 0.0022). (B) FACS analysis with hDRS.01 and the commercially available Alexis 
antibody showed binding of hDRS.01 to the non-DRS expressing CHO-WT cells. Dilution of the antibody 
did not show enhanced binding to DRS(L) or DRS(S) as compared to CHO-WT. (C) Effective DRS membrane 
expression downregulation using siRNA in A2780 could be visualized using both the Alexis and hDRS.01, 
although the decrease in MFI is more pronounced using the Alexis antibody. 
induce any caspase cleavage. This is in line with the lack of apoptosis induction by hDRS.01 
(Figure 6B). Next, hDRS.01 was also tested on DRS expressing A2780 cells and failed to 
induce apoptosis as well (Figure 6C). 
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Figure 6 I HDRS.01 did not induce apoptosis in colon or ovarian cancer cell lines. 
The apoptosis-inducing capacity of hDRS.01 was tested in Colo205 and A2780 cells. (A) Increasing 
concentrations of hDRS.01 up to 100 nM did not induce any apoptotic cell death in Colo205, while 1 nM 
of an agonistic DRS antibody was sufficient to induce 100% apoptotic cells death in these cells. (B) Western 
blot analysis of caspase 8 and caspase 3 demonstrated that treatment with rh1RAIL and D269H/E195R (both 
0.1 µg/ml) for 4 h induced strong cleavage of caspase 8 and caspase 3. However, hDRS.01 (25 and 50 nM) 
treatment for 24 h did not induce any caspase cleavage. (C) A2780 cells were treated with hDR.01 and an 
agonistic DR5 antibody (both 50 nM, 24 h). While many apoptotic cells were evident following treatment 
with the agonistic antibody, as observed by condensed nuclei and the formation of apoptotic bodies (arrows), 
hDRS.01 cells looked similar to the untreated controls. Discussion 
Until now, possible differences in functionality of the two DRS isoforms have been largely 
ignored. In the present study, we analyzed the properties of the two DRS isoforms and 
showed that both isoforms are commonly expressed in human ovarian, colon, breast, lung 
and testicular cancer cell lines. In addition, both DRS isoforms did bind rhTRAIL and 
D269H/El9SR, a DRS-selective variant of rhTRAIL, and each isoform induced an apoptotic 
signal upon treatment with DRS-targeted drugs. 
In the numerous combination studies that have been performed, DRS upregulation 
was observed more frequently compared to DR4 upregulation (30). However, isoform 
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specific upregulation was not described in those studies. Wang et al did examine isoform 
specific DRS upregulation and showed that upon treatment of breast cancer cells with 
different chemotherapeutics, the mRNA expression of both isoforms was upregulated 
(25). However, membrane expression and functionality of the upregulated DRS isoforms 
were not assessed in those experiments. Previously, the DRS isoforms were individually 
transfected in HEK293 cells (13). Transfection of each isoform induced equal and mild levels 
of spontaneous apoptosis in these cells in the absence of ligands. Membrane expression and 
rhTRAIL sensitivity was not assessed in this study. Our current data suggest that both DRS 
isoforms are individually functional as CHX and DRS-ligand treatment induced apoptosis 
in DRS(L) or DRS(S) overexpressing CHO cells. In addition, we have characterized the DRS 
isoforms with regard to rhTRAIL, D269H/E19SR, a DRS-selective rhTRAIL variant, and 
agonistic DRS antibody binding. However, to fully demonstrate individual functionality, 
the data we have obtained need to be confirmed in a human tumor cell background, as 
several post-translational and molecular mechanisms have been described that affect 
receptor expression and signal transduction (30). Thus, it is possible that functional 
differences occur depending on the cellular context, as the DRS isoforms differ in a 29 
amino acid long peptide. Our observation that DRS(S) expression was lower compared to 
DRS(L) at the mRNA and protein level, but substantially higher at the level of membrane 
expression indicates that translational modifications, transport to the membrane, or 
protein turnover at the membrane differ between the isoforms. This also indicates that 
drug-induced DRS upregulation might differentially affect membrane levels of each 
isoform. Post-translational modifications have been described to affect DRS signaling and 
these modifications vary among species and cell types. TRAIL-DR signaling is strongly 
affected by the levels of 0-glycosylation (13). 0-linked glycosylation involves the binding 
of glycosyl groups to serine and threonine side chains that can improve ligand binding and 
membrane protein activation (31). DRS(L) contains additional serine and threonine amino 
acids compared to DRS(S), providing additional 0-glycosylation sites, which may enhance 
signal transduction. Indeed, transfection of DRS(S) with mutated serines and threonines, 
resulting in mutations in all glycosylation sites, reduced the ligand-independent apoptotic 
effect compared to transfection with wild type DRS(S) (13). 
It has been reported that TRAIL decoy receptor 2 (DcR2) prevented apoptotic signaling 
via TRAIL-dependent complex formation with DRS, resulting in an ineffective DISC 
containing heterodimers/trimers of DRS and DcR2 (32). In this study, the presence of DRS(L) 
and DRS(S) in the complex were not taken into account, although DcR2 may have a different 
binding capacity to DRS(L) versus DRS(S). However, until now, no crystal structure of DRS 
interacting with DcR2 has been solved, which may allow in silico modeling of DRS(L)/ 
DcR2 and DRS(S)/DcR2 complexes. 
Our data showed that both isoforms can initiate apoptotic signaling. This suggests 
that agonistic antibodies with known binding characteristics to each isoform might not 
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Chapter 6 I Functional analysis of DRS isoforms be a advantageous strategy. The agonistic DRS antibodies that are currently available are indeed effective in vitro (19,33). However, until now the efficacy of these antibodies in the clinic is low (24). This indicates that DRS isoform specific targeting might improve clinical efficacy. Therefore, we aimed to develop isoform selective antibodies to further explore DRS isoform characteristics in the human context. Unfortunately, the hDRS.01 antibody was not isoform selective and did not induce apoptosis. We did however observe some differences between the two isoforms that are not directly related to membrane expression levels as described above. Both isoforms did bind to rh1RAIL and D269H/E195R, but competitive binding was increased in CHO-DRS(S) cells compared to CHO-DRS(L) cells. This suggests an increased affinity of the ligands towards DRS(S). A single nucleotide polymorphism (SNP) in DR4, resulting in a Glu228Ala substitution is of importance for rh1RAIL binding and efficacy (33). DR4, DRS(L) and DRS(S) are homologous for this glutamic acid (See figure lB, pink highlight). These results indicate that this region, which may include the 29 amino acid peptide proximal to the Glu228, could be of importance for rh1RAIL binding. In our experiments we did indeed show an increased binding capacity of D269H/E19SR to DRS(S) compared to rh1RAIL. In addition, DRS selective targeting with D269H/E19SR was beneficial in the CHO-DRS(S) cells compared to rh1RAIL. Therefore, D269H/E19SR may form a potential approach to effectively target DRS(S). Currently, it is unknown whether functional heterotrimers can be formed between DRS(S), DRS(L) and DR4. Taken together, although both DRS isoforms are functional, we can not exclude the possibility that DRS isoform specific targeting is superior to DRS targeting in general. This may especially be of importance for combination strategies with anticancer agents that cause DRS upregulation. In conclusion, the present study demonstrates that the two isoforms of DRS are commonly expressed, bind rh1RAIL and when individually overexpressed can initiate an apoptotic signal upon rhTRAIL binding. Acknowledgments This work was performed within the framework of Dutch Top Institute Pharma, project 'TNF-ligands in cancer' project nr T3-112. 
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Summary 
Targeting apoptosis, or programmed cell death, is a potential anti-cancer strategy in cancer 
treatment (1). TNF related apoptosis inducing ligand (TRAIL) is an interesting new agent in 
this respect, as it selectively induces apoptosis in cancer cells, without inducing toxicity to 
normal cells. In its recombinant human (rh) form, rhTRAIL forms a stable trimer and can 
be administered safely to patients. RhTRAIL induces the extrinsic apoptosis pathway in 
cancer cells via binding to the TRAIL death receptors DR4 (TRAIL-Rl) and DRS (TRAIL-R2), 
which induces receptor trimerization and initiates the apoptotic signal via formation of the 
death inducing signaling complex (DISC). Primary components of the DISC are trimerized 
DR4/DR5, FADD, caspase 8 and caspase 10. Subsequently, the caspase cascade is activated 
resulting in apoptotic cell death. Besides rhTRAIL, DR4- or DRS-selective variants of 
TRAIL and agonistic DR4 and DRS antibodies have been designed. Preclinical results with 
rhTRAIL alone and as part of various combination strategies showed potent antitumor 
activity. However, preliminary publications of phase 2 randomized trials in which rhTRAIL 
was combined with different chemotherapeutics, showed no additive effects of rhTRAIL. 
In this thesis, various new experimental strategies were explored to improve TRAIL­
DR targeted apoptosis induction in cell culture models, in particular of ovarian cancer. 
In chapter 2 an extensive literature study was presented in which factors influencing 
the initial steps of the TRAIL apoptosis signaling pathway were discussed. The review 
focused on mechanisms that modulate DISC assembly and caspase activation at the DISC 
as a crucial event in eradicating tumor cells. The DR-specific antibodies and rhTRAIL 
variants that are in development were discussed. In addition, cellular membrane 
factors such as lipid raft formation that affect DISC formation were addressed. Finally, 
post-translational modifications of DISC components that affect TRAIL efficacy and the 
influence of additional cellular proteins that can be recruited to the DISC were discussed. 
These insights can direct rational design of drug combinations with TRAIL-DR targeting 
ligands to maximize DISC-apoptosis signaling. 
Apoptosis is an elegant mechanism of cell death as it does not induce an inflammatory 
response. Interestingly, cancer cells display enhanced sensitivity to apoptosis induction 
by rhTRAIL compared to normal cells. In contrast, defects in the apoptosis machinery can 
cause resistance to apoptosis inducing therapy. In ovarian cancer, chemo-resistance is a 
major problem. Although initial response rates to platinum-based chemotherapy are over 
80%, 5-years survival rates of advanced stage ovarian cancer patients remains only 15-
25% due to chemo-resistance. In addition, rhTRAIL resistance has been described in 50% 
of cancer cell lines. Studies examing drug resistance are often performed using cell lines 
with different genetic backgrounds and sensitivity patterns, which impedes interpretation 
of causal relationships. In chapter 3, we used an isogenic ovarian cancer cell line model 
consisting of A2780 and its cisplatin-resistant daughter cell line named CP70 to investigate 
whether acquired cisplatin resistance affects sensitivity to rhTRAIL alone or in combination 
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Chapter 7 I Summary, general discussion and future perspectives with cisplatin. CP70 cells showed cross-resistance to rhTRAIL. Combining cisplatin and rhTRAIL strongly enhanced apoptosis in both cell lines. CP70 expressed less caspase 8 protein, while mRNA levels were similar compared to A2780. Pre-exposure of particularly CP70 to cisplatin resulted in strongly elevated caspase 8 protein and mRNA levels. Caspase 8 mRNA turnover and protein stability in the presence or absence of cisplatin did not differ between both cell lines. Cisplatin-induced caspase 8 protein levels were essential for the rhTRAIL-sensitizing effect as demonstrated using caspase 8 siRNA and caspase 8 overexpression constructs. c-FLIP and pS3 siRNA experiments showed that neither an altered caspase 8/c-FLIP ratio nor a pS3-dependent increase in DRS membrane expression were involved in the rhTRAIL sensitization by cisplatin. In conclusion, cisplatin enhances rhTRAIL-induced apoptosis in cisplatin resistant ovarian cancer cells and induction of caspase 8 protein expression is a key driver of rhTRAIL sensitization. Cisplatin induces DNA-damage, which results in pS3 activation. As pS3-induced DRS upregulation following cisplatin treatment was ruled out as an important factor for rhTRAIL sensitization in chapter 3, the effect of specific pS3 activation without DNA damage was explored to further enhance rhTRAIL-induced apoptosis in chapter 4. The novel anticancer agent nutlin-3 provides a promising alternative for pS3 activation as it disrupts the interaction between the negative feed-back regulator MDM2 and pS3. We examined whether nutlin-3 could enhance apoptosis induction by rhTRAIL and the DRS-selective rhTRAIL variant D269H/El9SR in a panel of wild type pS3-expressing ovarian, colon and lung cancer cells. Nutlin-3 dose dependently enhanced pS3, p21, MDM2 and DRS membrane expression. Although nutlin-3 alone did not induce any apoptosis, it preferentially enhanced D269H/El9SR-induced apoptosis over rhTRAIL­induced apoptosis. The mechanism of sensitization was further investigated in ovarian cancer models. Combination treatment potentiated the cleavage of caspases 8, 9, 3, and PARP. PS3 and MDM2 siRNA experiments showed that this enhanced apoptotic effect was mediated by wild type pS3 activation due to disruption of the MDM2-mediated pS3 inhibition. In agreement with this, OVCAR-3 cells harboring mutant pS3 could not be sensitized to TRAIL-DR-induced apoptosis with nutlin-3. Addition of the DNA damaging chemotherapeutic drug cisplatin to the combination of nutlin-3 and D269H/E19SR further increased the levels of both pS3 and DRS and enhanced D269H/E19SR induced-apoptosis. In ex vivo cultured tissue slices of primary human ovarian cancers, the combination of D269H/El9SR with nutlin-3 and cisplatin also massively induced caspase-3 activation and apoptosis. In conclusion, nutlin-3 is a potent enhancer of rhTRAIL- and especially D269H/El95R­induced apoptosis. Combined use with cisplatin further enhances apoptosis induction. Since an estimated SO% of cancers carry wild type pS3, the combination of nutlin-3, 
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Chapter 7 I Summary, general discussion and future perspectives cisplatin and rhTRAIL or D269H/El9SR is of potential interest for exploration in the clinic for the treabnent of cancer patients. Resistance to rhTRAIL can be partially explained by pro-survival signaling that counteracts rhTRAIL-induced apoptosis. In chapter 5, we tested whether rhTRAIL­induced apoptosis could be enhanced by simultaneous inhibition of pro-survival signaling of the insulin-like growth factor (IGF) system. The IGF system plays an important role in proliferation and energy metabolism. SiRNA was used to specifically downregulate the two receptors that are of importance for IGF signaling; the insulin receptor (IR) and the IGF-lR. The effect of IR and IGF-lR downregulation on DR4/DRS-mediated apoptosis was investigated using rh1RAIL and the DR-selective rhTRAIL-variants 4C7 (DR4-selective) and D269H/E19SR (DRS-selective). IR but not IGF-lR downregulation strongly enhanced apoptosis induction in a panel of ovarian and lung cancer cell lines. Combining IR downregulation with rhTRAIL or rh1RAIL variants resulted in strong cleavage of caspases 8, 3, 9, and PARP. IR downregulation in contrast to IGF-lR downregulation, enhanced DRS membrane expression and pS3 protein expression. PS3 siRNA experiments showed that the enhanced apoptotic effect of IR inhibition alone and in combination with rhTRAIL or rh1RAIL variants was pS3-dependent. Furthermore, IR siRNA, but not IGF-lR siRNA decreased cellular glucose uptake. To mimic IR siRNA-induced glucose deprivation, cells were treated with 2-deoxy-glucose (2-DG), a non-metabolized glucose analogue. Indeed, 2-DG enhanced pS3 and DRS expression and augmented DR4/DRS-mediated apoptosis similar to the effects of IR downregulation. In conclusion, IR but not IGF-lR downregulation strongly enhanced TRAIL death receptor-mediated apoptosis via a diminished glucose uptake in chemo- and rh1RAIL sensitive and resistant cell lines. These data provide a new rationale for combination therapy of rhTRAIL with IR targeted agents or glycolysis inhibitors such as 2-DG. Due to alternative splicing, two isoforms of DRS are expressed, designated DRS(S) for the short isoform and DRS(L) for the long isoform. Whether there is a functional difference between the two isoforms is still unclear. More knowledge concerning the functionality of the two DRS isoforms may provide a rationale for DRS isoform specific targeted therapy and could provide strategies to improve apoptosis induction in tumor cells. In chapter 6, we aimed to investigate the functionality of the two DRS isoforms in triggering apoptosis and to develop agonistic antibodies against either of the isoforms. We showed that both isoforms were commonly expressed in a panel of 16 human cancer cell lines with similar isoform expression levels within each cell line. Chinese hamster ovary (CHO) cells were stably transfected with each individual human DRS isoform. In this model, we showed that both isoforms could bind rh1RAIL as well as D269H/El9SR, a DRS-selective rhTRAIL variant. Additionally, both DRS(L) and DRS(S) are capable of initiating an apoptotic signal upon ligand binding. The 'agonistic' antibody against DRS that was developed, displayed binding to DRS as measured by ELISA. However, the antibody also had non-specific 
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binding activity in CHO cells stably expressing human DRS(L) and DRS(S), and in DRS 
expressing human A2780 ovarian cancer cells. Moreover, the candidate DRS agonistic 
antibody failed to trigger apoptosis in A2780 cells or Colo20S colon cancer cells. 
In conclusion, we showed that the two DRS isoforms are commonly expressed in 
human cancer cell lines and bind rhTRAIL. We have provided data that the individual 
isoforms can induce an apoptotic signal. General discussion and future perspectives 
Cancer represents one of the leading causes of death in developed countries and cancer 
mortality is expected to rise globally, thus emphasizing that new drugs are urgently required 
to improve prognoses. New apoptosis-inducing agents, such as rhTRAIL and agonistic 
antibodies against DR4 and DRS, are currently tested for use in the clinic. However, it has 
become evident that the combined use of these drugs with chemo- or targeted therapies 
is critical for optimal efficacy. Development of rationalized combinations and optimizing 
their antitumor activity is therefore of interest in the field of targeting apoptosis in cancer 
cells. In this thesis, we analyzed several strategies to improve targeting of the extrinsic 
apoptosis pathway via TRAIL-DRs. 
As reviewed in chapter 2, understanding the molecular mechanisms that regulate 
rhTRAIL-induced DISC formation is of key relevance for developing rhTRAIL-sensitizing 
approaches. The combination strategies described in chapters 3, 4 and S all indicated 
involvement of DISC components in the enhanced apoptotic effects. To further analyze 
this, tagged DR-selective rhTRAIL variants have to be employed to perform DISC 
immunoprecipitation experiments. In addition, to assess kinetics of caspase-like activation 
following the different combinations fluorescence resonance energy transfer (FRET) 
analysis can be used (2). The FRET technique allows real time analysis of the onset of 
caspase activity and kinetics in individual cells via fluorescent probes that upon cleavage 
by caspases show a decrease in energy transfer. In addition, the onset of mitochondrial 
outer membrane permeabilization (MOMP) can be determined. Using this technique, a 
threshold mechanism controlling apoptotic signaling has been demonstrated (2). Apoptotic 
effects as observed in vitro not always correspond to effects in vivo. Therefore, application 
of DISC- and FRET analysis will provide detailed mechanistic insight of apoptotic 
signaling, that will guide the design of optimal combinations, concentrations and timing 
of treatment, resulting in maximal DISC formation, caspase activation and apoptosis in 
models. Subsequently, this knowledge can be used to improve in vivo efficacy. 
In chapter 4, we have shown that direct activation of pS3 by nutlin-3 enhanced apoptosis 
induction by rhTRAIL and the DRS-selective rhTRAIL variant D269H/E19SR. These data 
demonstrate that DRS is an interesting therapeutic target, that can be exploited more 
effectively via DRS-selective rhTRAIL variants. Alternatively, agonistic DRS antibodies 149 7 
Chapter 7 I Summary, general discussion and future perspectives that are currently in clinical development may be applied (3-5). Our study was performed in cell line models expressing wild type p53 and we showed that the effect of nutlin-3 in combination with rh1RAIL or D269H/E195R was wild type p53 dependent. Interestingly, recent data in which nutlin-3 was combined in vitro with various chemotherapeutics in several tumor types, suggest that this combination is also effective in mutant p53 expressing cells (6,7). As our triple combination of nutlin-3, cisplatin and D269H/El95R was very effective, it is of interest to assess the effect of this combination also in mutant p53 expressing cells. Nutlin-3 is currently in early clinical development (8). Based on our findings, the efficacy of nutlin-3 in combination with cisplatin and eventually with DRS targeting agents might be explored in subsequent trials. In chapter 5, we have demonstrated that downregulation of the IR sensitized cancer cells to DR4- and DRS- induced apoptosis via a decrease in glucose deprivation, while IGF-lR downregulation had no effect. Traditionally, the focus of inhibition of the IGF system has been on targeting the IGF-lR. Anti-IGF-lR targeting therapies are currently in various phases of clinical development (9, 10). Despite promising preclinical data, an IGF-lR antibody added to chemotherapy had a detrimental effect on treatment outcome in colon cancer patients (11). However, dual IR/IGF-lR targeting might improve outcome. Currently, several strategies are being explored to target the IGF pathway in cancer, with a recent focus on the IR. Monoclonal antibodies against IGF-lR and the IR have been developed, as well as dual IGF-I/IGF-11 neutralizing antibodies. Considering the autocrine loop of IGF stimulation via IGFII present in several tumor types, this strategy is of great interest as well (12,13). The dual IGFI/IGFII antibody MEDI-573 potently inhibited IGF signaling and tumor growth, via inhibition of IGF-lR and IR-A. MEDI-573 is currently in phase 1 clinical trials (14). In addition, tyrosine kinase inhibitors (TKis) that inhibit both IR and IGF-lR due to the large homology between these receptors showed promising anti-tumor effects in pre-clinical studies (15-19). These drugs are currently in clinical development. As two isoforms of the IR exist that are differentially expressed between normal and cancer tissue, it is of major interest to further analyze their functionality and potential as anti-tumor targets (20,21). IR downregulation decreased cellular glucose uptake in our experiments. Currently, cancer cell metabolism is gaining attention for its role in tumorigenesis and the fact that it offers potential targets for therapy (22-25). Patients with excess body-mass index and hyperinsulinemia have worse cancer outcome and diabetic patients have moderately increased cancer risk. Therefore, the rapidly rising problem of obesity and diabetes in the Western world may affect cancer prevalence as well (26-28). This strengthens the need for a healthy life style and stresses the importance to regulate the IGF system. Interestingly, the combination of both cancer and diabetes has also put forward novel applications of 'old' drugs. Metformin, a drug commonly used for the treatment of diabetes has recently drawn attention as a potential anti-cancer drug as it decreases insulin resistance and activates AMPK, resulting in inhibition of mammalian target of rapamycin (mTOR) which 150 
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leads to decreased growth factor signaling (29). Based on our findings in chapter 5, it is 
highly interesting to combine an agent targeting the IGF receptors, metformin, or glucose 
metabolism targeting agents such as 2-DG with 1RAIL DR-targeting drugs in ovarian and 
NSCLC cancer. 
In both chapter 4 and 5 we have demonstrated effective apoptosis induction via DR­
selective agents. DR-selective signaling has been previously described by others in cancer 
cells derived from different tumor types (5,30). However, the effect of combination strategies 
on DR-selective signaling has been studied less well. In chapter 4, we have shown the 
preferential sensitizing effect of nutlin-3 on treatment with the DRS-selective rh1RAIL 
variant D269H/E195R over rh1RAIL. This rh1RAIL variant was also more effective 
compared to rh1RAIL in combination with cisplatin (31). In chapter 5, we have described 
the stronger apoptosis induction in ovarian and lung cancer cell lines following single 
treatment with the DR4-selective rhTRAIL variant 4C7, which was further enhanced upon 
combination with IR downregulation. In several other studies, more effective apoptosis has 
been induced in vitro and in vivo by DR-selective targeting over rh1RAIL (3-5,32-34). This 
indicates that either DR-selective targeting is beneficial over dual targeting by rhTRAIL due 
to circumvention of the DcRs, or tumor cells display preferential apoptosis signaling via 
one DR, or both. All together these data emphasize that DR-specific targeting can improve 
TRAIL-DR-induced apoptosis as single agents as well as in combination with chemo- or 
targeted therapy. Recently, we have even established that the combination of DR-induced 
apoptosis with IGF axis inhibition enhanced apoptosis via DRS, while DR4-mediated 
apoptosis was reduced (35). Therefore, screening patients for possible DR preference might 
support future drug selection in the individual patient, which stresses the need for DR­
specific biomarkers. In the meantime, it might be beneficial to combine two DR-selective 
agents. 
Current clinical data concerning rh1RAIL and agonistic DR antibodies show that these 
drugs are well-tolerated. As far as we can tell from available clinical trials, limited objective 
tumor responses, when administered as single agents, and no clear additive benefit in 
randomized phase 2 studies were observed with DR targeting drugs (3,36-39). 
This illustrates that the clinical setting is more complex than is reflected in the existing 
preclinical models. Novel preclinical models might support the testing of combinations 
that could potentially target the complex signaling in tumors in patients. In chapter 4, we 
have described a novel living ex-patient model of primary human ovarian cancers in which 
freshly isolated human tumor tissue was used to assess the efficacy of combination treatment 
with D269H/El95R, nutlin-3, and cisplatin. We and others showed that excellent tissue 
viability can be preserved following incubation of these slices up to 48 h (40-42). In addition, 
treatment effects can be evaluated with several techniques such as immunohistochemistry, 
ATP measurements, protein analysis using Western blotting for cellular proteins, or 
excreted protein specific ELISAs. Ex vivo models of cervical cancer and (pre)malignant 
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Chapter 7 I Summary, general discussion and future perspectives colorectal adenomas performed by our group also proved to be feasible (43,44). In contrast to cell line models, ex vivo models allow to take into account important factors such as tumor heterogeneity and tumor microenvironment. The additional advantage of the tissue slice model is that multiple slices can be generated facilitating assessment of various drug combinations. However, other important factors such as bioavailability and toxicity cannot be assessed in this ex vivo model. In this respect, a xenotransplant mouse model may be of interest, where freshly isolated human tumor specimens are implanted into NOD/SCID mice. When a sufficient size has been reached, the tumor is harvested, partially stored in liquid nitrogen and transplanted serially in other mice for multiple generations. This provides an in vivo model in which several drug combinations can be tested in small cohorts of expanded xenografts. This approach has been established in for example, ovarian and pancreatic cancer (45-48). Ideally, both the tissue slice model and the xenotransplant model could be used as predictive tools for individual patient response to treatment. To establish that, correlative studies comparing sensitivity in these models to clinical responses are required. In conclusion, the interesting new drug-combinations, techniques, and preclinical models that are underway provide potential opportunities and challenges to fully exploit targeting of the TRAIL-DR apoptosis pathway in cancer therapy and to fulfill the ambition of personalized medicine. 
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Om verouderde, beschadigde of gemfecteerde cellen te elimineren hebben multi-cellulaire 
organismen een gereguleerde vorm van celdood ontwikkeld, genaamd apoptose (1). 
Morfologisch wordt apoptose gekenmerkt door celkrimping, condensatie van de 
celkem en uiteindelijk de vorming van apoptotische celfragmenten omgeven door een 
membraan (apoptotic bodies), welke worden verwijderd door het immuunsysteem zonder 
een ontstekingsreactie te veroorzaken (2). Een evenwicht tussen apoptose en celdeling 
is essentieel voor het behoud van homeostase. Vermindering van apoptose en toename 
van het aantal celdelingen is een van de kenmerken van kankercellen (3). Het gericht 
induceren van apoptose in kankercellen is een belangrijk doel van de behandeling met 
anti-kanker middelen zoals chemotherapeutica. Echter, kankercellen hebben vaak een 
verlaagde apoptosecapaciteit door mutaties in belangrijke apoptose regulerende eiwitten 
en/of de verhoogde expressie van deze eiwitten. Deze apoptoseresistentie is een groot 
probleem bij de medicamenteuze behandeling van kankerpatienten, aangezien <lit kan 
leiden tot chemoresistentie. Het is daarom van belang om de mechanismen van resistentie 
te achterhalen om op die manier de apoptose-inductie in kankercellen te kunnen herstellen 
en/of maximaliseren. 
Apoptose kan gemitieerd worden via twee signaleringsroutes welke onderling 
gekoppeld zijn, namelijk de extrinsieke ( of death receptor) apoptoseroute en de intrinsieke 
(of mitochondriele) apoptoseroute (2). Beide signaleringsroutes worden gereguleerd door 
caspases, een familie van cysteine proteases, ofwel enzymen die eiwitten kunnen knippen 
in kleinere fragmenten ( 4,5). Chemotherapeutica en bestraling activeren beide de intrinsieke 
apoptoseroute, onder andere via de activatie van p53, een tumorsuppressoreiwit en 
belangrijke transcriptiefactor voor apoptose genen en celdeling remmende genen (6). In de 
intrinsieke apoptoseroute komen apoptose-inducerende eiwitten vrij uit de mitochondria 
wat leidt tot de activatie van caspase 9 en caspase 3 en uiteindelijk tot apoptose (7). De 
extrinsieke apoptoseroute wordt geactiveerd door binding van death ligands van de tumor necrosis factor (TNF) familie, zoals TNF-related apoptosis inducing ligand (TRAIL), Fas­
ligand en TNFa aan hun corresponderende receptoren, wat leidt tot apoptose-inductie. 
De recombinant humane variant van TRAIL (rhTRAIL) induceert in vitro specifiek 
apoptose in kankercellen en niet in normale cellen. Daamaast is geen toxiciteit gezien in 
diermodellen, maar wel effectiviteit tegen tumoren in deze diermodellen. Dit heeft ertoe 
geleid <lat rhTRAIL nu klinisch getest wordt (8). Voorlopig klinisch onderzoek toont aan 
<lat toediening van rhTRAIL niet veel bijwerkingen induceert (9,10). Rh TRAIL is een type II 
trans-membraan eiwit <lat een stabiele trimeer vormt (11,12). RhTRAIL induceert apoptose 
via binding aan twee receptoren, namelijk death receptor 4 (DR4) en death receptor 5 (DRS). 
RhTRAIL binding aan deze receptoren resulteert in receptortrimerisatie en initieert een 
apoptotisch signaal via de formatie van het death inducing signaling complex (DISC). De 
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DISC bestaat uit getrimeriseerde DR4 en DRS receptoren, FADD, caspase 8 en caspase 10. 
Vervolgens wordt de caspasecascade geactiveerd, wat resulteert in apoptotische celdood. 
De intrinsieke en extrinsieke apoptoseroutes zijn gekoppeld via caspase 8 gemduceerde 
activatie van Bid, een pro-apoptotisch eiwit behorende tot de Bcl-2 familie, dat vervolgens 
de intrinsieke route activeert. Om apoptoseresistentie te omzeilen, is het van belang 
om gelijktijdig zowel de intrinsieke als de extrinsieke apoptoseroutes te activeren (13). 
In een groot aantal preklinische studies is rhTRAIL gecombineerd met verschillende 
chemotherapeutica en bestraling wat zowel in vitro als in vivo resulteerde in verhoogde 
apoptose-inductie (14-22). Recente preliminaire klinische fase 2 gegevens lieten echter geen 
extra antitumoreffect van rhTRAIL zien wanneer het werd toegevoegd aan chemotherapie 
bij patienten met een niet-kleincellig longcarcinoom (23,24). 
Naast rhTRAIL zijn er ook DR4- en DRS-selectieve varianten van rhTRAIL en receptor 
specifieke antilichamen ontwikkeld om een sterkere apoptose-inductie te bewerkstelligen 
(25-28). D269H/El95R, een DRS-selectieve rhTRAIL-variant, was een sterkere apoptose­
induceerder in vergelijking met rhTRAIL in verschillende DRS-positieve cellijnen en in 
een bioluminescent xenograft muizenmodel van het ovariumcarcinoom (15,28). De DR4-
selectieve rhTRAIL-variant 4C7 toonde een hogere apoptose-inducerende capaciteit dan 
rhTRAIL in een panel van DR4-positieve cellijnen (29). 
Het doel van dit proefschrift was het verbeteren van rhTRAIL ge'induceerde apoptose 
in kankercellen. Ten eerste werden verschillende combinatiestrategieen met rhTRAIL 
onderzocht om een beter inzicht te krijgen in de mechanismen welke een sterkere 
apoptose-inductie mogelijk maken om zo een optimaal gebruik van rhTRAIL in de kliniek 
te kunnen bewerkstelligen. Ten tweede werden DR4- en DRS-selectieve varianten van 
rhTRAIL gebruikt om receptor specifieke effecten van chemotherapeutica en doelgerichte 
therapieen te onderzoeken en zo apoptose-inductie te optimaliseren. 
Samenvatting van dit proefschrift 
Na een korte introductie en een overzicht van de inhoud van dit proefschrift in hoofdstuk 1, 
werd in hoofdstuk 2 een uitgebreide literatuurstudie beschreven, waarin de huidige kennis 
over factoren die de initiele stappen in de TRAIL-gemedieerde apoptoseroute bemvloeden 
werd weergegeven. In deze literatuurstudie lag de nadruk op mechanismen die de vorming 
van de DISC en de activatie van caspases in dit complex moduleren. De DR- (DR4 of DRS) 
selectieve rhTRAIL-varianten en antilichamen die zijn ontwikkeld werden bediscussieerd, 
evenals de celmembraanfactoren zoals de vorming van lipid rafts welke de formatie van de 
DISC bemvloeden. Ook werden post-translationele modificaties van DISC-componenten 
die invloed hebben op de efficientie van apoptosesignalering beschreven, evenals de 
invloed van verschillende additionele eiwitten op de DISC formatie. Op basis van deze 
inzichten kunnen nieuwe therapeutische combinaties worden gedefinieerd die TRAIL-DR- 8 
gemedieerde apoptose-inductie kunnen verhogen. 
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Chapter 8 I Summary in Dutch (Nederlandse samenvatting) Apoptose is een elegante vorm van celdood welke vrij is van een ontstekingsreactie. Kankercellen vertonen over het algemeen een verhoogde gevoeligheid voor apoptose­inducerende middelen. Defecten in apoptotische signaleringsroutes kunnen echter resistentie veroorzaken. Resistentie tegen chemotherapeutica is een groot probleem bij de behandeling van het ovariumcarcinoom. Hoewel de meeste tumoren in eerste instantie goed reageren op behandeling met platinum bevattende chemotherapie, bedraagt de vijfjaarsoverleving van patienten met een gevorderd stadium van het ovariumcarcinoom slechts 15-25% als gevolg van resistentie tegen chemotherapie (30,31). Resistentie tegen rh1RAIL gemduceerde apoptose kornt voor in ongeveer 50% van de onderzochte humane kankercellijnen. Onderzoek naar resistentie wordt veelal belemmerd doordat cellijnen met een verschillende genetische achtergrond van hetzelfde turnortype worden vergeleken. In hoofdstuk 3 hebben we daarom chemotherapie- en rh1RAIL-resistentie onderzocht in een cellijnmodel bestaande uit de ovariumkankercellijn A2780 en de cisplatine-resistente dochtercellijn CP70. In dit model hebben we onderzocht of verworven resistentie tegen cisplatine effect heeft op de gevoeligheid voor rh1RAIL alleen en rh1RAIL in combinatie met cisplatine. CP70 bleek ongevoelig voor rh1RAIL. De combinatie cisplatine en rh1RAIL veroorzaakte een sterk verhoogde apoptose-inductie in zowel A2780 als CP70. In onbehandelde cellen bleek CP70 minder caspase 8 tot expressie te brengen dan A2780, terwijl de expressie van caspase 8 mRNA vergelijkbaar was tussen de twee cellijnen. Voorbehandeling met cisplatine van met name CP70 resulteerde in sterk verhoogde caspase 8 eiwit- en mRNA expressie. Caspase 8 mRNA aanrnaak en eiwitstabiliteit was gelijk in beide cellijnen, zowel basaal als na behandeling met cisplatine. Experirnenten met caspase 8 small interfering RNA (siRNA), een techniek om een gen van interesse specifiek uit te schakelen, en met caspase 8 overexpressie, een techniek om een gen van interesse specifiek hoog tot expressie te brengen, toonden aan dat de verhoogde caspase 8-expressie na cisplatine behandeling essentieel is voor een toennarne in rhTRAIL gevoeligheid. In de C-FLIP en pS3 siRNA experirnenten bleek dat noch een veranderde caspase 8/c-FLIP ratio, noch een pS3-afhankelijke verhoging van DRS expressie op de rnembraan na behandeling met cisplatine betrokken is bij de verhoogde rhTRAIL-gevoeligheid. Sarnenvattend laat deze studie zien dat cisplatine de rhTRAIL-gevoeligheid verhoogt in cisplatineresistente ovariurnkankercellen en <lat de verhoging van de caspase 8 eiwit expressie hierbij het belangrijkste mechanisme is. Cisplatine induceert DNA-schade dat vervolgens resulteert in activatie van pS3. In hoofdstuk 3 hebben we aangetoond dat pS3-gemduceerde verhoging van DRS expressie na cisplatine niet van belang is voor de toenarne in apoptose-inductie. Daarom hebben we in hoofdstuk 4 onderzocht of de gevoeligheid voor rhTRAIL te verhogen is via specifieke activatie van pS3 zonder DNA-schade te induceren. Het nieuwe anti-kankermiddel nutlin-3 vormt een interessant alternatief voor DNA beschadigende middelen om pS3 te activeren. Nutlin-3 verbreekt de interactie tussen pS3 en MDM2, een eiwit dat p53 inactiveert en 
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de afbraak van pS3 bewerkstelligt. We hebben onderzocht of nutlin-3 apoptose-inductie 
door zowel rhTRAIL als de DRS-selectieve rh1RAIL-variant D269H/El9SR kan versterken 
in ovarium-, colon- en longkankercellijnen welke allemaal wild-type pS3 tot expressie 
brengen. Nutlin-3 verhoogde pS3, p21, MDM2 en DRS expressie op dosisafhankelijke 
wijze. Behandeling met nutlin-3 alleen resulteerde niet in apoptose-inductie. Echter, 
de apoptose-inductie werd wel sterk verhoogd in combinatie met D269H/E19SR. Het 
mechanisme achter dit effect werd verder onderzocht in ovariumcarcinoommodellen. De 
gecombineerde behandeling versterkte de activatie van caspases 8, 9, 3 en de afbraak van 
PARP, een belangrijke marker voor apoptose-inductie. PS3 en MDM2 siRNA experimenten 
toonden aan dat het apoptose-stimulerende effect werd bewerkstelligd door de activatie 
van wild type p53 door het verbreken van de MDM2-pS3 interactie. Dit werd bevestigd 
in OVCAR-3 cellen, die mutant pS3 tot expressie brengen en niet gevoeliger werden voor 
rhTRAIL of D269H/El9SR door behandeling met nutlin-3. Het toevoegen van cisplatine 
aan de combinatiebehandeling leidde tot verdere verhoging van zowel de expressie van 
pS3 en DRS als de inductie van apoptose. In ex vivo gekweekte plakjes van primair humaan 
ovariumcarcinoomweefsel gaf de combinatiebehandeling met D269H/E19SR, nutlin-3 en 
cisplatine ook zeer sterke inductie van apoptose. 
In deze studie hebben we laten zien dat nutlin-3 een krachtige versterker is van 
rhTRAIL maar met name van D269H/E19SR-gemduceerde apoptose. In combinatie met 
cisplatine werd dit effect nog verder vergroot. Aangezien SO% van de kankers wild type 
pS3 tot expressie brengt is de combinatie van nutlin-3, cisplatine en rh1RAIL of D269H/ 
E19SR interessant voor verder onderzoek in de kliniek. 
Ongevoeligheid voor rhTRAIL kan deels worden verklaard door signalen die 
celoverleving stimuleren. In hoofdstuk 5 hebben we onderzocht of rhTRAIL-gemduceerde 
apoptose kan worden versterkt door het gelijktijdig remmen van overlevingsignalen van 
het insulin-like growth factor (IGF)-systeem. Het IGF-systeem is van belang voor celdeling en 
energiemetabolisme. SiRNA werd gebruikt om de twee receptoren van dit systeem welke 
van belang zijn voor IGF signalering; de insulin-like growth factor receptor 1 (IGF-lR) en de 
insulinereceptor (IR), specifiek uit te schakelen. Het effect van IR en IGF-lR siRNA op DR4/ 
DRS gemedieerde apoptose werd onderzocht met behulp van rhTRAIL, de DR4 selectieve 
rhTRAIL-variant 4C7 en de DRS selectieve rhTRAIL-variant D269H/El9SR. IR siRNA had 
een sterk positief effect op DR-gemedieerde apoptose-inductie in een panel van ovarium­
en longkankercellijnen. IGF-lR siRNA daarentegen had geen effect. De combinatie van 
IR-downregulatie en rhTRAIL of de rh1RAIL-varianten resulteerde in sterke activatie van 
caspases 8, 9 en 3 en in de afbraak van PARP, met andere woorden, in meer apoptose. In 
tegenstelling tot uitschakelen van IGF-lR, resulteerde het uitschakelen van IR in verhoogde 
expressie van pS3 en DRS op de celmembraan. PS3 siRNA experimenten toonden aan 
dat de verhoogde apoptose-inductie afhankelijk was van pS3. IR siRNA resulteerde in 
lagere glucose-opname door de tumorcellen, terwijl IGF-lR siRNA hier geen effect op 
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Chapter 8 I Summary in Dutch (Nederlandse samenvatting) had. De cellen werden vervolgens behandeld met 2-deoxy-glucose (2-DG), een glucose­analoog die niet kan worden gemetaboliseerd, om zo de door IR siRNA geinduceerde glucosedeprivatie na te bootsen. De behandeling met 2-DG resulteerde, net als IR siRNA, in verhoogde expressie van p53 en DRS en in een sterke apoptose-inductie via zowel DR4 als DRS. In deze studie werd aangetoond dat het uitschakelen van de IR leidt tot een sterke inductie van DR4- en DRS-gemedieerde apoptose, wat verklaard kan worden door de remming van de glucose-opname in zowel rhTRAIL of chemotherapie gevoelige als resistente kankercellen. De combinatie van rhTRAIL of rhTRAIL-varianten met doelgerichte therapie tegen de IR of met glycolyseremmers zoals 2-DG bieden nieuwe mogelijkheden voor therapie. Als gevolg van altematieve splicing, een mechanisme waardoor meerdere verschillende transcripten uit een messenger RNA gevormd worden, bestaan er twee isovormen van DRS, genaamd DRS(L) voor de langere isovorm en DRS(S) voor de kortere isovorm. Of deze isovormen verschillen in functionaliteit is niet bekend. Meer kennis betreffende de functie van deze twee isovormen zou kunnen pleiten voor isovorm-specifieke therapie en zou nieuwe strategieen kunnen opleveren om apoptose-inductie te maximaliseren. Het doel van hoofdstuk 6 was het onderzoeken van de functionaliteit van de twee DRS isovormen. Bovendien wilden we nieuwe agonistische antilichamen specifiek gericht tegen DRS(L) of DRS(S) ontwikkelen. Beide DRS isovormen bleken aanwezig te zijn in een panel van 16 humane kankercellijnen en expressielevels van beide isovormen was gelijk binnen elke cellijn. Vervolgens zijn Chinese hamster ovanJ (CHO) cellen stabiel getransfecteerd met de individuele DRS isovormen. In dit model hebben we aangetoond dat beide DRS isovormen op de celmembraan rhTRAIL en D269H/E19SR, de DRS-selectieve rhTRAIL­variant, kunnen binden. Daamaast lieten we zien dat zowel DRS(L) als DRS(S) apoptose kunnen initieren na binding van een ligand. Het 'agonistische' DRS gerichte antilichaam <lat was ontwikkeld, toonde specifieke binding aan ge'isoleerd DRS en niet aan ge'isoleerd DR4 eiwit in een ELISA. Echter, het antilichaam bleek ook te binden aan CHO cellen, terwijl deze cellen geen humaan DR4 of DRS eiwit hebben. Ook was er niet-specifieke bindingsactiviteit in de humane ovariumkankercellijn A2780, waarin de DRS-expressie was verlaagd met behulp van siRNA. Het 'agonistische' DRS antilichaam induceerde geen apoptose in A2780 cellen en Colo20S colonkankercellen, alhoewel beide cellijnen DRS op de celmembraan tot expressie brengen en wel gevoelig zijn voor rhTRAIL. In deze studie hebben we laten zien <lat de twee DRS isovormen algemeen tot expressie komen in humane kankercellen. Bovendien kunnen beide isovormen rhTRAIL binden. Verder hebben we aanwijzingen dat beide isovormen individueel een apoptotisch signaal kunnen initieren. Het ontwikkelen van een isovorm specifiek agonistisch DRS antilichaam was niet succesvol. 
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Conclusie 
In dit proefschrift hebben we verschillende manieren onderzocht om TRAIL-DR 
geYnduceerde apoptose te maximaliseren. We hebben aangetoond dat apoptose-inductie 
kan worden versterkt en zo chemo- en 1RAILresistentie kan worden omzeild door het 
toepassen van verschillende nieuwe combinatietherapieen met rh1RAIL en door het 
gebruik van DR-selectieve rh1RAIL-varianten. Tevens hebben we een nieuw ex vivo 
model gepresenteerd welke wellicht beter de complexiteit van de tumor reflecteert dan de 
huidige in vitro modellen. 
Deze interessante nieuwe combinatie therapieen en dit ex vivo model bieden 
mogelijkheden en uitdagingen om 1RAIL-DR gemduceerde apoptose effectiever toe te 
passen en verder te ontwikkelen richting de kliniek. 
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Dankwoord Dankwoord Als nieuwsgierig aagje was het voor mij aan het begin van mijn studie biologie al duidelijk dat ik de onderzoekswereld in zou duiken en ik koos dan ook vol overtuiging deze richting. Tijdens deze studie krijg je steeds meer tijd om aan onderzoeksprojecten te besteden; van een paar dagen in het eerste jaar (waarbij we voomamelijk iets blauws bij iets doorzichtigs pipetteerden zonder eigenlijk te weten wat er dan precies gebeurde), via een paar weken in de daaropvolgende jaren, tot een vol half jaar in de afstudeerfase. Geweldig vond ik dat! Eindelijk de tijd om vol een onderwerp in te duiken en echt iets te onderzoeken. Een half jaar bleek in beide gevallen toch gevoelsmatig veel te kort om er volledige voldoening uit te halen. Vol enthousiasme begon ik bijna 5 jaar geleden dan ook aan dit promotie traject. Zoveel tijd moest toch genoeg zijn?! Deze jaren zijn echter ook weer omgevlogen en ook nu was het echt moeilijk om te stoppen. Maar dat maakte het niet minder leuk! Ik heb met veel plezier aan dit proefschrift gewerkt en daarom wil ik hier graag een aantal mensen bedanken voor hun bijdrage aan dit plezier. Prof. dr. S. de Jong, beste Steven, wat een eer om je als eerste op deze manier te mogen aanspreken! Hartelijk dank voor je intensieve begeleiding, je bijna onhoudbare enthousiasme en je onuitputtelijke bron van ideeen. Je deur stond letterlijk bijna altijd open, al kon ik na een tijd wel aan je gezicht wel zien of je ook echt openstond voor vragen. Goede herinneringen bewaar ik aan de vrijdagen, laat in de middag waar we volgens mij allebei op ons best waren; we begonnen met een leeg white board, welke na een lange, vruchtbare en vooral leuke discussie volstond met receptoren, pijlen, routes en ideeen. Dank daarvoor! Daamaast heb ik het altijd zeer gewaardeerd dat je naast dit alles nog ruimte vond voor interesse in de persoon achter de onderzoeker. Jaloers ben ik zoals je weet op je geheugen, maar gelukkig had ik ook af en toe wel eens gelijk. Prof. dr. E.G.E. de Vries, beste Liesbeth, hartelijk dank voor het vertrouwen op basis waarvan ik de mogelijkheid kreeg deze promotie bij de medische oncologie uit te voeren. Je hebt me geleerd met een klinische blik naar mijn data te kijken en deze data vervolgens krachtig op te schrijven. Ondanks je ongeevenaarde snelheid bij het nakijken van mijn stukken wist je altijd precies de vinger op de zere plek van elk stuk te leggen, om vervolgens met constructieve oplossingen te komen. Prof. dr. F.A.E. Kruyt, beste Frank, we werkten al samen binnen het TIPharma project, maar na je verhuizing van Amsterdam naar Groningen werd je direct betrokken bij mijn begeleiding. Door je andere kijk op (ons) onderzoek was dit een verfrissing, waar ik eerst wel even aan moest wennen. Dank voor je begeleiding, maar ook voor de vele gesprekken over de onderzoekswereld, het regelen van een eventuele plek in Duitsland, en voor alle 'donkey bridges' ! 
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Alle co-auteurs op de verschillende papers wil ik graag hartelijk bedanken. Een aantal van 
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Dr. B.E. Pennarun, dear Bodvael, many thanks for the very pleasant and fruitful! 
collaboration which resulted in chapter 2. I don't know how many hours we spend 
matching our reference files and checking 250 references, but cookies and your humour 
made it feel less tiring and it was definitely all worth it. I wish you all the best in Boston. 
Dr. E.W. Duiker, beste Evelien, ik heb me altijd 'jouw opvolger' gevoeld en dat was een 
eervolle taak! Bedankt voor onze samenwerking voor hoofdstuk 3, de aanhouder wint! Ook 
voor de slice experimenten ben ik je veel dank verschuldigd; door jouw voorbereidende 
werk kon ik zonder problemen met deze experimenten beginnen. Er zijn prachtige data uit 
voortgekomen. 
A.RM. van der Bilt, beste Ame, bedankt voor jouw bijdrage aan hoofdstuk 3, maar vooral 
bedankt voor alle discussies en gezelligheid. Jouw humor levert een grote positieve 
bijdrage aan het lab aangezien je mij en anderen, zelfs bij een <10% success rate bij het 
blotten nog aan het lachen weet te maken. 
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Hetty en Coby, hartelijk dank voor al jullie labondersteuning. Hetty, ik kon met werkelijk 
elke vraag, lab-gerelateerd of niet, bij je terecht, dank daarvoor! Coby, dank voor met 
name de spoedbestellingen in de laatste maanden van mijn labtijd en voor je hulp bij onze 
'favoriete factuur' . 
Gretha, hartelijk dank voor je secretariele ondersteuning. Met name in de laatste fase heb 
je ervoor gezorgd dat alles zeer soepel en snel verliep. Bedankt! 
Kaamar, Mariette en Elise, bedankt voor 2 gezellige TIPharma cursussen! 
Wat is een promotietijd zonder fijne kamergenoten?! Pauline en Bea wat heb ik het met 
jullie getroffen! Heel erg bedankt voor onze fijne tijd samen, jullie luisterend oor en onze 
etentjes bij 'our favourite Thai'. Ik hoop dat we deze zullen blijven voortzetten. 
Paul en Rudolf hebben elk de kamer af en toe voorzien van het nodige testosteron, dank 
daarvoor! 
Het laatste half jaar zat ik op een nieuwe kamer, met nieuwe leuke kamergenoten. 
Roeliene (de filmavond was voor herhaling vatbaar), Milind (again sorry for your plant) 
en Saravanan (thanks for the tasty Indian snacks), bedankt voor een leuk laatste half jaar! 
1k had de eer om deel te mogen uitmaken van de feestcommissie 2008-2009, wat een 
feest! Diva's Thijs, Maartje, Patrick en Kim erg bedankt voor een geweldig leuk jaar vol 
vergaderingen (lees etentjes), borrels, gezelligheid en natuurlijk de beste labdag ooit. We 
moeten nodig weer eens vergaderen. 
Tijdens mijn promotie heb ik verschillende studenten in meer of mindere mate mogen 
begeleiden. Rianne Veenstra, Ingrid Mellendijk, Charlotte de Jong, Jan Koetje, Irene 
Lammers en Judith Land, bedankt voor jullie bijdrage aan dit proefschrift! Mede door 
jullie en vele anderen die ik wegwijs heb mogen maken in ons lab, heb ik ingezien dat het 
onderwijs de volgende stap is in mijn carriere. 
1k ben ervan overtuigd dat goed en hard werken wordt bevorderd door geluk buiten het 
werk. Wanneer je dit proefschrift hebt gekregen betekent dit daarom dat je direct of indirect 
een bijdrage hebt geleverd aan dit proefschrift. Dank daarvoor! Een aantal van jullie wil ik 
graag in het bijzonder noemen. 
Heika en Gerlinde, squash bleek een waardevolle volleybalvervanger. Wat was het fijn om 
na een lange labdag met jullie op de baan te staan. Ik hoop dat we elkaar blijven zien, ook 
al hebben we het squashen inmiddels opgegeven. 1 71 
Dankwoord Janske en Lydian, waar een loopbaancursus al niet goed voor is! Ik ben zeer blij jullie daar ontmoet te hebben en heb genoten van alles wat we sindsdien samen hebben gedaan. Jullie zijn een fijne uitlaatklep. Pauline, Dianne, Dorenda, Janet en Haukeline, wat begon als een soort eenmalige tienerfilmmarathon met collega' s is geeindigd in vele avonden gezelligheid met vriendinnen. Dank! Het was gezellig in hetzelfde schuitje. Allard en Yta, dank voor de vele vrijdagmiddagborrels en etentjes, maar vooral voor onze gezamenlijke wadavonturen. Lieve Anneke, Marjolein, Susan, Kim en Els, ooit zijn we zomaar bij elkaar in een volleybal team gegooid. Wie had gedacht dat daar zo'n mooie vriendschap uit zou ontstaan?! Gezien onze totaal verschillende achtergronden waardeer ik het zeer dat jullie altijd zoveel interesse in mijn onderzoek hebben getoond. Dank voor de ontelbare feesten, stapavonden, borrels, weekendjes weg, Leins vrijgezellenfeest en trouwerij, het volleybal, de vele toernooien, etentjes en alles wat we samen hebben beleefd. Ik denk dat we de afgelopen tijd hebben ingezien wat onze vriendschap voor ons en wat we voor elkaar betekenen en dat is me zeer dierbaar. Lieve Jan, Anke en Hilde, al meer dan 10 jaar vormen we een prachtig viertal. Met niemand kan ik zoveel lachen maar ook zoveel huilen als met jullie. Jan, dank voor je enthousiasme, openhartigheid, de mannenpraat, je 5-sterren diners en je luisterend oor. Wij hebben aan een blik genoeg. Anke, dank voor onze goede gesprekken, je kunst om altijd weer met iets opbeurends te komen en het feit dat je er altijd voor me bent. Ik bewonder je doorzettingsvermogen en kracht ontzettend. Bedankt dat je mijn paranimf wilt zijn. Hilde, dank voor je oprechtheid en heldere kijk op dingen. Ik heb het gevoel alles aan je kwijt te kunnen om vervolgens altijd een goede tip, de juiste vraag of het juiste antwoord terug te krijgen. Dank voor de ontelbare etentjes, feestjes, weekendjes weg, kopjes koffie en alles wat we samen hebben beleefd. Ook wij hebben tijdens mijn promotietijd ingezien hoeveel we voor elkaar betekenen en ook dat is me zeer dierbaar. Ik heb jullie lief! Lieve Bea, Theo, Bart en Roelfien, bedankt voor alle gezelligheid! Ik heb me altijd zeer welkom gevoeld in jullie gezin. 
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Lieve Inge, mijn grote zus! Wat ben ik er trots op jouw kleine zus te zijn. Geweldig bedankt 
voor je liefde, interesse, wijze raad en vertrouwen. Wat kan er nog mis gaan als jij op mijn 
grote <lag aan mijn zijde staat?! Bedankt <lat je mijn paranimf wilt zijn. Lieve Johannes, het 
was prettig een mede-AIO als zwager te hebben! Dank voor al je tips en alle gezelligheid. 
En dan Hilde, wat een geweldig nieuw zonnetje ben jij in onze familie! 
Ik heb dankzij mijn ouders een heerlijke en onbezorgde jeugd gehad, waarin ik helaas iets 
te vroeg volwassen moest worden. Mijn vader ben ik dan ook dankbaar voor alle mooie 
herinneringen. Lieve mam, bedankt voor je onvoorwaardelijke liefde, zorg en steun. Je 
bent er altijd voor me. Je staat achter al mijn keuzes en maakt deze telkens weer, ook in de 
nabije toekomst, mogelijk. Ik ben je daar zeer dankbaar voor. Ik bewonder je kracht en hoe 
je in het leven staat nu papa er niet meer is. Ik hou van je! 
Lieve, lieve Wouter, bij jou voel ik me thuis, overgelukkig en op mijn plek. Je bezit de gave 
me altijd tot rust te laten komen, hoe groot de chaos in mijn hoofd ook is. Jouw bijdrage aan 
<lit proefschrift is dan ook groot, bedankt daarvoor. Ik hou heel veel van je! 1 73 

